{
  "Topic 1": {
    "64773": "introduction objective advanced heart failure hf remains major cause mortality identification new prognostic risk factor therefore priority anemia frequent comorbidity hf patient recognized trigger symptom recently received considerable attention context several study demonstrated association anemia increased mortality stable chronic hf patient however prognostic impact comorbidity survival advanced hf patient remains unclear aim assess whether anemia marker advanced hf also independent predictor mortality method performed retrospective study consecutive patient admitted single advanced hf care unit divided two group according presence absence anemia admission demographic clinical laboratory therapeutic data compared group anemia defined hemoglobin admission g dl woman g dl men appropriate statistical test multivariate analysis used identify independent predictor one year overall mortality median follow year result group anemic patient n older v year p included higher number patient ischemic cardiomyopathy v p fewer dilated cardiomyopathy v p admission group lower systolic blood pressure mmhg v mmhg p higher mean c reactive protein mg dl v mg dl p creatinine mg dl v mg dl p gender prevalence cardiovascular risk factor previous medication left ventricular ejection fraction statistically different group discharge fewer anemic patient received digoxin v p mortality rate month v p one year v p follow v p significantly higher group multivariate analysis demonstrated anemia independent predictor mortality one year p median follow p anemic group linear relationship hemoglobin level mortality also detected conclusion population anemia frequent comorbidity independent negative impact long term mortality correction could improve outcome advanced hf patient:0.0537668609410046",
    "142133": "objective admission hyponatremia related poor outcome patient heart failure hf study examined influence hyponatremia prognosis hf patient without previous admission aim determine whether baseline hyponatremia predicts worse outcome cohort real world hf patient admitted first episode acute hf method reviewed medical record patient year age admitted within two year period first episode decompensation hf divided sample according presence hyponatremia defined serum sodium meq l compared one year cause mortality rate group using cox regression analysis result patient mean serum sodium admission patient hyponatremia hyponatremic patient lower hematocrit value compared rest global mortality rate higher across evaluation one three month hyponatremia group although statistical significance reached one year follow difference patient baseline sodium value found died survivor v p natremia admission considered continuous variable hr ic associated mortality however multivariate cox regression analysis confirm association conclusion admission hyponatremia uncommon even patient admitted first time acute hf however hyponatremia cohort patient seem influence significantly short mid term mortality:0.0505335258233690",
    "52272": "background dyslipidaemia studied prognosis heart failure hf little known role dyslipidaemia aetiopathogenesis dilated cardiomyopathy dcm aim assess serum lipid level dcm considering severity heart failure association dcm lipid abnormality prognostic significance lipid dcm method study group consisted patient angiographically proven dcm mean age year male nyha class iii iv mean left ventricular ejection fraction lvef whose fasting serum lipid assessed diagnosis patient lipid level compared observed healthy control n age gender bmi matched related finding reported population sample pol monica study n n n three patient received lipid lowering drug transplant free survival assessed study group statistical analysis nonparametric wilcoxon test uni multivariate logistic cox regression analysis used result serum total cholesterol tc ldl ldl c hdl cholesterol hdl c tended lower difference n nyha class iii iv patient v class ii tc v mg dl ldl c v mg dl hdl c v mg dl respectively triglyceride tg lower advanced hf v nyha class ii v mg dl p dcm patient hdl c lower control v mg dl p tg level higher v mg dl p hdl c tg level control similar observed population sample multivariate analysis age low hdl defined mg dl male mg dl female hypertg tg l mg dl showed low hdl c ci p hypertg ci p independently associated dcm low hdl c level occurred frequently female dcm patient v male v p trend towards frequent occurrence hypertg male patient v female v p mean follow time year cox univariate analysis low tc tended prognostic factor p cox multivariate analysis nyha class hr ci p lvef hr ci p turned independent predictor poor outcome conclusion dyslipidaemia might play role aetiopathogenesis dcm low tc independent prognostic factor dcm:0.0493804879504585",
    "96968": "aim patient acute heart failure ahf included clinical trial regardless difference baseline clinical characteristic aim study assess patient ahf according presence central peripheral congestion hospital admission evaluate treatment response outcome studied phenotype method result investigated retrospectively patient mean age year men hospitalized due ahf sign congestion admission patient divided according type sign congestion three group isolated pulmonary congestion n b isolated peripheral congestion n c sign mixed peripheral central congestion n patient group lower concentration urea bilirubin gamma glutamyl transferase whereas higher level haematocrit albumin leukocyte admission highest baseline n terminal pro b type natriuretic peptide level median v v pg ml percentage patient chronic heart failure v v v b v c respectively p observed group c difference term demographic co morbidity left ventricular ejection fraction applied treatment studied group patient group highest systolic blood pressure admission v v mmhg biggest decrease systolic blood pressure v v mmhg heart rate v v b p lowest weight change v v kg p h hospitalization difference short term long term outcome favourable result group group experienced less frequent hospital heart failure worsening first h v v shorter length hospital stay v v day lower year cause mortality v v p presence peripheral congestion admission independent predictor cause mortality within year hazard ratio confidence interval p conclusion pattern congestion ahf associated difference clinical characteristic treatment response outcome need considered planning clinical trial ahf:0.0484567899365840",
    "141878": "objective investigate predictive value n terminal type b natriuretic peptide nt probnp prognosis elderly hospitalized patient without heart failure non heart failure method elderly patient aged year older admitted beijing hospital september february enrolled study patient clinical diagnosis heart failure left ventricular ejection fraction lvef excluded patient divided group based serum nt probnp level low nt probnp group ng l high nt probnp group ng l patient followed month enrollment major adverse event recorded composite endpoint event included cause mortality readmission emergency department visit cardiovascular event include death readmission emergency room treatment due cardiogenic shock myocardial infarction angina pectoris arrhythmia heart failure stroke transient ischemic attack result total elderly patient non heart failure included analysis average age year including male median follow time day one hundred seventy eight composite endpoint event recorded follow patient died patient lost follow case low nt probnp group case high nt probnp group patient older prevalence atrial fibrillation myocardial infarction higher mmse score adl score albumin creatinine clearance rate lower high nt probnp group low nt probnp group p year follow incidence composite endpoint event significantly higher high nt probnp group low nt probnp group v p cardiovascular event common high nt probnp group low nt probnp group v p kaplan meier survival analysis showed composite endpoint event log rank p cardiovascular event log rank p higher high nt probnp group low nt probnp group cause mortality also significantly higher highnt probnp group lownt probnp group v p kaplan meier survival analysis demonstrated borderline statistical significance log rank p cox proportional hazard regression analysis showed adjusting age sex creatinine clearance rate myocardial infarction atrial fibrillation nt probnp remained independent risk factor composite endpoint event hr ci p cardiovascular event hr ci p cause mortality p conclusion nt probnp level admission important predictive value rehospitalization cardiovascular event hospitalized elderly non heart failure patient nt probnp examination helpful risk stratification patient cohort:0.0478021404508782",
    "161521": "objective explore predictive value pulmonary effective arterial elastance ea patient heart failure hf method retrospective cohort study retrospectively included patient hf underwent right heart catheterization heart failure center fuwai hospital september february data regarding baseline clinical characteristic hemodynamic profile prognosis collected ea calculated mean pulmonary arterial pressure stroke volume patient divided ea group ea group according median value ea mmhg ml mmhg kpa primary outcome primary clinical event set first occurrence series composite event including cause death heart transplantation left ventricular assist device implantation hf rehospitalization event free survival defined absence primary clinical event spearman correlation analysis used calculate correlation coefficient ea parameter reflective right heart function kaplan meier analysis used compare different group estimation outcome log rank test used cox proportional hazard regression model estimate hazard ratio hr primary clinical event subgroup analysis performed based age gender new york heart association nyha functional class left ventricular ejection fraction presence pulmonary hypertension serum n terminal pro b type natriuretic peptide nt probnp value used receiver operating characteristic roc curve calculate area curve auc ea predicting event free survival patient hf result median age year patient male ea pulmonary vascular resistance pvr significantly correlated r p correlation ea pulmonary arterial elastance pac even significant r p compared ea group ea group presented higher serum nt probnp value ng l v ng l p higher pvr wood v wood p lower cardiac output l min v l min p lower pac ml mmhg v ml mmhg p median follow time day kaplan meier survival curve demonstrated lower event free survival rate ea group compared ea group p log rank multivariate adjustment ea hr p remained significantly associated primary outcome subgroup analysis indicated ea associated primary outcome across subgroup auc p ea predict event free survival calculated roc analysis conclusion ea closely related parameter reflective right ventricular afterload increased ea independent predictor adverse outcome patient hf:0.0468533421214188",
    "133124": "aim many study show association malnutrition poor prognosis heart failure hf patient research aimed analyse sex difference patient hf reduced ejection fraction hfref emphasizing nutritional status influence selected parameter prognosis method result enrolled consecutive patient diagnosed hfref nutritional status assessed using mini nutritional assessment mna geriatric nutritional risk index gnri body mass index bmi mean follow period day analysed group included men median age interquartile range iqr year among patient almost classified nyha iii iv half participant risk malnutrition malnourished follow patient died female sex associated higher occurrence malnutrition p nutritional risk p according mna coherently gnri score differ significantly sex p contrast bmi significantly higher male v p impaired nutritional status assessed method mna gnri bmi significantly associated worse prognosis multivariable analysis nyha class lower estimated glomerular filtration rate higher b type natriuretic peptide bnp higher n terminal fragment probnp higher uric acid independent sex age predictor cause mortality conclusion sex difference nutritional status hfref patient apart lower bmi female impaired nutritional status associated mortality men woman:0.0465454967708061",
    "29086": "introduction previous study associated heart failure hf ischemic etiology worse prognosis compared hf non ischemic cardiomyopathy hf treatment evolved significantly recent year evolution impact prognostic gap objective aim study compare patient advanced hf nonischemic versus ischemic etiology term baseline characteristic treatment hospital long term prognosis including death heart transplantation hospital readmission method performed retrospective study including consecutive patient systolic hf admitted hf unit january june compared two group according hf etiology group ischemic cardiomyopathy n group b non ischemic cardiomyopathy n mean follow month result group older v year p higher proportion male v p diabetes anemia dyslipidemia smoker required prolonged treatment inotropic drug frequent treatment statin antiplatelet agent nitrate admission group b patient presented lower serum sodium higher aminotransferase level difference occurrence cardiogenic shock dysrhythmias baseline ecg rhythm frequency left bundle branch block renal function bnp left ventricular ejection fraction heart rate implantation intracardiac device group higher hospital mortality v p multivariate analysis showed predictor hospital mortality serum sodium mmol l also showed hf etiology predictor endpoint previous medication angiotensin converting enzyme inhibitor protective factor kaplan meier analysis observed long term significant difference either survival rate v p combined endpoint survival free death heart transplantation v p survival free death heart transplantation hospital readmission v p conclusion although hospital mortality higher ischemic cardiomyopathy variable independent predictor mortality difference appears fade long term contrast reported older study agreement recent data:0.0462582753062578",
    "20532": "background mild anaemia frequently occurs patient chronic heart failure chf particularly advanced stage disease correction anaemia erythropoietin therapeutic possibility aim study assess prospectively relationship prevalence anaemia haemoglobin level g l prognosis unselected chf population method consecutive patient diagnosis chf admitted department january april considered present study secondary cause anaemia excluded patient followed november month survivor end point study cause mortality result total patient enrolled mean age year new york heart association nyha classification ii iii iv left ventricular ejection fraction lvef ischaemic aetiology whole population mean haemoglobin level g l anaemia found patient significantly common woman men v respectively p severe chf symptom frequency nyha ii iii iv respectively nyha iv v iii p related clinical index univariate analysis revealed nyha class iii iv hazard ratio ci p low lvef hazard ratio ci p anaemia hazard ratio ci p predictor month mortality multivariate analysis anaemia remained independent predictor death adjusted nyha class lvef hazard ratio ci p anaemic patient month survival ci compared patient normal haemoglobin level p conclusion mild anaemia significant independent predictor poor outcome unselected patient chf correction low haemoglobin level may become interesting therapeutic option chf patient:0.0457057542969662",
    "168699": "aim data available regarding role tricuspid annulus plane systolic excursion pulmonary artery systolic pressure tapse pasp measurement right ventricular pulmonary artery coupling patient chronic heart failure left ventricular systolic dysfunction method result retrospective single centre study included outpatient left ventricular systolic dysfunction ejection fraction evaluated january december tapse pasp evaluated continuous variable tertiles according value first visit primary outcome study composite cause mortality heart failure hf event last available follow result total patient included mean age year male mean left ventricular ejection fraction interquatile range patient lower tapse pasp co morbidity e atrial fibrillation chronic kidney disease previous cardiovascular implantable electronic device higher new york heart association class p sign congestion p probability receive intravenous furosemide visit p median follow day interquartile range day total patient died patient experiencing cardiovascular related death total patient experienced composite outcome patient hf event kaplan meier analysis showed estimated year rate primary outcome higher lowest tertile compared intermediate highest tertiles p value log rank tapse pasp ratio continuous variable independently associated primary outcome adjusted hazard ratio mm mmhg increase ci p predominantly driven higher risk hf event follow analysing impact tapse pasp tertiles primary outcome independent associated confirmed multivariate analisys highest versus lowest tertile adjusted hazard ratio ci p conclusion tapse pasp independently associated mortality hf event among ambulatory patient left ventricular systolic dysfunction:0.0452206295117056"
  },
  "Topic 2": {
    "176564": "background cardiac ischemia predominant cause heart failure marked profound mitochondrial dysfunction dysregulated ion homeostasis maladaptive cellular remodeling compromise cardiac performance mitochondrial inner membrane protein leucine zipper ef hand containing transmembrane protein letm implicated wolf hirschhorn syndrome essential mitochondrial function although genetic alteration letm linked cardiomyopathy specific contribution cardiac pathophysiology particularly context ischemic heart disease remain poorly defined study aim elucidate role letm ischemic cardiac pathology mechanistic impact cardiomyocyte function method letm expression assessed human murine model heart failure due ischemic cardiomyopathy icm cardiac hypertrophy letm overexpressed neonatal rat ventricular cardiomyocytes adult mouse cardiomyocytes human induced pluripotent stem cell ipsc derived cardiomyocytes study mitochondrial function seahorse assay structural molecular remodeling fluorescence microscopy transmission electron microscopy tem qpcr immunoblotting transcriptomic proteomic profile calcium handling electrophysiology patch clamp autophagic flux bafilomycin lc rfp gfp cell survival result letm markedly upregulated icm human murine heart unchanged hypertrophic heart failure overexpression letm cardiomyocytes resulted profound mitochondrial dysfunction including downregulation oxidative phosphorylation oxphos gene impaired membrane potential reduced atp output increased proton leak elevated ro level metabolic shift toward glycolysis observed accompanied reduced fatty acid oxidation electron microscopy revealed mitochondrial fragmentation mitophagic vesicle sarcomeric disarray transcriptomic proteomic analysis highlighted dysregulation gene linked mitochondrial organization ion transport autophagy electrophysiologically letm reduced l type ca current density significantly shortened action potential duration leading impaired contractility letm overexpression activated upstream autophagy regulator ampk ulk enhanced lc ii p accumulation autophagic flux impaired confirmed lc rfp gfp reporter exacerbated bafilomycin treatment dysregulated autophagy coupled mitochondrial stress increased apoptosis cleaved caspase reduced cardiomyocyte viability conclusion study indicates letm upregulation drive mitochondrial dysfunction electrophysiology alteration activation autophagy apoptosis culminating cardiomyocyte injury ischemic cardiomyopathy disrupting oxphos calcium handling cell survival pathway letm contributes ischemic remodeling cardiac dysfunction targeting letm present promising therapeutic strategy alleviate ischemic damage preserve cardiac function:0.0599897677730488",
    "129287": "background calcium ca key regulator energy metabolism impaired ca homeostasis damage mitochondrion causing cardiomyocyte death pathological hypertrophy heart failure study investigates regulation role mitochondrial ca uniporter mcu chronic stress induced pathological cardiac remodeling method mcu knockout transgenic mouse infused isoproterenol iso mg kg per day week cardiac hypertrophy remodeling evaluated echocardiography histology primary cultured rodent adult cardiomyocytes treated iso nmol l hour intracellular ca handling cell death pathway monitored adenovirus mediated gene manipulation used vitro result chronic administration beta adrenergic receptor agonist iso increased level mcu mcu complex cardiac mitochondrion raising mitochondrial ca concentration vivo vitro iso also upregulated mcu without affecting regulatory protein adult cardiomyocytes interesting iso induced cardiac hypertrophy fibrosis contractile dysfunction cardiomyocyte death exacerbated global mcu knockout mouse cardiomyocytes knockout mouse overexpressing dominant negative mcu exhibited defective intracellular ca handling activation multiple cell death pathway conversely cardiac specific overexpression mcu maintained intracellular ca homeostasis contractility suppressed cell death prevented iso induced heart hypertrophy iso upregulated mcu expression activation ca calmodulin kinase ii deltab camkiideltab promotion nuclear translocation via calcineurin mediated dephosphorylation serine nuclear camkiideltab phosphorylated creb camp response element binding protein bound mcu promoter enhance mcu gene transcription conclusion beta adrenergic receptor camkiideltab creb pathway upregulates mcu gene expression heart mcu upregulation compensatory mechanism counteracts stress induced pathological cardiac remodeling preserving ca homeostasis cardiomyocyte viability:0.0563446492145111",
    "197507": "background cardiomyocyte proteostasis calcium homeostasis critical maintaining cardiac function dysregulation contributing cardiac hypertrophy heart failure tripartite motif protein trim well characterized chromatin reader transcriptional regulator cancer recently emerged potential player cardiac biology however precise role cardiomyocytes remains unclear using molecular structural functional approach study investigates impact trim cardiomyocyte function gene regulation method dissect molecular functional role trim conducted rna sequencing rna seq chromatin immunoprecipitation sequencing chip seq neonatal rat ventricular cardiomyocytes nrvcms identify trim regulated pathway transcriptional target super resolution microscopy proteomics analysis employed examine influence chromatin organization calcium handling protein distribution calcium imaging cardiomyocyte contractility assay performed nrvcms human induced pluripotent stem cell derived cardiomyocytes ipsc cm assess functional effect additionally nfat activity assessed investigate role trim mediated hypertrophic signaling result rna seq chip seq identified trim bidirectional transcriptional regulator predominantly acting repressor also exhibiting context dependent activation gene involved e g cytoskeletal organization calcium signaling chip seq identified trim binding nfatc locus validated motif analysis functional study revealed trim regulates nfatc protein level activity enhancing upon overexpression reducing upon knockdown furthermore trim overexpression altered expression organization ryanodine receptor ryr sarcoplasmic endoplasmic reticulum ca atpase serca calsequestrin casq leading calcium handling defect super resolution microscopy revealed loss chromatin organization altered clustering calcium handling protein despite reduction serca level trim activated pi k akt pln pathway increasing phospholamban phosphorylation compensatory calcium reuptake functional assay trim overexpression increased beating frequency calcium cycling nrvcms ipsc cm conclusion finding establish trim novel regulator chromatin remodeling cardiomyocyte transcription directly influencing calcium homeostasis contractility potential implication cardiac disease:0.0559245842400503",
    "73383": "rationale cardiac fibrosis play critical role pathogenesis heart failure excessive accumulation extracellular matrix ecm resulting cardiac fibrosis impairs cardiac contractile function increase arrhythmogenicity current treatment option cardiac fibrosis however limited clear need identify novel mediator cardiac fibrosis facilitate development better therapeutic exploiting coexpression gene network analysis rna sequencing data failing human heart identified txndc thioredoxin domain containing cardiac fibroblast cf enriched endoplasmic reticulum protein potential novel mediator cardiac fibrosis completed experiment test hypothesis directly objective objective study determine functional role txndc pathogenesis cardiac fibrosis method result rna sequencing western blot analysis revealed txndc mrna protein highly upregulated failing human left ventricle hypertrophied failing mouse left ventricle addition cardiac txndc mrna expression level positively correlated transcript encoding transforming growth factor beta ecm protein vivo txndc mrna protein increased human cf hcf transforming growth factor beta stimulation vitro knockdown txndc attenuated transforming growth factor beta induced hcf activation ecm protein upregulation independent smad smad family member whereas increasing expression txndc triggered hcf activation proliferation increased ecm protein production experiment showed txndc protein disulfide isomerase facilitated ecm protein folding depletion txndc led ecm protein misfolding degradation cf addition txndc promotes hcf activation proliferation enhancing c jun n terminal kinase activity via increased reactive oxygen specie derived nad p h oxidase transforming growth factor beta induced txndc upregulation hcf dependent endoplasmic reticulum stress activating transcription factor mediated transcriptional control targeted disruption txndc mouse txndc revealed protective effect isoproterenol induced cardiac hypertrophy reduced fibrosis approximately markedly improved left ventricle function post isoproterenol left ventricular ejection fraction versus p txndc versus wild type mouse respectively conclusion endoplasmic reticulum protein txndc promotes cardiac fibrosis facilitating ecm protein folding cf activation via redox sensitive c jun n terminal kinase signaling loss txndc protects beta agonist induced cardiac fibrosis contractile dysfunction targeting txndc therefore could powerful new therapeutic approach mitigate excessive cardiac fibrosis thereby improving cardiac function outcome patient heart failure:0.0559022026689170",
    "199245": "background disturbance protein synthesis degradation play crucial role various biological pathological process e ubiquitin ligase substrate binding adaptor spop speckle type poz poxvirus zinc finger protein substantially involved cancer progression study aim investigate biological function spop cardiac hypertrophy heart failure method generated cardiac specific transgenic knockout mouse evaluate functional role spop transverse aortic constriction induced cardiac hypertrophy heart failure rna sequencing proteomics protein mass spectrometry analysis multiple molecular biological methodology employed investigate function mechanism cardiac hypertrophic mouse result spop significantly upregulated human heart failure hypertrophic mouse heart ang ii angiotensin ii treated neonatal mouse ventricular cardiomyocytes spop induced expression hypertrophic marker anp atrial natriuretic peptide bnp b type natriuretic peptide beta mhc beta myosin heavy chain increased cardiomyocyte size whereas spop deficiency exhibited opposite effect hypertrophic neonatal mouse ventricular cardiomyocytes furthermore cardiac specific overexpression spop led cardiac hypertrophy heart failure mouse contrast cardiac specific knockout spop markedly attenuated transverse aortic constriction induced cardiac hypertrophy improved heart failure parallel spop presented prohypertrophic effect spop loss function substantially rescued ang ii induced hypertrophic phenotype neonatal mouse ventricular cardiomyocytes mechanistically spop transcriptionally activated p cardiac hypertrophy subsequently interacting promoting ubiquitination mediated degradation tfeb transcription factor eb independently phosphorylation status key regulator transcription lysosomal biogenesis autophagy related gene leading blockage autophagy mitophagy eventually cause cardiac hypertrophy heart failure overexpression tfeb rescued spop induced alteration noticeably specific inhibitor spop able prevent development cardiac hypertrophy heart failure conclusion spop detrimental factor pathological cardiac hypertrophy via promoting ubiquitination induced degradation tfeb critical regulator autophagy lysosomal pathway targeting spop represents promising therapeutic strategy hypertrophy related heart failure:0.0555307270106808",
    "194876": "rationale internal modification mammalian rna suggested essential maintenance cardiac homeostasis however role rna cytosine methylation c heart remains largely unknown method bulk single cell rna sequencing data tissue human heart exploited analyzing expression rna c modifying protein neonatal rat adult mouse cardiomyocytes isolated assess impact nsun cellular hypertrophic response cre loxp mediated gene knockout recombinant adeno associated virus serotype raav employed respectively achieve cardiac specific interference expression related gene mouse subjected heart stress aging aortic constriction angiotensin ii stimulation rna c immunoprecipitation sequencing c rip seq rna pull polysome profiling reporter gene analysis ionoptix measurement conducted elucidate involved regulatory mechanism result nsun expression significantly elevated human rat mouse hypertrophic myocardial cell knockout nsun alphamhc cre ert nsun flox abolished hypertrophic response mouse diverse stress accelerating progression heart failure mechanistically nsun specifically methylates pka catalytic subunit alpha prkaca mrna substantially promotes prkaca translation ybx dependent manner nsun ablation markedly attenuated activation pka signaling evidenced reduced pka activity protein phosphorylation level pka substrate impaired myocyte contraction relaxation disturbed calcium transient overexpressing nsun prkaca utr transcript myocardium sensitized desensitized heart hypertrophic response respectively whereas co administration pka inhibitor h overexpressing prkaca utr transcript lacking nsun methylating region failed produce corresponding response reiterating significance nsun prkaca regulation cardiac hypertrophic program conclusion observation reveal importance nsun prkaca regulation cardiac homeostasis provides novel insight heart function modulation shed light future treatment hypertrophic remodeling associated heart disease:0.0548994044650527",
    "114979": "pathological remodeling heart hallmark chronic heart failure hf structural change perpetuate disease cardiac fibroblast critical cell type responsible maintaining structural integrity heart stress condition myocardial infarction mi activate quiescent fibroblast synthetic contractile myofibroblasts g protein coupled receptor kinase grk important mediator cardiovascular homeostasis dampening gpcr signaling expressed heart regulated human hf note grk demonstrated translocate nucleus cardiomyocytes calcium calmodulin ca cam dependent manner promoting hypertrophic gene transcription activation nuclear factor activated cell nfat interestingly nfat also involved fibroblast activation grk highly expressed active cardiac fibroblast however pathophysiological role crucial cardiac cell unknown demonstrate using adult cardiac fibroblast genetic deletion grk inhibits angiotensin ii angii mediated fibroblast activation fibroblast specific deletion grk mouse led decreased fibrosis cardiac hypertrophy chronic angii infusion ischemic injury compared nontransgenic littermate control nlcs mechanistically show nuclear translocation grk involved fibroblast activation data demonstrate grk regulator fibroblast activation vitro cardiac fibrosis vivo add previously published data demonstrate potential beneficial effect grk inhibition context cardiac disease:0.0546007699887451",
    "169022": "background cardiac hypertrophy characterized upregulation fetal gene increased protein synthesis enlargement cardiac myocytes mechanistic target rapamycin complex mtorc responds fluctuation cellular nutrient energy level play pivotal role regulating protein synthesis cellular growth attempt inhibit mtorc activity application rapamycin analog demonstrated limited efficacy investigation warranted method result show serinc expression downregulated transverse aortic constriction tac induced hypertrophic myocardium vivo vitro reduction serinc expression result pathological hypertrophic growth whereas serinc overexpression exhibit protective effect rna sequencing analysis following serinc knockdown reveals transcriptomic shift toward pro hypertrophic profile suggests significant interplay serinc amino acid mtor lysosome hub mtor activation moreover show serinc localizes lysosome hinders mtorc recruitment lysosomal membrane response amino acid stimulation playing critical role regulating amino acid signaling pathway involved activation p k ebp hela cell deficiency exacerbates mtorc activity mtorc dependent subsequent protein synthesis abrogated rapamycin line vitro finding serinc knockout mouse subjected tac surgery exhibit elevated phosphorylation p k ebp inhibition mtorc signaling amino acid deprivation prevents activation impedes progression pathological cardiac remodeling conclusion illustrated serinc localizes lysosomal membrane modulates amino acid mtorc signaling cardiomyocytes serinc therefore present potential therapeutic target mitigating excessive protein synthesis improving heart failure hemodynamic stress:0.0541344212442998",
    "156778": "aim mitochondrion play vital role cellular metabolism energetics support normal cardiac function disrupted mitochondrial function homeostasis cause variety heart disease fam family sequence similarity member novel mitochondrial gene identified hub gene mouse cardiac remodeling multi omics study human fam mutation associated sarcopenia however physiological role molecular function fam remain elusive heart aim determine biological role molecular mechanism fam regulating mitochondrial function cardiac health vivo method result tamoxifen induced alphamhc mcm driven conditional knockout fam mouse cardiomyocytes induced progressive dilated cardiomyopathy heart failure ultimately causing mortality fam deficient cardiomyocytes exhibit severe mitochondrial morphological disruption functional decline accompanied myofilament disarray late stage cardiomyopathy furthermore observed increased mitochondrial reactive oxygen specie production disturbed mitochondrial membrane potential reduced respiratory activity cardiomyocytes early stage contractile dysfunction heart failure multi omics analysis indicate fam deficiency persistently activates integrated stress response isr resulting transcriptomic translatomic proteomic metabolomic reprogramming ultimately leading pathogenic progression heart failure mechanistically mitochondrial polysome profiling analysis show fam loss function compromise mitochondrial mrna translation lead reduced mitochondrial encoded protein followed disrupted proteostasis observed decreased fam protein expression human ischemic heart failure mouse myocardial infarction tissue sample corroborate fam function heart aav mediated overexpression fam promotes mitochondrial encoded protein expression improves cardiac mitochondrial function partially rescue murine heart cardiac remodeling damage ischemia induced heart failure conclusion result suggest fam mitochondrial translation regulator maintain mitochondrial homeostasis normal cardiomyocyte contractile function study also offer new therapeutic target treating ischemic heart disease translational perspective mitochondrial homeostasis critical maintaining healthy cardiac function disruption mitochondrial function cause severe cardiomyopathy heart failure present study show fam mitochondrial translation regulator required maintaining cardiac mitochondrial homeostasis vivo cardiomyocyte specific fam deficiency lead mitochondrial dysfunction spontaneous cardiomyopathy moreover result indicate fam downregulated human mouse ischemic heart failure sample overexpression fam protects heart myocardial infarction induced heart failure suggesting fam mediated mitochondrial translation regulatory pathway potential therapeutic target ischemic heart disease:0.0540610413499794",
    "184990": "pathological cardiac hypertrophy involves multiple regulator several signal transduction pathway currently mechanism well understood differentially expressed fdcp homolog def reported participate immunity bone remodeling cancer effect def pathological cardiac hypertrophy however yet fully characterized initially determined expression profile def found def upregulated hypertrophic heart cardiomyocytes vivo result revealed def deficiency mouse alleviated transverse aortic constriction tac induced cardiac hypertrophy fibrosis dilation dysfunction left ventricle conversely cardiomyocyte specific def overexpression aggravated hypertrophic phenotype mouse chronic pressure overload similar animal experiment vitro data showed adenovirus mediated knockdown def remarkably inhibited phenylephrine pe induced cardiomyocyte hypertrophy whereas def overexpression exerted opposite effect mechanistically exploration signal pathway showed mitogen activated extracellular signal regulated kinase mek extracellular signal regulated kinase erk cascade might involved prohypertrophic effect def coimmunoprecipitation gst glutathione transferase pulldown analysis demonstrated def directly interact small gtpase ra related c botulinum toxin substrate rac rac activity assay revealed activity rac altered def expression tac cardiac hypertrophy pe triggered cardiomyocyte hypertrophy end western blot rescue experiment using rac inhibitor nsc constitutively active mutant rac g v verified requirement rac mek erk activation def mediated pathological cardiac hypertrophy study substantiates def act deleterious regulator cardiac hypertrophy activating rac mek erk signaling pathway suggests def may potential treatment target heart failure:0.0539534359656421"
  },
  "Topic 3": {
    "129861": "background dissecting aneurysm sinus valsalva sov interventricular septum rare entity multilobulated form dissection rupturing left ventricle lv never reported literature case summary year old male presented dyspnoea palpitation wide pulse pressure peripheral sign distal run continuous murmur along left parasternal area echocardiography revealed dilated right coronary cusp rcc burrowed interventricular septum iv forming multi loculated cystic lesion ruptured lv associated restrictive ventricular septal defect vsd severe aortic regurgitation computed tomography ct angiography confirmed cm x cm x cm multiseptated aneurysm surgery involved excision aortic valve av sinus ligation penetrating portion crest iv closure vsd av replacement postoperative echocardiography showed complete collapse iv component sov aneurysm normally functioning mechanical av discussion dissecting aneurysm iv rare variant sov aneurysm usually arising rcc mostly congenital origin wide variety presentation like congestive heart failure palpitation recurrent syncope chest pain sudden cardiac arrest infective endocarditis cerebral infarction asymptomatic aortic regurgitation present case conduction disturbance first degree block complete heart block common echocardiogram ct angio magnetic resonance imaging useful diagnosis surgical repair option treatment:0.0644231303808711",
    "178459": "background sinus valsalva aneurysm sovas infrequent finding generally diagnosed incidentally sova may risk rupture would lead aorto cardiac shunt patient present similarly decompensated heart failure case presentation present case year old female ruptured non coronary sova diagnosed echocardiogram evaluation exertional dyspnoea trans oesophageal echocardiogram tee revealed cm non coronary sova windsock communication right atrium patient refused surgery two year later presented florid right heart failure preserved left ventricular function right ventricle severely dilated hypokinetic right atrial enlargement finally agreeing surgery pre operative catheterization revealed non obstructive coronary significant left right shunt elevated pulmonary pressure patient suboptimal response diuretic therapy sent successful repair aneurysm closure aorto atrial fistula via bovine pericardial patch resolution left right shunt demonstrated intra operative tee right sided heart failure symptom subsequently resolved discussion sova rare finding still considered differential young middle aged patient symptom acute heart failure hemodynamic compromise new continuous heart murmur early surgical repair highly recommended prevent acute long term complication:0.0612896137675110",
    "166410": "background persistent left superior vena cava lsvc connection left atrium la rare anomaly serious clinical implication depending direction flow intracardiac shunt clinical presentation varies cyanosis paradoxical embolism overt right heart failure case summary year old man repaired ventricular septal defect vsd infancy presented symptom progressive exercise intolerance cardiac imaging revealed large defect posterior wall lsvc entry coronary sinus c connecting lsvc la resulting diversion pulmonary venous return c pulmonary vein connect normally la large left right intracardiac shunt led significant right ventricular dilation tricuspid regurgitation underwent successful anatomical repair transcatheter implantation covered stent lsvc c redirecting pulmonary venous return la year follow exercise capacity improved cardiac imaging showed complete seal lsvc defect without obstruction pulmonary venous return discussion case first knowledge report unusual anatomic variant lsvc la connection complete repair transcatheter treatment previous case report form lsvc la connection treated surgery device occlusion without reconnection lsvc case highlight efficacy safety innovative percutaneous technique management complex congenital heart lesion meticulous procedural planning modelling simulation vital mitigate risk innovative procedure:0.0593836084688605",
    "71223": "case year old woman history hiv congestive heart failure secondary unknown congenital heart defect hypertension presented emergency department worsening edema room air oxygen saturation percent l oxygen via nasal cannula oxygen saturation percent physical examination notable central cyanosis facial lid edema ii vi holosystolic murmur across right chest radiating entire right back hemithorax decreased breath sound base pulmonary crackle clubbing finger edema bilateral lower extremity patient related lifelong knowledge congenital heart defect seen cardiologist adult asymptomatic yet sedentary one year ago first multiple hospitalization acute decompensated heart failure chest x ray showed massive cardiomegaly right sided calcified aortic arch patchy bilateral infiltrates transthoracic echocardiogram revealed severe right ventricular hypertrophy ventricular septal defect overriding aorta ejection fraction percent consistent unrepaired tof utilized multimodality imaging technique including ct angiography cardiac mri defined cardiac anatomy finding consistent unrepaired tof pulmonary atresia pulmonary artery arose directly aorta confluent fashion via large patent ductus arteriosus major aortopulmonary collateral artery arterialized pulmonary artery aneurysmal dissection mural thrombus formation discussion case illustrates patient rare presentation unrepaired tof pulmonary atresia go undiagnosed adulthood early recognition utilizing multimodality imaging approach lead proper diagnosing hopeful surgical repair provide considerable improvement functional status long term survival:0.0592293898593365",
    "198706": "type aortic dissection taad stanford classification previous cardiac surgery rare serious complication incidence previous site cannulation cross clamping anastomosis vein graft reported potential entry point aortic dissection case aortic dissection rupture neighboring atrial chamber due dense postoperative adhesion report present rare case taad aorto right atrial fistula double valve replacement dvr provide literature review year old japanese man presented exertional dyspnea due severe aortic regurgitation moderate severe mitral regurgitation paroxysmal atrial fibrillation preoperative plain computed tomography ct revealed ascending aorta sinus valsalva diameter mm dvr left atrial appendage laa occlusion performed uneventfully discharged postoperative day pod six month discharge patient complained chest back pain orthopnea appetite loss family doctor firstly diagnosed muscle pain belatedly realized suffered acute heart failure possible taad leading referral hospital contrast enhanced ct echocardiography revealed aorto right atrial fistula caused subacute taad despite medical management heart failure could controlled necessitating emergency surgery operation entry point taad identified healthy aortic wall located behind previous aortotomy mm fistula right atrium observed false lumen fistula closed two polypropylene felted mattress suture false lumen side ascending aorta replaced j graft postoperative magnetic resonance imaging revealed left pontine infarction postoperative examination unremarkable patient transferred another hospital pod six month taad operation underwent debranching thoracic endovascular aortic repair tevar residual descending aortic dissection alive five year since tevar successful closure fistula replacement ascending aorta achieved patient aorto right atrial fistula caused subacute taad dvr laa occlusion preoperative imaging show ascending aorta diameter mm may reasonable discus concomitant replacement aortic root ascending aorta partial hemi arch cannulation strategy line american college cardiology american heart association acc aha class iia guidance given paucity aaf case valve surgery multicenter series registry data needed validate optimal diameter threshold cannulation approach preventing postoperative dissection:0.0587741348222017",
    "42473": "patent arterial duct pad congenital heart abnormality defined persistent patency term infant older three month isolated pad found around full term infant higher prevalence found preterm infant especially low birth weight female male ratio patient asymptomatic duct small moderate large duct characteristic continuous heart murmur loudest left upper chest infraclavicular area typical precordium may hyperactive peripheral pulse bounding wide pulse pressure tachycardia exertional dyspnoea laboured breathing fatigue poor growth common large shunt may lead failure thrive recurrent infection upper respiratory tract congestive heart failure majority case pad identifiable cause persistence duct associated chromosomal aberration asphyxia birth birth high altitude congenital rubella occasional case associated specific genetic defect trisomy rubinstein taybi charge syndrome familial occurrence pad uncommon usual mechanism inheritance considered polygenic recurrence risk rare family isolated pad described mode inheritance appears dominant recessive familial incidence pad also linked char syndrome familial thoracic aortic aneurysm dissection associated patent arterial duct familial patent arterial duct bicuspid aortic valve associated hand abnormality diagnosis based clinical examination confirmed transthoracic echocardiography assessment ductal blood flow made using colour flow mapping pulsed wave doppler antenatal diagnosis possible pad normal structure antenatal life condition sign symptom pulmonary overcirculation secondary left right shunt must excluded coronary systemic pulmonary arteriovenous fistula peripheral pulmonary stenosis ventricular septal defect aortic regurgitation collateral vessel must differentiated pad echocardiogram preterm infant symptomatic heart failure secondary pad treatment may achieved surgical ligation medical therapy blocking prostaglandin synthesis indomethacin ibuprofen transcatheter closure duct usually indicated older child pad preterm low birth weight infant associated significant co morbidity mortality due haemodynamic instability asymptomatic patient small duct normal vital prognosis lifetime risk endocarditis patient moderate large duct significant haemodynamic alteration may develop irreversible change pulmonary vascularity pulmonary hypertension:0.0575601451675353",
    "150142": "severe tricuspid regurgitation especially caused pulmonary hypertension primary tricuspid regurgitation absence pulmonary hypertension unknown etiology rare condition scarce data diagnosis treatment follow particularity surgery indication outcome still clearly known year old woman medical history coronary artery bypass grafting three year ago presented shortness breath low limb edema physical examination revealed prominent bilateral jugular turgescence hepatomegaly peripheral edema left midsternal border holosystolic murmur suggestive tricuspid regurgitation echocardiogram confirmed diagnosis showed preserved right left ventricular dimension function coronary angiography showed new obstructive lesion patent surgical graft right cardiac catheterization revealed mild pulmonary hypertension increased right atrium pressure cardiac magnetic resonance showed mild right ventricular dilation normal systolic function normal left chamber late gadolinium enhancement detected persistent symptom even optimization medical therapy patient submitted tricuspid valve replacement surgery immediately surgery patient developed significant right ventricular dysfunction need continuous hemodynamic support progressive clinical recovery confirmed serial echocardiogram showed improvement right ventricular volume function patient discharged sign symptom right heart failure histopathological examination showed significant diffuse myxomatous degeneration leaflet sign infection vegetation disruption strand observed report illustrates rare case symptomatic primary isolated severe tricuspid regurgitation caused myxomatous degeneration leaflet thoroughly diagnostic workup presented histopathological analysis leaflet revealed etiologic process surgical treatment indicated onset right ventricular failure essential patient full recovery:0.0572657995379697",
    "179083": "year old man history new york heart association nyha class iii heart failure paroxysmal atrial fibrillation presented recurrent chest pain exertional dyspnea exercise intolerance diagnosed acute myocardial infarction underwent stenting left anterior descending artery hospitalization transthoracic echocardiography revealed sinus venosus atrial septal defect asd moderate tricuspid regurgitation right heart dilation raising suspicion partial anomalous pulmonary venous drainage papvd imaging confirmed cm sinus venosus asd left right shunt papvd right superior pulmonary vein superior vena cava svc persistent left svc draining coronary sinus coronary angiography demonstrated multivessel coronary artery disease patient underwent successful surgical correction including coronary artery bypass grafting intracardiac repair rerouting anomalous pulmonary vein left atrium asd closure using autologous pericardial patch postoperative recovery uneventful aside transient supraventricular tachycardia preserved sinus node function conduction abnormality need pacemaker two follow echocardiograph demonstrated normalization right heart dimension resolution shunt preserved ejection fraction case underscore importance considering congenital anomaly adult patient new worsening cardiac symptom particularly incidental finding emerge evaluation ischemic heart disease:0.0570135143535733",
    "179813": "aorto cameral fistula acf rare abnormal communication aorta cardiac chamber often resulting trauma ruptured sinus valsalva aneurysm infective endocarditis aortic dissection iatrogenic cause clinical presentation vary asymptomatic case severe hemodynamic compromise including heart failure arrhythmia sudden cardiac death present year old female exertional dyspnea fatigue year penetrating chest trauma transthoracic echocardiography cardiac ct revealed mm fistulous connection right sinus valsalva right ventricular outflow tract surgical repair cardiopulmonary bypass successfully closed defect prolene suture confirmed intraoperatively without residual shunting aortic valve dysfunction patient recovered uneventfully discharged postoperative day four case highlight diagnostic challenge chronic traumatic acf emphasizes importance multimodal imaging early detection timely surgical intervention prevent long term hemodynamic deterioration given potential delayed complication clinician maintain high index suspicion post traumatic cardiac fistula even year initial injury:0.0565961945098688",
    "194736": "introduction ilio iliac arteriovenous fistula iiavf secondary rupture common iliac artery aneurysm ciaa rare sudden arteriovenous shunting subsequent fistula enlargement result acute cardiac failure immediate diagnosis treatment required however clinical symptom differ free wall rupture aortic aneurysm making quick diagnosis difficult thus reported case patient severe right sided cardiac failure due arteriovenous shunt formation secondary iiavf underwent artificial blood vessel replacement favorable result case presentation year old male patient presented hospital polypnea palpitation initial early phase computed tomography ct revealed mm diameter right ciaa inferior vena cava ivc dilatation severe congestive heart failure due arteriovenous shunt formation secondary iiavf diagnosed massive shunt blood flowed right common iliac artery cia right common iliac vein civ underwent emergency open abdominal aortic replacement ivc ran anomalously anterior giant right ciaa strongly adhered ivc right civ two guidewires inserted bilateral femoral vein ivc intraoperatively moreover occlusion balloon inserted right civ thus bleeding fistula well controlled time aneurysm opening proximal side artificial graft anastomosed abdominal aorta right left peripheral branch prosthesis anastomosed right external iliac artery left cia respectively conclusion reported case giant right ciaa directly created shunt right civ contrast enhanced ct useful method confirming working diagnosis iiavf particular case ivc anomaly strong perivenous tissue adhesion bleeding controlled using device occlusion balloon meticulous surgical plan:0.0561043555839422"
  },
  "Topic 4": {
    "90982": "medical management chronic illness consumes percent every health care dollar spent united state provision economical accessible high quality chronic disease care continuing concern across health care setting type diabetes hypertension hyperlipidemia congestive heart failure prime example common chronic disease cause substantial morbidity mortality require long term medical management support disease condition majority care occurs outpatient setting well established clinical practice guideline used guide treatment decision despite availability guideline practice recommendation often implemented contributes suboptimal clinical outcome shortage primary care clinician outpatient care setting identified barrier provision comprehensive chronic disease care provides impetus develop test strategy expanding role responsibility member interdisciplinary team help meet continually increasing need chronic disease care effort serve veteran improve quality efficiency chronic disease care department veteran affair va implementing patient aligned care team pact model primary care transformation build widely disseminated effort chronic care model va pact adaptation patient centered medical home includes following core principle wide ranging team based care patient centered orientation toward whole person care coordinated across element health care system patient community enhanced access care us alternative method communication system based approach quality safety va pact clinical team may include nurse registered nurse rn licensed practical nurse lpn well primary care provider clinical pharmacist behavioral health specialist clinic facilitator organizing principle care team utilize personnel highest level skill set institute medicine recommended expansion nurse role responsibility allow practice full extent education training report contribution nurse improving access quality care patient selected chronic condition using detailed structured protocol developed consultation physician began late robust evidence supporting effectiveness nurse providing patient education chronic disease treatment self care management secondary prevention strategy well ability nurse practitioner np provide effective cost effective primary care largest segment health care workforce nurse ideally suited collaborate professional meeting increasing demand chronic care nurse experienced accustomed working multidisciplinary team clearly defined clinical protocol additional training safely practice beyond usual scope practice may well able order relevant diagnostic test adjust routine medication regimen appropriately refer complicated unstable patient medical evaluation va process developing protocol policy expanding nurse role member pact team protocol contains series action accordance current clinical guideline standard practice implemented nurse manage patient condition va emerging interest allowing nurse practice expanded role includes medication initiation titration guideline protocol lack certainty regarding outcome associated use clinical protocol non np nurse expanded role led va commission evidence synthesis thus synthesized current literature describe effect nurse managed protocol outpatient management adult high impact chronic condition type diabetes hypertension hyperlipidemia congestive heart failure chf:0.0976408956117193",
    "170537": "background cardiovascular disease common cause death worldwide highlighting need study determine option palliative care within management patient heart failure although promising example integrated palliative care heart failure intervention heterogeneity term country healthcare setting multidisciplinary team delivery mode delivery intervention component hence review vital identify work circumstance integrating palliative care heart failure objective develop programme theory context desired outcome occur use programme theory co produce stakeholder key implication inform best practice future research design realist review literature underpinned realist meta narrative evidence synthesis evolving standard quality reporting standard data source search bibliographic database conducted november using following database embase medline psycinfo amed hmic cinahl relevant document identified via alert stakeholder group review method realist review theory orientated explanatory approach synthesis evidence realist synthesis used synthesise evidence successful implementation integrated palliative care heart failure depends context people involved realist synthesis followed pawson five iterative stage locating existing theory searching evidence document selection extracting organising data synthesising evidence drawing conclusion recruited international stakeholder group n including national health service management healthcare professional involved delivery palliative care heart failure policy community group plus member public patient advise give u feedback throughout project along health education england disseminate finding result total document identified met inclusion criterion narrowed included document based programme theory discussion stakeholder realist analysis developed refined overarching context mechanism outcome configuration sub context mechanism outcome configuration realist synthesis literature stakeholder feedback helped uncover key intervention strategy likely support integration palliative care heart failure management included protected time evidence based palliative care education choice educational setting e g online face face hybrid importance increased awareness benefit palliative care key intervention strategy emotive intellectual need integrating palliative care heart failure via credible champion seeing direct patient benefit prioritising palliative care heart failure guideline practice implication finding outlined capability opportunity motivation behaviour model limitation realist approach analysis mean finding based interpretation data future work future work use implication initiate optimise palliative care heart failure management conclusion ongoing refinement programme theory stakeholder meeting allowed u co produce implication implication outline required step ensure core component determinant behaviour place key player capacity opportunity motivation integrate palliative care heart failure management study registration study registered prospero crd funding award funded national institute health care research nihr health social care delivery research programme nihr award ref nihr published full health social care delivery research vol see nihr funding award website award information:0.0833001179206148",
    "168460": "context heart failure high growing global prevalence morbidity mortality leading cause death serious health related suffering low middle income country person centred care pcc critical component high quality healthcare particularly vital context serious illness heart failure however limited data exploring pcc population low middle income setting aim aim study explore clinical service could respond pcc need individual living heart failure thailand potential adaptation setting specific objective understand experience need person living heart failure caregiver hcps ii explore specific practical action help deliver pcc heart failure patient setting method cross sectional qualitative study depth semi structured interview conducted thailand heart failure patient n caregiver n healthcare professional n framework analysis conducted deductive coding populate priori coding frame based santana et al pcc model giusti et al systematic review inductive coding novel finding expand frame study reported accordance consolidated criterion reporting qualitative research guideline coreq result finding reveal specific practice action deliver pcc person living heart failure thailand compassionate communication healthcare professional ii effective teamwork amongst multidisciplinary healthcare professional iii proactive response physical psychosocial relational information need patient caregiver iv engaging patient family symptom management v providing opportunity patient cared community vi responding social determinant health illness healthcare access conclusion person centred healthcare system must aim address social determinant illness place focus community home based care heart failure patient caregiver must supported self manage including recognise symptom take appropriate action delivering pcc way potential improve outcome patient enhance patient sense agency experience care improve health equity reduce hospital admission relieving pressure hospital system reducing overall cost care:0.0817081248882489",
    "62759": "background reported rise number people chronic illness also referred long term disease western world one hundred million people united state least one chronic condition united kingdom uk many million adult may living chronic disease new model care developed recognise complexity managing care overlap wider community health care system provider organisation example chronic care model expert patient programme new model herald shift away idea chronically ill patient passive recipient care towards active engagement partnership health professional managing care partnership ideally involves collaborative care self management education may support self care alongside medical preventative health maintenance intervention context nature patient practitioner consultation promoting self care take new importance objective overall objective review determine best available evidence regarding promotion support self care management adult living community chronic illness patient practitioner encounter specifically review sought determine effectiveness patient practitioner encounter promoting supporting self care management people chronic illness individual organisational factor help hinder recognition promotion support chronic disease self care management strategy similarity difference effectiveness defined context patient different practitioner inclusion criterion review focussed self caring adult aged nineteen year older living community physical chronic illness currently treated patient example people diabetes asthma arthritis coronary disease lung disease heart failure epilepsy kidney disease inflammatory bowel disease since patient meet various professional variety community setting regarding care practitioner review included doctor physician general practitioner nurse nurse specialist dietician podiatrist community health worker variety outcome measure used evaluate effective self care management included physiological measurement hba c blood pressure body weight lipid lifestyle measurement example physical activity self care determinant knowledge attitude self care behaviour regarding example diet physical exercise medication outcome measure used explore meaningfulness patient practitioner encounter concerned patient physician nurse view perception self care management support review considered type quantitative qualitative evidence regarding patient practitioner encounter self care chronic illness focus quantitative study reviewed included systematic review randomised controlled trial rcts quasi experimental study survey study qualitative study reviewed included interview design vignette technique qualitative evaluation grounded theory exploratory descriptive design search strategy search sought find published unpublished study year deemed appropriate since precedes development chronic care model self management support people living chronic illness heralded important part care management initial search cinahl medline database undertaken identify appropriate search term regarding self care chronic illness search strategy developed using identified mesh heading key word following database searched ovid cinahl ovid medline r ovid embase ovid ebm review cdsr acp journal club dare cctr assia sigle digital dissertation british library zetoc service data collection thirty two paper considered applicable review topic title abstract two reviewer used appropriate critical appraisal instrument designed joanna briggs institute jbi assess methodological quality paper retrieved review agreed paper inclusion total paper reporting study included review paper reported study quantitative study qualitative study study using mixed method paper heterogeneous nature diverse subject matter considered wide range physiological psychological sociological behavioural self care outcome measure data extracted two independent reviewer using variety data extraction instrument developed jbi data analysis heterogeneous nature quantitative study prevented meta analysis study presented narrative summary meta synthesis qualitative data performed six qualitative piece following process meta synthesis set jbi qari software package process meta synthesis embodied programme involves aggregation synthesis finding seven synthesis produced fifty finding result effective patient centeredness established patient able discus idea self care action including lifestyle management unhurried fashion practitioner time willing listen patient centred intervention aimed provider patient centred training patient centred material shown positive effect patient centeredness encounter effect self care outcome clear intervention directed enhancing patient participation encounter shown effect diabetes self care self behaviour nurse shown effective role educating patient facilitating adherence treatment patient found nurse approachable study showed given choice patient likely contact nurse doctor regarding care professional intervention education organisational intervention management regular review follow shown improve process outcome management patient practitioner encounter patient orientated intervention added professional organisational intervention patient education role nurse enhanced patient health outcome improved different patient orientated intervention reviewed highlighted element effectively support self care management patient practitioner encounter information giving including use guidebook use care plan structure treatment using checklist education support staff collaboratives comprehensive well paced user friendly information effective supporting promoting self care management variety way informs reassures patient family used doctor patient consultation assist communication doctor patient may help patient feel involved care information effect self care management important given diagnosis onwards implication good self care management relation long term health outcome established care plan self management plan useful facilitating patient discussion self care action lifestyle management organisational factor affect opportunity professional support patient self care management include time resource existing configuration expectation consultation opportunity open access appointment ability see doctor early referral professional group correlational design study indicated individual psychological factor attachment style autonomy support given patient patient practitioner encounter relationship self care behaviour outcome correlational design study indicated general communication diabetic specific communication used patient practitioner encounter positive effect patient self care management outcome patient diabetes consultation self care patient chronic illness tend medically focussed always include discussion patient view routine self care action lead tension unresolved issue patient professional study context diabetes self management reveal professional effectively support patient number way include assisting orientation patient towards skill competency needed self care sharing knowledge information endorsing patient view reliable accurate source information physiological function trusting patient interpretation physiological function modifying advice response patient accordance bodily cue experience conclusion nature patient practitioner encounter multifaceted involving patient professional organisational factor patient orientated intervention effective effecting positive self care behavioural health outcome patient participation patient practitioner encounter key factor influencing self care outcome patient self care management involves social well medical management professional need recognise value patient view experience order support self care management implication practice patient need information diagnosis onwards enable good self care management important enable patient participation patient practitioner encounter patient self care need addressed opportunity patient talk diet routine lifestyle management need incorporated encounter extra time consultation may required care plan help facilitate discussion support patient self care management sharing medical nursing knowledge recognition value patient knowledge experience vital nurse relate well patient want discus self care management professional intervention organisational intervention improve management patient practitioner encounter patient orientated intervention addition good management encounter improve health care outcome implication research patient focussed intervention positive effect patient self care outcome research regarding patient self care health outcome behaviour needed establish patient focussed intervention particular effective qualitative research proved important understanding different way professional patient approach self care management encounter qualitative research would assist understanding process inspire effective partnership patient professional support establishment self care management chronic illness:0.0813884876784812",
    "193463": "background enable educate nurture advise life end model nurse led early palliative care originally developed u patient advanced cancer family caregiver adapted patient heart failure enable coaching topic include problem solving communication advance care planning symptom management self care purpose paper detail qualitative study protocol assess cultural acceptability enable among heart failure patient family caregiver iran method qualitative study employ reflexive thematic analysis rta guide cultural adaptation enable model study conducted two phase phase enable content translated validated persian using forward backward translation process expert panel review ensure linguistic cultural appropriateness phase semi structured interview conducted individual living hf caregiver healthcare provider tehran university medical science one one semi structured interview explore three main area primary need challenge faced individual heart failure family caregiver extent patient involvement healthcare decision making participant preference content delivery method enable maximum variation sampling employed ensure diverse representation data collection continue saturation achieved interview audio recording transcribed verbatim analyzed using braun clarke reflexive thematic analysis approach analysis involve iterative coding identify pattern development theme align core component enable model ensuring cultural relevance trustworthiness rigor ensured reflexivity peer debriefing data triangulation ensuring credible robust finding guide cultural adaptation enable model iran discussion study develop framework adapting enable model iran offering insight cultural contextual factor influencing palliative care adapted model aim enhance quality life individual hf caregiver addressing gap palliative care delivery iran:0.0807060838481568",
    "91662": "background end life may time high service utilisation older adult transition care setting occur frequently may produce little improvement symptom control quality life patient ensuring patient experience co ordinated care move occur individual need rather system imperative crucial patient well containing health care cost objective aim study understand experience influence consequence transition setting older adult end life three condition focus study chosen represent differing disease trajectory setting england participant thirty patient aged year last year life diagnosed heart failure lung cancer stroke caregiver decedent aged year died heart failure lung cancer stroke chronic obstructive pulmonary disease selected cancer provider commissioner service primary care hospital hospice social care ambulance service design method mixed method study composed four part depth interview older adult qualitative interview structured questionnaire bereaved carers older adult decedent telephone interview care commissioner provider using case scenario derived interview carers analysis linked hospital episode statistic he mortality data relating hospital admission heart failure lung cancer england result transition care setting last year life common component end life care across data set made study many move made shortly death patient carers experience transition disjointed system organisational process prioritised individual need many case family carer co ordinator provider care home excluded participation institutional care lacking information support extend role confidence general practitioner gp valued central figure end life care across setting though discipline critical gps expertise adherence guideline hour service care home identified many contributor unnecessary transition good relationship communication professional different setting sector recognised family one important influence transition rarely acknowledged staff conclusion development shared understanding professional carer role end life transition may one effective way improving patient experience patient carers manage many aspect end life care identifying way extend skill strengthen voice particularly hospital setting would welcomed may reduce unnecessary end life transition experience carers appear changed little despite implementation range relevant policy important question answered recommendation future research include relationship policy intervention experience end life carers identification way harmonise understanding carers role strengthen voice particularly hospital setting identification way reduce influence interprofessional tension end life care development intervention enhance patient experience across transition funding national institute health research health service delivery research programme:0.0805774647003229",
    "94905": "background series systematic review summarised evidence regarding intervention reduce preventable hospital admission although intervention effect dependent context review revealed consistent picture reduction across different intervention targeting cardiovascular respiratory condition research reported sought provide depth understanding intervention shown reduce admission condition may work view supporting effective implementation practice objective map available evidence intervention used uk nh reduce preventable admission cardiovascular respiratory condition conduct realist synthesis implementation evidence related intervention method mapping review six database searched study published october study included conducted uk usa canada australia new zealand recruited adult cardiovascular respiratory condition evaluated described intervention could reduce preventable admission admission descriptive summary key characteristic included study produced study included mapping review helped inform sampling frame subsequent realist synthesis wider evidence base also engaged supplementary searching data extraction form developed using appropriate framework implementation framework intervention template realist logic template following identification initial programme theory theoretical literature empirical study insight patient public involvement group review team extracted data evidence table programme theory examined individual intervention type collectively set resultant hypothesis functioned synthesised statement around explanatory narrative referenced underpinning evidence base developed additional search mid range overarching theory carried using google scholar google inc mountain view ca usa result total publication included mapping review largest group originated usa included study uk showed similar distribution map whole evidence country specific feature prominence study telehealth realist synthesis found intervention strong evidence effectiveness overall necessarily demonstrated effectiveness uk setting could barrier using intervention nh facilitation implementation intervention often reported inadequately reported many intervention diverse way delivered also considerable overlap content intervention role specialist nurse highlighted several study five programme theory identified supported varying degree empirical literature provided valuable insight limitation research conducted small team time resource limited team ability consult full range stakeholder conclusion overall implementation appears favoured support self management patient family carers support service signpost patient consider alternative seeing general practitioner appropriate recognition possible reason patient seek admission support health care professional diagnose refer patient appropriately support workforce role promote continuity care co ordination service future work research focus understanding discrepancy national international evidence transferability finding different context design evaluation implementation strategy informed theory intervention implemented might work qualitative research decision making around hospital referral admission funding national institute health research health service delivery research programme:0.0801369634882328",
    "47178": "background living heart failure complex situation family caregiver many study addressing challenge faced heart failure family caregiver already conducted western societal setting sociocultural factor perspective influence family caring experience role ethnic culturally based difference family caring behavior make subject worth exploration clarification purpose study explores experience family caregiver iran caring patient heart failure method descriptive exploratory qualitative approach applied gain authentic insight experience participant purposive sampling used recruit family caregiver three educational hospital isfahan iran data collected using semistructured interview field note interview field note transcribed verbatim concurrently analyzed result three major theme emerged analysis transcript caregiver uncertainty lack familial organizational support allah centered caring participant believed basic knowledge related disease drug addition received little guidance healthcare team lack support insurance well financial issue major problem faced caregiver accepted providence allah noted allah always help accomplish caregiving responsibility conclusion implication practice care performed caregiver patient heart failure exceeds individual capability nurse healthcare provider health policy maker may use finding study develop effective program address challenge provide effective support sociocultural factor perspective primary factor affecting caregiving experience participant study improved understanding factor perspective help healthcare provider develop implement suitable intervention program caregiver healthcare professional develop context based intervention program promote caregiver capability encourage caregiver participate facilitate caregiving role caregiver:0.0800286479933824",
    "87792": "background north america industrialized country heart failure hf become national public health priority study indicate significant heterogeneity approach treat manage hf suggest targeted change health care delivery needed reduce unnecessary health care utilization optimize patient outcome recent published study reported care hf patient tertiary care hospital perspective non specialist stakeholder hf management general practitioner clinic hospital administrator rarely considered study explores current state community based hf care canada experienced various healthcare stakeholder providing coordinating care hf patient method study employed qualitative exploratory research design consisting semi structured telephone interview conducted health care provider health care administrator working outside tertiary care four populous canadian province modified thematic analysis process used different data source triangulated finding collectively interpreted author result twenty eight participant recruited study eight cardiologist five general practitioner family physician eight nurse practitioner registered nurse four hospital pharmacist three health care administrator director participant reported lack stakeholder engagement throughout continuum care hinders implementation coordinated approach quality hf care four substantive theme emerged indicated challenge gap optimal treatment management hf community setting challenge risk assessment early diagnosis hf challenge ensuring efficient consistent transition acute care setting community challenge primary care provider optimally treat manage hf patient challenge promoting holistic approach hf management conclusion health system evolve tertiary based care community based outpatient service management chronic disease study finding pinpoint challenge observed canadian context stimulate orient dialogue toward solution coordinated approach improve care hf patient reduce pressure healthcare system:0.0799554048980130",
    "197565": "background heart failure complex syndrome affecting million people globally average patient age year management challenge include medication titration difficulty patient self management issue care home housing approximately resident heart failure face unique challenge managing condition study aimed investigate care home staff experience supporting resident heart failure method glaserian grounded theory approach employed explore perception challenge strategy used care home staff supporting resident heart failure twenty care home staff member northern ireland varied role experience level participated online semi structured interview interview audio recorded transcribed verbatim data collection analysis occurred concurrently following theoretical sampling principle february march three stage coding process open axial selective used analysis rigour ensured member checking data source triangulation reflexivity ethical approval obtained prior data collection result three main category developed data training support communication training revealed care home staff received limited education heart failure management primarily focused acute setting rather chronic care needed care home support highlighted various facilitator barrier staff faced making clinical decision regarding heart failure care communication addressed experience staff engaging resident family managing heart failure category linked core category c empowerment encompassed challenge staff faced training support communication empowerment illustrated staff navigated obstacle provide effective heart failure care within unique context care home discussion study highlight significant challenge managing heart failure care home including inadequate training limited professional development insufficient support system key barrier include lack specialist education tailored long term care setting restricted access heart failure specialist effective communication proactive care identified critical need alongside holistic care approach addressing gap targeted education specialist integration evidence based strategy could empower staff optimise care quality potentially improve outcome resident:0.0797293348341714"
  },
  "Topic 5": {
    "75826": "background previous clinical trial reported ivabradine effectively treat heart failure hf however systematic review explored efficacy safety hf systematic review aim evaluate efficacy safety ivabradine treatment patient hf method search literature following electronic database inception january cochrane central register controlled trial embase mediline web science cumulative index nursing allied health literature allied complementary medicine database chinese biomedical literature database china national knowledge infrastructure vip information wanfang data randomized controlled trial rcts ivabradine hf fully considered inclusion without restriction additionally grey literature including clinical trial registry dissertation reference list included study conference abstract also searched two researcher review literature extract data assess risk bias included rcts separately data pooled either fixed effect model random effect model meta analysis conducted appropriate result primary outcome cause mortality secondary outcome comprise change body weight urine output change serum sodium adverse event conclusion result study summary provide dated evidence assessing efficacy safety ivabradine hf ethic dissemination necessary acquire ethical approval systematic review individual patient data used study result systematic review published peer reviewed journal systematic review registration prospero crd:0.0838283152135236",
    "132881": "objective whether glucose insulin potassium gik used adjuvant therapy ischaemic myocardial disease remains controversial nowadays reperfusion era meta analysis aimed assess effect preinitiated gik patient undergoing planned percutaneous coronary intervention pci design systematic review meta analysis data source pubmed web science medline embase cochrane library clinicaltrials gov searched november eligibility criterion randomised controlled trial involving participant preinitiated gik placebo planned pci included data extraction synthesis two independent reviewer used standardised method search screen code included trial risk bias assessed cochrane tool pooled analysis conducted using random effect model according heterogeneity subgroup analysis carried dosage gik ongoing myocardial ischaemia result randomised controlled trial rcts including participant evaluated found patient preconditioned gik pci showed significant increase thrombolysis myocardial infarction flow event angioplasty ci p also revealed improved hospital left ventricular ejection fraction weighed mean difference wmd ci p myocardial salvage index wmd ci p nevertheless benefit observed cause mortality neither day ci p month ci p furthermore gik intervention associated higher occurrence complication phlebitis ci p hypoglycaemia ci p hyperkalaemia ci p liquid overload ci p hospital heart failure ci p conclusion study show preconditioning gik exhibit myocardial reperfusion cardiac function benefit patient planning receive pci intervention also complication phlebitis hypoglycaemia accompany prospero registration number crd:0.0793359115675172",
    "187598": "introduction chronic disease self management cdsm vital component congestive heart failure chf programme recent chf guideline downgraded cdsm programme citing lack gold standard evidence protocol describes aim method systematic review collate synthesise published research evidence determine effectiveness cdsm programme intervention patient treated chf method medline pubmed embase central cinahl cochrane central register controlled trial psycinfo scopus web science science citation index register clinical trial searched addition reference list shortlisted article reviewed randomised controlled trial case management intervention cdsm chf reported major adverse cardiovascular event mace extracted analysed restriction language study protocol template developed cochrane collaboration reporting adheres preferred reporting item systematic review meta analysis protocol guideline systematic review meta analysis two independent author apply inclusion exclusion criterion limit article search assess bias certainty evidence rating data extraction study description included study include quality appraisal study quantitative synthesis data undertaken ascertain evidence study aim subgroup analysis conducted different cdsm programme primary outcome significant change mace parameter intervention control arm meta analysis conducted using statistical software feasible ethic dissemination ethic approval sought study collecting primary patient data result study disseminated peer reviewed scientific journal also presented audience meeting scientific conference prospero registration number crd:0.0783237309352123",
    "69622": "background chronic heart failure chf one important cardiovascular disease worldly high morbidity mortality fuling sini decoction fsd used management chf widely china effective evidence clear systematic review meta analysis evaluate fsd chf lacking hence propose protocol systematic evaluation efficacy safety chf method search following electronic database inception october including embase cochrane center registration controlled trial cochrane library pubmed medline international clinical trial registry platform china biomedical literature database cbm china national knowledge infrastructure cnki chinese scientific journal database vip wan fang database randomized controlled trial rcts fsd alone combined management chf included two independent reviewer screen literature extract data according cochrane handbook method assessment bias risk data synthesis subgroup analysis meta analysis finally meta analysis performed using revman v software result systematic review provide high quality evidence may first evaluate efficacy safety fsd treatment chf conclusion systematic review provide evidence judging whether fsd effective management chf prospero registration number crd:0.0770485940202673",
    "195735": "background effectiveness adverse effect coenzyme q heart failure remain unclear owing small sample size variation quality existing study literature method database embase pubmed web science cinahl database scopus cochrane central register controlled trial vip wanfang cnki searched randomized controlled trial coenzyme q assisted treatment heart failure relevant literature retrieved data extracted risk bias included study evaluated two investigator independently using review manager software stata software result total study included meta analysis showed cause mortality rr ci p grade moderate quality hospitalization heart failure rr ci p grade moderate quality new york heart association classification md ci p grade low quality brain natriuretic peptide level md ci p grade low quality lower coenzyme q group control group meanwhile left ventricular ejection fraction md ci p grade low quality min walk test result md ci p grade moderate quality better control group conclusion according existing evidence coenzyme q reduces cause mortality hospitalization heart failure new york heart association classification brain natriuretic peptide level improves left ventricular ejection fraction min walk test result heart failure without major adverse effect trial registration study protocol registered international prospective register systematic review prospero http www crd york ac uk prospero registration number crd:0.0770478644487595",
    "99215": "background sacubitril valsartan first class angiotensin receptor neprilysin inhibitor used treat heart failure evidence novel medication largely based one pivotal phase iii trial stopped early due significant clinical benefit shown however potential limitation trial design highlighted recent literature necessitating thorough review evidence sacubitril valsartan method review conducted using prisma reporting guideline relevant randomised controlled trial rcts sacubitril valsartan systematically searched medline pubmed embase cochrane library google scholar web science toxline scopus clinical trial registry searched eight grey literature database addition unpublished clinical study report csrs relevant trial requested european medicine agency ema clinical study data request database study included involve randomising adult patient heart failure either sacubitril valsartan usual care either active comparator placebo control heart failure subtype nyha class included relevant clinical safety outcome reviewed particularly hospitalisation due heart failure cardiovascular mortality two reviewer assess eligibility selected study inclusion data extraction performed separately trial publication clinical trial registry csrs using piloted form methodological quality included trial published source assessed separately using cochrane risk bias tool rob narrative synthesis included study conducted appropriate meta analysis clinical efficacy safety outcome discussion review collate available rct data sacubitril valsartan including published unpublished source order obtain complete picture evidence base sacubitril valsartan registration protocol registered prospero reference crd:0.0769488200561633",
    "160535": "background patient heart failure high rehospitalisation rate poor cardiovascular outcome home based monitoring hbm emerged promising result different setting however long term effect patient recently admitted acute decompensated heart failure adhf remain uncertain method systematically searched pubmed embase cochrane library randomised controlled trial rcts comparing hbm usual care uc published database inception june included study patient admitted adhf previous month minimum follow month excluded study patient hospitalised reason adhf study disproportional education intervention arm statistical analysis performed using r software version pooled risk ratio rr mean difference md confidence interval ci categorical continuous outcome respectively cochrane collaboration tool assessing risk bias rcts rob used assess study quality publication bias assessed via funnel plot egger test heterogeneity assessed statistic sensitivity analysis protocol systematic review meta analysis registered international prospective register systematic review prospero crd finding included rcts comprising patient randomised hbm men follow ranged six fifteen month compared uc hbm significantly reduced cause mortality rr ci p cause hospitalisation rr ci p cardiovascular cv mortality rr ci p hospitalisation heart failure rr ci p cv hospitalisation rr ci p significant difference length hospital stay md day ci p interpretation patient recently admitted adhf hbm significantly reduces long term cause mortality hospitalisation cv mortality hospitalisation hospitalisation heart failure compared uc support implementation hbm standard practice optimise patient outcome following admission adhf however future study warranted evaluate efficacy safety implementing hbm real world setting funding none:0.0760642451885616",
    "122165": "objective estimate combined effect educational intervention ei decreased readmission time hospital stay adult heart failure compared usual care method systematic review sr meta analysis randomized controlled trial followed recommendation prisma statement protocol registered prospero crd search made inception july database pubmed medline embase cochrane central lilac web science scopus conducted random effect model effect measure used dichotomous outcome relative risk rr continuous outcome mean difference md used confidence interval ci heterogeneity evaluated inconsistency statistic result study identified included sr study follow six month showed decrease readmission rr ci month follow evidenced reduction rr ci analysis favor ei group regarding time hospital stay reduction found approximately two day patient received ei md ci conclusion finding support benefit ei reduce readmission day hospital stay adult patient heart failure:0.0760088751393549",
    "172536": "background heart failure hf global health concern affecting million individual worldwide leading significant morbidity mortality despite advance conventional therapeutic strategy prognosis hf patient remains challenging constant search novel therapeutic option among panax quinquefolius saponin pqs demonstrated promising pharmacological property may benefit hf however efficacy safety pqs hf comprehensively evaluated objective systematic review meta analysis aim provide reliable estimation efficacy safety pqs hf help clinician make informed decision regarding potential use pqs managing hf patient method comprehensively systematically searched published randomized controlled trial rcts following eight electronic database pubmed cochrane library embase web science wos china national knowledge infrastructure cnki china science technology journal database vip wanfang data china biology medicine database cbm database inception march cochrane risk bias rob assessment tool used quality assessment review manager revman version used meta analysis mean difference md credible interval ci relative risk rr estimate calculated random effect model also used grade profiler gradepro version analyze quality outcome addition protocol registered international platform registered systematic review meta analysis protocol inplasy registry number result study included nine rcts involving total patient hf result meta analysis random effect model showed adjuvant pqs therapy significantly increased lvef md ci p mwtd md ci p decreased bnp nt pro bnp md ci p lvedv md ci p lvedd md ci p lvesv md ci p patient hf conclusion evidence provided systematic review suggests adjunctive pqs therapy hf improved clinical efficacy hold potential advantage improving cardiac function increasing exercise tolerance however given limitation inherent review conclusion study interpreted cautiously therefore clinical practice recommended physician tailor treatment strategy according specific circumstance individual patient systematic review registration http inplasy com:0.0755495678668619",
    "89130": "background cell transplantation offer potential therapeutic approach repair regeneration damaged vascular cardiac tissue acute myocardial infarction ami resulted multiple randomised controlled trial rcts across world objective determine safety efficacy autologous adult bone marrow stem cell treatment acute myocardial infarction ami focusing clinical outcome search method cochrane review update previous version published searched cochrane central register controlled trial central issue medline march embase march cinahl march transfusion evidence library march addition searched several international ongoing trial database march handsearched relevant conference proceeding january selection criterion rcts comparing autologous bone marrow derived cell cell patient diagnosed ami eligible data collection analysis two review author independently screened reference assessed risk bias included trial extracted data conducted meta analysis using random effect model throughout analysed outcome short term less month long term month follow dichotomous outcome reported risk ratio rr continuous outcome reported mean difference md standardised md smd performed sensitivity analysis evaluate result context risk selection performance attrition bias exploratory subgroup analysis investigated effect baseline cardiac function left ventricular ejection fraction lvef cell dose type timing administration well use heparin final cell solution main result forty one rcts total participant cell therapy control eligible inclusion cell treatment associated change risk cause mortality versus rr ci participant study moderate quality evidence cardiovascular mortality versus rr ci participant nine study moderate quality evidence composite measure mortality reinfarction hospitalisation heart failure versus rr ci participant six study moderate quality evidence long term follow statistical heterogeneity low serious periprocedural adverse event rare generally unlikely related cell therapy additionally cell therapy effect morbidity quality life performance lvef measured magnetic resonance imaging meta analysis lvef measured echocardiography single photon emission computed tomography left ventricular angiography showed evidence difference mean lvef treatment group although mean difference ranged accepted clinically relevant result robust risk selection performance attrition bias individual study author conclusion result review suggest insufficient evidence beneficial effect cell therapy ami patient however evidence come small trial showed difference clinically relevant outcome adequately powered trial needed efficacy intervention remains unproven:0.0753787887295760"
  },
  "Topic 6": {
    "177498": "objective evaluate potential value machine learning ml model using radiomic feature late gadolinium enhancement lge cine image magnetic resonance imaging mri along relevant clinical information conventional mri parameter prediction major adverse cardiac event mace st segment elevation myocardial infarction stemi patient method retrospective study included patient first stemi mace consisted new onset congestive heart failure ventricular arrhythmia cardiac death radiomic feature extracted cine lge image inter class correlation coefficient icc calculated assess inter observer reproducibility lasso least absolute shrinkage selection operator method used radiomic feature selection seven separate model using different combination available information investigated classification repeat random sampling done using adaptive boosting k nearest neighbor naive bayes neural network random forest stochastic gradient descent support vector machine algorithm result extracted radiomic feature showed good inter observer agreement lasso feature selected among ml algorithm neural network showed highest predictive performance average area curve auc best calculated model one using clinical parameter cmri parameter selected radiomic feature model diagnostic performance follows auc classification accuracy sensitivity specificity positive predictive value ppv negative predictive value npv conclusion radiomics based ml model incorporating clinical conventional mri parameter promising predicting mace occurrence stemi patient follow period key point acute coronary occlusion result variable change cellular level ranging myocyte swelling myonecrosis depending duration ischemia metabolic state heart cause subtle heterogeneous signal change imperceptible human eye cardiac mri radiomics based machine learning analysis cardiac mr image promising risk prediction combining mri derived parameter clinical variable increase accuracy predictive model:0.0542164167244329",
    "152072": "background acute pulmonary embolism ape fatal cardiovascular disease yet missed diagnosis misdiagnosis often occur due non specific symptom sign simple objective technique help clinician make quick precise diagnosis population study machine learning ml play critical role characterizing cardiovascular risk predicting outcome identifying biomarkers work sought develop ml model helping ape diagnosis compare current clinical probability assessment model method single center retrospective study patient suspected ape continuously enrolled randomly divided two group including training testing set total ml model including random forest rf naive bayes decision tree k nearest neighbor logistic regression multi layer perceptron support vector machine gradient boosting decision tree developed based training set diagnose ape thereafter model best diagnostic performance selected evaluated current clinical assessment strategy including well score revised geneva score year algorithm eventually ml model internally validated assess diagnostic performance using receiver operating characteristic roc analysis result ml model constructed using eight clinical feature including dimer cardiac troponin ctnt arterial oxygen saturation heart rate chest pain lower limb pain hemoptysis chronic heart failure among eight ml model rf model achieved best performance highest area curve auc auc compared current clinical assessment strategy rf model outperformed well score p inferior clinical probability assessment strategy auc rf model diagnosing ape onset internal validation set conclusion based rf algorithm novel prediction model finally constructed ape diagnosis compared current clinical assessment strategy rf model achieved better diagnostic efficacy accuracy therefore ml algorithm useful tool assisting diagnosis ape:0.0522324340301888",
    "191674": "background aim tuberculous pericarditis tbp severe life threatening complication yet diagnosis highly challenging due lack sufficient diagnostic tool aim study develop validate diagnostic prediction model suitable primary healthcare institution predict risk tbp method collected detailed medical history imaging examination result laboratory test data clinical characteristic patient used least absolute shrinkage selection operator lasso technique combined logistic regression analysis construct predictive model diagnostic efficacy model assessed using receiver operating characteristic roc curve calibration curve decision curve analysis dca result total patient included study median age year diagnosed tuberculous pericarditis patient randomly assigned training validation set ratio lasso logistic regression analysis revealed weight loss p body mass index bmi p history tuberculosis p history dust exposure p moderate severe kidney disease p erythrocyte sedimentation rate esr p b type natriuretic peptide bnp p independent risk factor tbp based factor constructed nomogram area receiver operating characteristic curve auc training validation set indicating high discriminative ability model calibration curve analysis showed good consistency model dca result indicated model significant clinical application value threshold probability set training set validation set conclusion successfully developed nomogram model predicting tuberculous pericarditis assist clinician improving diagnostic accuracy reducing misdiagnoses missed diagnosis primary healthcare setting:0.0518890605936655",
    "175909": "background heart failure hf diabetes mellitus dm frequently coexist exacerbating disease progression increasing hospital readmission risk accurate prediction readmission hf patient dm remains clinical challenge study aim develop validate machine learning ml based model incorporating inflammatory metabolic biomarkers enhance risk stratification method retrospective cohort study included hf patient dm hospitalized january february total patient randomly divided training validation set seven ml model developed using clinical parameter inflammatory marker metabolic index model performance assessed using area receiver operating characteristic curve auc roc calibration sensitivity specificity brier score among others external validation conducted using independent cohort patient shapley additive explanation shap analysis applied model interpretability web based dynamic nomogram developed clinical implementation result among patient readmitted within one year random forest rf model demonstrated superior performance auc brier score outperforming ml model external validation confirmed generalizability auc shap analysis identified age brain natriuretic peptide bnp new york heart association nyha class hf classification triglyceride glucose body mass index tyg bmi key predictor dynamic nomogram provided individualized risk prediction enhancing clinical applicability conclusion study developed ml based model integrating inflammatory metabolic biomarkers predicting readmission hf patient dm model demonstrated robust performance interpretability showing potential supportive tool early risk identification personalized risk communication clinical setting:0.0517723601025762",
    "192249": "background develop machine learning ml based prediction model focused one year mortality risk patient advanced heart failure adhf aiming improve prediction accuracy integrating inflammatory biomarkers clinical parameter assist clinical decision making enhance patient outcome method retrospective cohort study data obtained electronic medical record system affiliated hospital xuzhou medical university adhf patient admitted icu cardiology department january december included one year follow variable potentially affecting prognosis incorporated lasso algorithm used feature selection dimensionality reduction data split training validation set seven ml algorithm applied build evaluate model shap method used model analysis dynamic nomogram created result study included adhf patient random forest rf model performed best area curve auc confidence interval accuracy sensitivity f score key predictor one year mortality risk included beta blocker acei arb arni bnp crp nlr af mi nyha class age shap analysis revealed elevated crp nlr age associated increased risk beta blocker acei arb arni lower bnp value associated reduced risk online dynamic nomogram developed provide personalized risk prediction based patient specific condition conclusion successful ml based prediction model developed accurately predict one year mortality risk adhf patient inflammation driven factor significant rf model integrating clinical feature inflammatory marker showed excellent performance could assist clinical decision making future research conduct larger multi center prospective study validate finding:0.0517053097911783",
    "180773": "background heart failure hf severe common complication type diabetes mellitus dm associated increased morbidity mortality although biomarker nt probnp cut value pg ml demonstrated satisfactory discriminatory power predicting hf risk dm patient measurement remains inaccessible primary healthcare setting china study aimed develop externally validate machine learning based nomogram predicting risk elevated nt probnp pg ml surrogate hf risk patient dm method retrospectively enrolled dm patient development cohort two external center validation cohort feature selection via least absolute shrinkage selection operator regression five machine learning model constructed evaluated using fold cross validation optimal model presented static nomogram deployed online web application clinical use result six key predictor identified estimated glomerular filtration rate age serum albumin hemoglobin urine albumin creatinine ratio binary indicator age year interpretability analysis using shapley additive explanation revealed estimated glomerular filtration rate influential feature final machine learning based nomogram achieved auc ci training ci external validation good calibration clinical utility furthermore nomogram score showed significant positive correlation established trs hf dm risk stratum supporting clinical relevance conclusion developed validated interpretable machine learning based nomogram effectively predicts risk elevated nt probnp dm patient using six routine clinical variable tool demonstrates robust performance generalizability offering practical accessible solution hf risk stratification resource limited primary care setting china:0.0511442862377941",
    "182984": "objective risk stratification patient congestive heart failure hf vital clinical practice aim study construct machine learning model predict hospital cause mortality intensive care unit icu patient hf method extreme gradient boosting algorithm xgboost used construct new prediction model xgboost model medical information mart intensive care iv database mimic iv training set eicu collaborative research database dataset eicu crd used external validation test set xgboost model performance compared logistic regression model existing model get guideline heart failure model mortality test set area receiver operating characteristic cure brier score employed evaluate discrimination calibration three model shapley additive explanation shap value applied explain xgboost model calculate importance feature result total patient congestive hf training set test set respectively included study hospital cause mortality occurred patient respectively training set feature highest predictive value selected model lasso regression acute physiology score iii aps iii age sequential organ failure assessment sofa strongest predictor shap external validation xgboost model performance superior conventional risk predictive method area curve confidence interval brier score evaluation clinical effectiveness machine learning model brought positive net benefit threshold probability prompting evident competitiveness compare two model model translated online calculator accessible freely public http nkuwangkai app mortality prediction app mhkf streamlit app conclusion study developed valuable machine learning risk stratification tool accurately assess stratify risk hospital cause mortality icu patient congestive hf model translated web based calculator access freely:0.0506650507007107",
    "192639": "background although assessment hospital mortality risk among heart failure patient intensive care unit icu crucial clinical decision making currently lack comprehensive model accurately predicting prognosis machine learning technique offer powerful mean identify potential risk factor predict outcome within multivariable clinical data method study based mimic iii database extracted demographic characteristic vital sign laboratory test value comorbidity information heart failure patient using structured query language lasso regression employed feature selection various machine learning algorithm utilized train model including logistic regression lr random forest rf gradient boosting gb among others ensemble learning model based soft voting mechanism constructed model performance evaluated using accuracy recall precision f score auc value cross validation independent test set result five fold cross validation soft voting ensemble learning model demonstrated best overall performance accuracy auc value additionally rf gb model also performed well rf achieving accuracy auc independent test set gb model achieved accuracy auc contrast model lr svm knn exhibited poorer performance term accuracy auc value indicating significant advantage ensemble method handling complex clinical prediction task conclusion study demonstrates potential machine learning model particularly ensemble learning model based soft voting mechanism predicting hospital mortality risk among heart failure patient icu overall performance ensemble learning model confirms effectiveness adjunct clinical decision making tool future research optimize model validate broader patient population enhance practical utility accuracy real clinical setting:0.0505682301895537",
    "194293": "background early prediction heart failure hf acute myocardial infarction ami essential personalized treatment aimed use interpretable machine learning ml method develop risk prediction model hf ami patient method retrospectively included patient initially ami received percutaneous coronary intervention pci hospital november february primary endpoint occurrence hf within year operation developing predictive model hf risk ami patient least absolute shrinkage selection operator lasso regression used feature selection four ml algorithm including random forest rf extreme gradient boost xgboost support vector machine svm logistic regression lr employed develop model training set performance evaluation prediction model carried training set testing set utilizing metric including auc area receiver operating characteristic curve calibration plot decision curve analysis dca addition used shapley additive explanation shap value determine importance selected feature interpret optimal model result total ami patient included patient developed hf follow among four evaluated ml model xgboost model exhibited exceptional accuracy auc value shap method showed left ventricular ejection fraction lvef left ventricular end systolic diameter lvds lactate dehydrogenase ldh identified three important characteristic predict hf risk ami patient individual risk assessment performed using shap plot waterfall plot analysis conclusion research demonstrates potential ml method early prediction hf risk ami patient furthermore enhances interpretability xgboost model shap analysis guide clinical decision making:0.0504849934459073",
    "180026": "objective elderly patient perioperative adverse cardiovascular event pace may poorer prognosis higher mortality early identification patient risk developing pace essential step preventing controlling pace develop validate model predict likelihood pace clarify specific classification pace different risk stratification elderly patient noncardiac surgery integrating clinical data biomarkers established risk factor importantly help support clinical decision making improve patient prognosis method retrospective study included elderly patient undergoing noncardiac surgery six hospital chongqing city china march july logistic regression machine learning algorithm used construct model evaluated receiver operating characteristic curve decision curve calibration curve sensitivity specificity f score used interpret model result diagnostic criterion pace encompassed delirium major adverse cardiovascular event myocardial injury noncardiac surgery new perioperative atrial fibrillation perioperative acute heart failure pain infection cardiovascular event pose threat perioperative safety influence patient prognosis pace identified expert anesthesiologist accordance asa classification day preceding surgery result patient included analysis suspected pace logistic regression model chosen area curve ci pro bnp cardiac function grading creatinine cre related factor pace new composite indicator pcc developed combining initial three indicator logistic regression model decision curve calibration curve indicated indicator respectable clinical value addition machine learning model built accurately predict pace different risk stratification elderly precision recall curve prediction showed low risk precision medium risk precision high risk precision f value greater especially high risk prediction effect reach sensitivity specificity prediction model respectively indicating best predictive performance risk stratification pace therefore reasonably assume two model effectively predict risk pace noncardiac surgery study demonstrated ability accurately identify high risk pace patient using interpretable approach conclusion study established risk prediction model patient pace based patient medical record good predictive accuracy model expected provide scientific basis quickly formulating adjusting diagnostic treatment plan elderly patient provide clinical strategy pace prevention intervention monitoring could potentially reduce mortality risk patient pace:0.0504317784476721"
  },
  "Topic 7": {
    "127956": "heart failure preserved ejection fraction hfpef represents one greatest challenge facing cardiovascular medicine today despite common form heart failure worldwide limited success developing therapeutic syndrome largely due incomplete understanding biology driving systemic pathophysiology heterogeneity clinical phenotype increasingly recognized distinct hfpef phenogroups development efficacious therapeutic fundamentally relies robust preclinical model faithfully recapitulate key feature clinical syndrome also enable rigorous investigation putative mechanism disease context clinically relevant phenotype review propose preclinical research strategy conceptually grounded model diversification aim better align evolving understanding heterogeneity clinical hfpef although heterogeneity often viewed major obstacle preclinical hfpef research challenge notion argue embracing may key demystifying pathobiology first provide overarching guideline developing hfpef model stepwise approach comprehensive cardiac extra cardiac phenotyping present overview currently available model focused leading phenogroups primarily based aging cardiometabolic stress chronic hypertension discus well model reflect clinically relevant phenogroup highlight recent mechanistic insight providing complex pathophysiology underlying hfpef:0.0359839144877329",
    "199391": "obesity chronic multifactorial disease major global public health challenge defined excessive fat accumulation obesity significantly increase risk numerous disease including type diabetes mellitus dm cardiovascular disease heart failure metabolic dysfunction associated steatotic liver disease contributing rising morbidity mortality rate worldwide although several pharmacological treatment demonstrated notable efficacy weight management concern regarding drug safety remain significant challenge metabolic bariatric surgery mb emerged effective intervention achieving long term sustained weight loss however typically reserved advanced stage disease moreover role mb managing obesity related comorbidities remains topic ongoing debate review provide comprehensive analysis epidemiology obesity associated comorbidities along latest insight mechanism underlying obesity induced chronic complication growing evidence highlight crucial role imbalance white brown adipose tissue alteration gut microbiota genetic epigenetic modification immune system dysregulation driving obesity related condition emerging insight unveiled numerous potential therapeutic target promising weight reducing effect furthermore advancement understanding signal transduction pathway may pave way future multimodal therapeutic strategy obesity management ushering new era precision medicine:0.0357370955976298",
    "99550": "cardiovascular disease represent major cause morbidity mortality worldwide multiple study conducted far order develop treatment able prevent progression pathology despite progress made last decade current therapy still hampered poor translation actual clinical application major drawback strategy represented limited regenerative capacity cardiac tissue indeed ischaemic insult formation fibrotic scar take place interfering mechanical electrical function heart hence ability heart recover ischaemic injury depends several molecular cellular pathway imbalance result adverse remodeling culminating heart failure complex scenario new chapter regenerative medicine opened past year discovery induced pluripotent stem cell ipscs cell share characteristic embryonic stem cell escs generated patient specific somatic cell overcoming ethical limitation related esc use providing autologous source human cell similarly escs ipscs able efficiently differentiate cardiomyocytes cm thus hold real regenerative potential future clinical application however cell based therapy subjected poor grafting may cause adverse effect failing heart thus last year bioengineering technology focused attention improvement survival functionality ipsc derived cm combination two field study burst development cell based three dimensional structure organoids mimic realistically vivo cell behavior toward path possibility directly induce conversion fibroblast cm recently emerged promising area situ cardiac regeneration review provide date overview latest advancement application pluripotent stem cell tissue engineering therapeutically relevant cardiac regenerative approach aiming highlight outcome limitation future perspective clinical translation:0.0341770181389110",
    "94946": "purpose review despite major advance term prevention diagnosis risk stratification management rehabilitation atherosclerosis atherothrombosis continue major morbidity mortality implication worldwide since unraveling pivotal role inflammation atherothrombosis pathophysiology several focused treatment proposed ultimate goal preventing treating myocardial infarction stroke peripheral artery disease particular given centrality interleukin il targeted anti il agent attracted substantial attention effort yet uncertainty persists real risk benefit cost benefit balance anti il agent patient risk atherothrombosis recent finding several trial recently completed atherothrombosis prevention treatment anti il agent ranging instance large canakinumab antiinflammatory thrombosis outcome study canto trial series translational study conducted within virginia commonwealth university anakinra remodeling trial vcu art platform light present scoping umbrella review appears evident anti il agent reduce systemic inflammation improve surrogate marker cardiac vascular function potential benefit risk new worsening heart failure one trial suggested increased risk major adverse event anti interleukin agent possibly due rebound phenomenon based post hoc analysis small number event supported pertinent trial canto study showed potential hazard due increased risk fatal infection effect size rather small addition cost issue limit foreseeable scope treatment strategy unselected patient calling instead refined prescribing evidence base risk benefit cost benefit profile anti il agent atherothrombosis prevention treatment expanded substantially last decade largely dominated landmark canto trial effect estimate also including vcu art trial suggest complex short long term effect may prove favorable carefully selected patient acute chronically sustained inflammation conversely liberal use appears less promising study currently available agent novel one eagerly needed better define role era precision molecular medicine:0.0338615183397210",
    "90575": "nanotechnology impacted tremendously medical research increasing importance development new therapeutic approach application among application use nanocarriers gained particular interest order achieve successful delivery therapeutic imaging agent treatment diagnostics different disease cancer infection diabetes lung brain cardiovascular disease heart failure hf complex clinical syndrome derived multiple cause arise secondary inherited acquired abnormality cardiac structure function myocardial infarction mi major cause hf continues increasing problem term morbidity mortality healthcare cost worldwide currently established pharmacological drug proven effective reducing hypertrophy remodeling myocardium reducing morbidity mortality patient hf however despite optimal treatment existing drug prognosis hf poor also possible deleterious effect therapeutic agent must considered used dos required desired therapeutic effect therefore novel therapeutic strategy urgently needed prevent high morbidity mortality associated mi hf review present recent development nanomedicine research envisaged important impact treatment cardiovascular disease particularly mi addition discus use different advanced modified nanosystems molecular imaging therapeutic mi presenting several vitroand vivoexamples finally conclude overview potential nanomedicines future treatment cardiovascular disease:0.0333040851361086",
    "176728": "prevalence heart failure hf developed country reached epidemic proportion continues rise despite therapeutic advance hf remains associated significant morbidity mortality thus constitutes major public health problem necessitates new treatment option cell therapy potential new approach improve outcome hf first introduced two decade ago evolved significantly since although mechanism action remains unclear pivotal large scale trial performed numerous study demonstrated safety using various cell product patient hf several randomized double blind phase ii iii trial shown beneficial effect cell therapy particularly mesenchymal stromal cell msc clinical outcome ischemic nonischemic cardiomyopathy administration single dose cell potential efficacy signal coupled robust record safety provide solid rationale pursuing study conclusively evaluate efficacy new cell type induced pluripotent cell derived myocytes new strategy repeated dos intravenous delivery tested ongoing trial contrast embryonic stem cell unlikely become clinical therapy rigorous well designed large clinical trial potential pave way cell therapy become useful treatment option patient hf review summarizes conceptual clinical progress made understanding cell therapy hf particularly past decade explores future horizon application treatment hf:0.0328284512694254",
    "96259": "rna modulation become promising therapeutic approach treatment several type disease emerging field noncoding rna based therapy come attention cardiovascular research could provide valuable advancement comparison current pharmacotherapy small molecule drug antibody review focus noncoding rna based study conducted mainly large animal model including pig rabbit dog nonhuman primate obstacle promise targeting long noncoding rna circrnas therapeutic modality human specifically discussed also describe novel ex vivo method based human cell tissue engineered heart tissue living myocardial slice could help bridging gap vivo model clinical application future finally summarize antisense oligonucleotide drug already approved food drug administration targeting mrna discus progress noncoding rna based drug clinical trial additional factor drug chemistry drug formulation different route administration advantage rna based drug also included present review recently first therapeutic mirna based inhibitory strategy tested heart failure patient well healthy volunteer study effect wound healing nct nct summary combination novel therapeutic rna target large animal model ex vivo study human cell tissue new delivery technique likely lead significant progress development noncoding rna based next generation therapeutic cardiovascular disease:0.0326584783391254",
    "174630": "considered forgotten valve ventricle tricuspid valve right ventricle recognized critical structure significant clinical prognostic implication growing evidence highlighted tricuspid regurgitation tr right heart failure merely secondary phenomenon resolve following treatment left sided heart disease instead tr right heart failure contribute adverse outcome increased mortality left untreated paradigm shift fueled extensive clinical research leading deeper understanding pathophysiology tr right ventricular rv dysfunction additionally advancement cardiovascular imaging facilitated early detection risk stratification innovative therapeutic approach tr right heart failure article explores evolving landscape tricuspid valve disease emphasizing importance early recognition role emerging imaging technology improving patient outcome thanks progress imaging technology especially echocardiography well cardiac magnetic resonance cardiac computer tomography enhanced study conducted tricuspid valve pathology delineate various mechanism involved tr rv dysfunction offer patient tailored medical well surgical transcatheter therapy unparalleled technological advance would possible without hard work physician scientist surgeon interventional cardiologist echocardiographers worldwide despite many challenge experience daily every procedure many patient tr present advanced stage disease progression often severe regurgitation clinical manifestation associated poor outcome additionally significant proportion patient either undergone previous open heart surgery left sided valvular disease considered high risk surgical candidate due multiple comorbid condition recent year transcatheter therapy emerged viable alternative high risk population offering less invasive option previously deemed inoperable breakthrough transformed therapeutic landscape valvular heart disease particularly tr providing new hope improved outcome patient left limited treatment option:0.0325442451157432",
    "37644": "last year renin angiotensin system ra become increasingly important focus basic clinical cardiovascular research one main conceptual step forward made discovery tissue ra understanding critical pathophysiological role atherogenesis plaque destabilisation major effort find new strategy blocking ra produced new class drug expected clinically important management hypertension heart failure landmark clinical study demonstrated inhibition ra significantly reduces morbidity mortality coronary heart disease myocardial infarction heart failure concept rapidly emerged blocking ra strategy choice preventing cardiovascular disease recently basic research however continuously extended understanding complexity systemic tissue ras longer viewed one way street one single effector angiotensin ii act solely major receptor meanwhile clinical trial challenged concept blocking ra effective preventive strategy patient target organ consistent recent understanding ra encompasses number distinct effector acting different receptor promote opposite effect growing body basic clinical evidence suggests blunting ra double edge sword beneficial effect counterbalanced deleterious one resulting net effect critically depends experimental condition clinical characteristic study population particular clinical relevance number clinical trial point somewhat provocative conclusion beyond blood pressure lowering effect antihypertensive drug decrease angiotensin ii formation less stroke protective one increase angiotensin level review focus recent experimental evidence demonstrating angiotensin ii derivative acting non receptor involved protective mechanism cerebral ischaemia discusses light recent large cardiovascular prevention trial clinical relevance new concept perspective renewal therapeutical strategy optimise prevention target organ damage perhaps even disease ageing loss cognitive function emphasised:0.0325080422148950",
    "197327": "background cardiovascular disease cvds leading cause global morbidity mortality imposing significant healthcare economic burden despite advance treatment current therapy limitation underscore need safer effective alternative acorus tatarinowii tatarinowii well known herb traditional chinese medicine shown promising cardioprotective effect primarily attributed active compound mainly including alpha asarone beta asarone purpose review systematically explores pharmacological mechanism tatarinowii bioactive component contribute cvd management also examines potential nanotechnology based delivery system enhance therapeutic efficacy study design conducted comprehensive review recent preclinical pharmacological study evaluate therapeutic potential mechanism action clinical prospect tatarinowii treatment cvds method data retrieved web science pubmed sciencedirect focusing principally publication past five year study selected based investigation pharmacological property cardiovascular application nanodelivery formulation tatarinowii active compound result tatarinowii exhibit range pharmacological activity including anti inflammatory antioxidant anti apoptotic anti autophagic hypolipidemic hypoglycemic effect mechanism contribute therapeutic potential managing hypertension coronary artery disease heart failure myocardial ischemia reperfusion injury arrhythmia moreover emerging nano delivery system lipid nanoparticles polymeric carrier shown improve bioavailability stability overall therapeutic potential bioactive compound reducing dose dependent toxicity conclusion review highlight tatarinowii bioactive component innovative candidate cvd management incorporation nanotechnology represents transformative strategy optimize pharmacological effect future research focus clinical validation mechanistic study facilitate translation modern cardiovascular medicine:0.0324738401063549"
  },
  "Topic 8": {
    "7200": "left ventricular lv diastolic function determinant exercise tolerance however relation early diastolic velocity mitral annulus ea obtained tissue doppler imaging exercise tolerance unknown patient impaired lv systolic function investigate feasibility evaluating exercise tolerance using tissue doppler imaging studied consecutive patient mean age year lv ejection fraction mean measured peak early diastolic velocity transmitral flow e ea lateral border mitral annulus calculated e ea ratio echocardiography measured peak oxygen consumption anaerobic threshold cardiopulmonary exercise testing echocardiographic parameter best correlation e ea ratio r p peak oxygen consumption correlated well ea e ea ratio r r respectively p peak oxygen consumption correlate conventional doppler index using ml min kg cutoff separate severe exercise intolerance normal mild moderate exercise intolerance receiver operating characteristic curve showed e ea ratio best combination sensitivity specificity exercise tolerance correlated e ea ratio patient impaired lv systolic function conclusion evaluation lv diastolic function using tissue doppler imaging useful predicting exercise tolerance patient heart failure:0.0678656242217576",
    "125159": "background advanced heart failure hf levosimendan increase peak oxygen uptake vo investigated whether peak vo increase linked cardiovascular respiratory muscular performance change method result twenty patient hospitalized advanced hf underwent shortly levosimendan infusion different cardiopulmonary exercise test personalized ramp protocol repeated arterial blood gas analysis standard spirometry including alveolar capillary gas diffusion measurement rest peak exercise b step incremental workload cardiopulmonary exercise testing continuous near infrared spectroscopy analysis cardiac output assessment bioelectrical impedance analysis levosimendan significantly decreased natriuretic peptide improved peak vo interquartile range ml kg min p decreased minute ventilation carbon dioxide production relationship slope p parallel spirometry showed minor increase forced expiratory volume whereas peak exercise dead space ventilation unchanged however exercise smaller edema formation observed levosimendan infusion inferable change diffusion component membrane diffusion capillary volume end tidal pressure co isocapnic buffering period increased levosimendan mm hg mm hg p exercise cardiac output increased parallel vo levosimendan total oxygenated tissue hemoglobin deoxygenated hemoglobin increased exercise phase conclusion advanced hf levosimendan increase peak vo decrease formation exercise induced lung edema increase ventilation efficiency owing decrease reflex hyperventilation increase cardiac output muscular oxygen delivery extraction:0.0675646929654843",
    "35731": "background left ventricular diastolic dysfunction oxidative stress important determinant heart failure development peak oxygen uptake maximal oxygen consumption metabolic equivalent met ventilatory response time respiratory gas exchange assess cardiopulmonary capacity aim aim study investigate impact oxidative stress diastolic index cardiopulmonary exercise capacity hypertensive patient left ventricular diastolic dysfunction method mitral flow velocity e ejection fraction left atrial ventricular diameter assessed doppler echocardiography superoxide dismutase sod glutathione peroxidase activity blood evaluated sixty patient aged year essential hypertension preserved systolic function ejection fraction performed bicycle exercise test forty patient showed impaired left ventricular relaxation e deceleration time e m assigned group normal relaxation group result increase sod significantly blunted exercise group compared group p significant difference group glutathione peroxidase level observed exercise p significantly lower value peak oxygen uptake met p p respectively prolonged respiratory exchange ratio p group compared group met significantly influenced sod level p conclusion lower antioxidative protection impaired relaxation decrease cardiopulmonary capacity hypertensive patient:0.0673369790075476",
    "18420": "objective doppler echocardiography well recognized primary noninvasive imaging technique assess global regional cardiac function cardiopulmonary exercise testing become powerful tool predict outcome chronic heart failure chf looked cardiac determinant using resting echocardiographic parameter exercise tolerance patient chf method transthoracic echocardiography standardized cardiopulmonary exercise testing performed patient year chf new york heart association functional class ii iii systolic diastolic function filling pressure left ventricular right ventricular left atrial la regional function assessed using doppler tissue velocity strain value result maximal workload w peak oxygen ml min kg correlated left ventricular filling pressure estimate e ea e vp also end diastolic pulsed doppler tissue velocity mitral annulus aa la volume regional la function assessed strain analysis multivariate analysis maximum workload peak oxygen shown correlate right ventricular peak strain although aa e ea best predictor exercise capacity conclusion capacity exercise patient chf understandable resting echocardiography filling pressure la right ventricular function cardiac best determinant adding aa peak velocity resting echocardiographic evaluation patient chf found useful:0.0672024726448085",
    "39888": "objective sought investigate effect sildenafil phosphodiesterase pde inhibitor lung function exercise performance chronic heart failure chf background chf nitric oxide mediated regulation lung vascular tone alveolar capillary membrane conductance impaired contributes exercise intolerance potential benefit due increased nitric oxide availability unexplored method patient chf normal subject measured min sildenafil mg placebo ejection fraction pulmonary hemodynamics carbon monoxide diffusion capacity dlco membrane capillary blood volume v c subcomponents endothelial function brachial reactive hyperemia rest peak oxygen uptake vo increment vo versus work rate deltavo deltawr change ventilation versus co production vco slope recovery vo time constant tau exertion result chf sildenafil affect cardiac index wedge pulmonary pressure ejection fraction significantly p decreased pulmonary mean artery pressure arteriolar resistance vco slope recovery tau increased p dlco peak vo deltavo deltawr brachial reactive hyperemia variation occurred normal subject placebo change dlco related vco slope r p change brachial hyperemia correlated deltavo deltawr r p conclusion study show chf pde inhibition modulates pulmonary pressure vascular tone improves dlco exercise peak vo aerobic deltavo deltawr ventilatory vco slope efficiency oxygen debt recovery tau endothelial mechanism may underlie effect:0.0668298286577635",
    "2724": "context exercise training patient chronic heart failure improves work capacity enhancing endothelial function skeletal muscle aerobic metabolism effect central hemodynamic function well established objective evaluate effect exercise training left ventricular lv function hemodynamic response exercise patient stable chronic heart failure design prospective randomized trial conducted setting university department cardiology outpatient clinic germany patient consecutive sample men aged year younger chronic heart failure lv ejection fraction approximately intervention patient randomly assigned week hospital ergometer exercise minute time per day followed month home based ergometer exercise training minute per day peak oxygen uptake n intervention control group n main outcome measure ergospirometry measurement central hemodynamics thermodilution rest exercise echocardiographic determination lv diameter volume baseline month follow exercise training v control group result month patient exercise training group statistically significant improvement compared control new york heart association functional class maximal ventilation exercise time exercise capacity well decreased resting heart rate increased stroke volume rest exercise training group increase baseline month follow observed mean sd resting lv ejection fraction v p mean sd total peripheral resistance tpr peak exercise reduced dyne cm exercise training group v increase dyne cm control group p concomitant increase mean sd stroke volume ml v ml control group p small significant reduction mean sd lv end diastolic diameter mm v increase mm control group p change baseline resting tpr group correlated change stroke volume r p lv end diastolic diameter r p conclusion patient stable chronic heart failure exercise training associated reduction peripheral resistance result small significant improvement stroke volume reduction cardiomegaly jama:0.0661676181717027",
    "112281": "background iron deficiency id frequent associated diminished exercise capacity heart failure hf contribution unexplained dyspnea without hf diagnosis rest remains unclear method result consecutive patient unexplained dyspnea normal echocardiography pulmonary function test rest underwent prospective standardized cardiopulmonary exercise testing echocardiography tertiary care dyspnea clinic id defined ferritin microg l transferrin saturation impact peak oxygen uptake peakvo biventricular response exercise peripheral oxygen extraction assessed patient underwent cardiopulmonary exercise testing echocardiography id similar respiratory exchange ratio patient id lower peakvo ml kg minvs ml kg min p maximal workload watt v watt p even adjustment presence anemia rest patient id similar left ventricular right ventricular rv contractile function exercise patient id lower cardiac output reserve p depressed rv function tricuspid p tricuspid annular plane systolic excursion p rv end systolic pressure area ratio p rv pulmonary artery uncoupling measured tricuspid annular plane systolic excursion systolic pulmonary arterial pressure ratio p rv end systolic pressure area ratio change rest peak exercise load insensitive metric rv contractility lower patient id mm hg cm v mm hg cm p id associated impaired peripheral oxygen extraction peakvo peak cardiac output p cardiopulmonary exercise testing echocardiography resulted diagnosis hf preserved ejection fraction patient based exercise e e ratio equal distribution patient without id p none finding influenced sensitivity analysis adjusted final diagnosis hfpef etiology unexplained dyspnea conclusion patient unexplained dyspnea without clear hf rest id common associated decreased exercise capacity diminished biventricular contractile reserve decreased peripheral oxygen extraction:0.0647806666176289",
    "179784": "background hypertrophic cardiomyopathy hcm heterogeneous myocardial disease conventional prognostic model primarily focused sudden cardiac death often fail identify patient risk clinically relevant event heart failure progression rehospitalization cardiopulmonary exercise testing cpet quantifies functional capacity stress echocardiography se provides mechanistic insight exercise induced hemodynamic change combined application cpet se may enhance risk stratification patient hcm method retrospective study patient obstructive non obstructive hcm mean age year male underwent baseline cpet se followed median year iqr echocardiographic parameter assessed rest peak exercise cpet index included peak oxygen consumption pvo ventilatory efficiency anaerobic threshold primary outcome composite heart failure hospitalization progression end stage hcm result median follow year patient experienced event primary outcome patient developed primary outcome greater left atrial diameter v mm p indexed volume rest v ml p dilation stress p increased lv wall thickness p higher average e e rest stress p higher pulmonary artery systolic pressure rest p stress p cpet finding included lower pvo v ml kg min p reduced predicted pvo p earlier anaerobic threshold p impaired ventilatory efficiency p chronotropic incompetence p patient experienced primary outcome multivariable analysis identified dyslipidemia higher e e lower pvo independently associated primary outcome conclusion cpet se provided comprehensive evaluation patient hcm associating aerobic capacity hemodynamic determinant reduced pvo showed strongest association adverse outcome exercise induced diastolic dysfunction elevated pulmonary pressure identified high risk phenotype incorporating cpet se longitudinal management patient hcm may enable earlier detection physiological decompensation guide personalized therapeutic strategy:0.0643674894688894",
    "91046": "aim heart failure patient reduced preserved left ventricular lv ejection fraction ef show reduced exercise capacity explored relationship exercise capacity systolic diastolic myocardial function heart failure patient method result exercise capacity peak oxygen uptake vo assessed patient year nyha functional class ef lv systolic function ef global longitudinal strain gls right ventricular function assessed echocardiography left atrial volume index ratio peak early diastolic filling velocity e early diastolic mitral annular velocity e measure diastolic function thirty seven patient heart failure preserved ef hfpef defined ef echocardiographic diastolic dysfunction lv gls peak pulmonary arterial systolic pressure independently correlated peak vo total study population hfpef separately lv gls superior ef identifying patient impaired peak vo ml kg min shown receiver operating characteristic analysis area curve v p patient hfpef gls reduced normal correlated e e r p left atrial volume index r p ef conclusion gls correlated independently peak vo patient reduced preserved ef superior identifying patient reduced exercise capacity hfpef systolic function gls impaired significant relationship diastolic function gls confirming coupling diastolic longitudinal systolic function hfpef:0.0643266820164746",
    "170374": "diastolic dysfunction play major role precipitating congestive heart failure patient hypertrophic cardiomyopathy hcm many patient symptom unmasked exercise left ventricular lv filling pressure normal rest increase exercise sought establish whether abnormal postexercise diastolic parameter associated reduced exercise capacity patient hcm examined patient asymptomatic minimally symptomatic hcm age year men body mass index kg beta blocker hcm dimensional doppler echocardiography rest maximal treadmill exercise echocardiography tse complete echocardiogram including lv ejection fraction lv thickness lv outflow tract lvot gradient degree mitral regurgitation recorded diastolic parameter septal lateral e velocity mitral annulus peak early e late mitral inflow velocity e ratio e e right ventricular systolic pressure rvsp left atrial volume index recorded rest tse exercise functional capacity recorded divided age gender predicted metabolic equivalent agp mets maximal exercise patient least moderate mitral regurgitation mean lvot gradient mm hg e ratio average e e ratio peak rvsp mm hg patient achieved agp mets mean mets multivariable logistic regression analysis higher body mass index odds ratio beta blocker use higher left atrial volume index higher peak stress lvot gradient lvotg peak stress e e higher rvsp independently associated agp mets achieved p conclusion patient asymptomatic minimally symptomatic hcm underwent tse significant independent association abnormal diastolic response exercise reduced exercise capacity hcm incorporating diastolic parameter stress echocardiography could provide incremental diagnostic utility deciphering exact etiology dyspnea patient:0.0640667369497262"
  },
  "Topic 9": {
    "174353": "objective sodium glucose co transporter sglt inhibitor reshaped heart failure hf management however evidence regarding effect cardiac structure particularly dapagliflozin remains inconsistent study evaluates dapagliflozin impact echocardiographic parameter concordance clinical response material method prospective randomized controlled study included hf patient left ventricular lv dysfunction divided dapagliflozin treated dapagliflozin naive group echocardiography speckle tracking strain analysis conducted baseline six month primary outcome change indexed lv mass secondary outcome included lv function volume dimension functional mitral regurgitation global longitudinal strain gls diastolic function right ventricular rv function clinical response assessed using kansa city cardiomyopathy questionnaire kccq score result among participant received dapagliflozin addition guideline directed medical therapy dapagliflozin naive adjusted regression analysis showed significant improvement lv mass index g ci p end systolic volume ml ci p end diastolic volume ml ci p improvement also observed lv ejection fraction ci p gls ci p e ratio ci p effective regurgitant orifice area eroa cm ci p tricuspid annular plane systolic excursion tapse cm ci p composite clinical outcome hr ci p lvef gls e ratio tapse inferior vena cava diameter left atrial area correlated clinical response conclusion dapagliflozin emerges potential therapy patient left ventricular dysfunction enhancing lv systolic function diastolic performance alongside favorable clinical response future study extensive assessment right ventricular function longer follow warranted graphical abstract http www europeanreview org wp wp content uploads abstract jpg:0.0561283194457361",
    "103638": "background echocardiographic evaluation longitudinal axis left ventricular lv function used diagnosis assessment heart failure normal ejection fraction hfnef evaluation global segmental peak systolic longitudinal strain pslss two dimensional speckle tracking echocardiography ste may correlate conventional echocardiography finding aimed use ste evaluate longitudinal function lv patient hfnef method study patient hfnef diastolic dysfunction normal subject conventional echocardiography underwent ste evaluation including lv end diastolic end systolic dimension interventricular septal thickness posterior wall thickness lv volume lv ejection fraction left atrial volume index early diastolic peak flow velocity late diastolic peak flow velocity ratio deceleration time early diastolic myocardial velocity e late diastolic myocardial velocity systolic myocardial velocity global basal mid apical pslss correlation method assessed result mean age year hfnef patient year control group hfnef group comprised male female normal group consisted male female global basal mid apical pslss significantly lower hfnef group p value significant positive correlation global psls septal e p value negative correlation global psls e e ratio p value significant negative correlation e e ratio mid psls p value basal psls p value weak positive correlation septal e mid psls p value basal psls p value also weak negative correlation isovolumic relaxation time global psls p value mid psls p value also new york heart association functional class mid psls p value basal psls p value conclusion hfnef patient conventional echocardiography different ste finding compared normal subject indicative diastolic dysfunction longitudinal systolic function lv measured ste reduced segment denoting degree subclinical systolic dysfunction patient:0.0532555025941466",
    "142883": "background propionic acidemia pa myocardial involvement common includes development cardiomyopathy life threatening acute heart failure acquired long qt syndrome sought investigate echocardiographic parameter left ventricular systolic diastolic function indicate early cardiac disease manifestation pa method prospective observational study cross sectional design tertiary medical care center individual confirmed pa enrolled following cardiac investigation performed study individual echocardiographic measurement systolic diastolic left ventricular lv function lv fractional shortening lv f lv ejection fraction biplane modified simpson lv ef mitral annular plane systolic excursion mapse lv global longitudinal strain lv gls speckle tracking echocardiography ste pulsed doppler analysis mitral valve mv inflow velocity mv e mv deceleration time dt e tissue doppler imaging tdi mitral annulus mv e e lv myocardial performance index lv mpi lv left atrial la diameter assessed lead electrocardiogram ecg recorded corrected qt interval qtc calculated clinical phenotype laboratory parameter time cardiac investigation assessed besides descriptive analysis analyzed frequency onset combination echocardiographic ecg data well correlation clinical biochemical finding effect age visit lv functional parameter qtc analyzed multiple regression result total patient confirmed pa enrolled median age pa onset day range day median age visit cardiac evaluation year range year lv gls abnormal lv ef mapse mv e e lv mpi lv f mv e case normal near normal lv f lv gls pathological lv ef mapse probability developing lv dysfunction systolic diastolic increase age lv mpi reliable parameter indicate systolic lv dysfunction combination dilated lv e dilated cardiomyopathy dcm pa multiple regression reveals significant positive association lv diameter qtc abnormal lv gls significantly correlate reduced muscle strength muscle tone abnormal gross motor function conclusion data suggests high prevalence cardiac disease manifestation pa considerably higher previous study lv f used assess lv function usage advanced echocardiographic technique lv gls assessment may allow early detection subtle lv dysfunction pa may lead timely cardiac treatment also consideration liver transplantation prevent development manifest cardiac complication:0.0520239200262899",
    "185660": "cardiac resynchronization therapy crt induces left ventricle reverse remodeling however effect right ventricular rv volume function well described study aimed assess effect crt rv patient enrolled mean age year including male patient met criterion crt implantation followed month month interval standard dimensional dimensional echocardiography speckle tracking analysis conducted assessment lv left atrium la rv maximum diameter tricuspid lateral annular systolic velocity tricuspid annular plane systolic excursion fractional area change rv global rv chamber strain rv csl rv free wall strain rvfwsl addition echocardiographic assessment rv done crt implantation follow visit mean follow period month total patient lv responder lvr whereas rest nonresponders lvnr group similar baseline characteristic risk factor device implantation programming value lvr significant reduction rv basal diameter together significant improvement rv systolic performance systolic velocity fractional area change rv csl rvfwsl derived rv volume ejection fraction compared baseline value addition pulmonary arterial systolic pressure decreased lvr reduction tricuspid regurgitation severity lv response percentage change rv csl la end systolic volume index la emptying fraction month follow independent predictor rv response multivariate analysis reduced left ventricular end systolic volume sensitivity specificity conclusion crt induced rv reverse remodeling improved rv arterial coupling effect associated left side response crt:0.0515593366173212",
    "1084": "background biventricular pacing biv therapy recently shown improve systolic function cause reverse remodeling patient advanced heart failure electromechanical delay patient benefit right ventricular rv based pacing controversial compared acute change systolic diastolic function left ventricular lv volume intraventricular synchronicity biv pacing rv pacing without pacing mean echocardiography tissue doppler imaging tdi method tdi performed patient heart failure undergoing pacemaker implantation device randomized biv rv pacing mode result systolic function improved biv pacing rv pacing included ejection fraction v rv v biv v v p v dp dt p myocardial performance index p isovolumic contraction time p mitral regurgitation reduced biv pacing p lv early diastolic function depressed rv biv pacing detected transmitral flow v v cm p tdi mean myocardial early diastolic velocity basal segment v v cm p lv end diastolic v v p end systolic v v p volume decreased biv pacing systolic synchronicity significant delay peak systolic contraction lateral septal wall v m p revealed tdi pacing abolished biv pacing septal contraction delayed v m p significant however rv pacing restored lateral wall delay systolic asynchrony reappeared v m p diastolic asynchrony septal lateral wall evident patient affected either pacing mode conclusion biv pacing rv pacing improves systolic function reduces mitral regurgitation lv volume patient heart failure electromechanical delay attributed improvement systolic synchronicity diastolic synchronicity unaffected whereas early diastolic function could jeopardized either pacing mode:0.0510368992894218",
    "38325": "objective determine short term effect cardiac resynchronization therapy crt measurement left ventricular lv diastolic function patient severe heart failure background cardiac resynchronization therapy improves systolic performance however effect diastolic function load dependent pulsed wave doppler transmitral index variable method fifty patient severe heart failure evaluated two dimensional doppler echocardiography immediately prior month crt measurement included lv volume ejection fraction ef pulsed wave doppler pwd derived transmitral filling index e wave velocity e ratio deceleration time dt diastolic filling time dft isovolumic relaxation time tissue doppler imaging used measurement systolic diastolic em velocity four mitral annular site mitral e wave em ratio calculated estimate lv filling pressure color mode flow propagation velocity also obtained result crt lv volume decreased significantly p lvef increased patient accompanied reduction pwd mitral e wave velocity e ratio p increased dt dft p lower filling pressure e e wave em septal p patient lvef response crt significant change measurement diastolic function lv relaxation e em velocity worsened group conclusion heart failure patient receiving crt improvement lv diastolic function coupled improvement lv systolic function:0.0507294893769768",
    "106690": "background cardiac resynchronization therapy crt effective treatment patient advanced heart failure hf nearly candidate inadequate responder benefit patient right sided heart failure crt still matter debate examined effect crt right ventricular rv dimension overall systolic function whether rv function prior crt could impact crt response method patient mean age year including female advanced hf ef lbbb m non lbbb m nyha iii ambulatory class iv enrolled underwent crt implantation standard two dimensional echocardiography tissue doppler imaging assessment left ventricular lv end diastolic lvedv end systolic volume lvesv ejection fraction rv maximum basal rvd basal maximum mid rvd mid transverse maximum longitudinal rvd long diameter tapse fractional area change fac tricuspid lateral annular systolic velocity addition rv global longitudinal strain rvgls measured speckle tracking echocardiography done crt implantation end follow period month patient presenting reduction lvesv termed volumetric responder statistical analysis result case volumetric responder group matched regarding demographic clinical ecg echocardiographic criterion apart rv significantly smaller transverse diameter significantly better systolic function parameter responder group prior crt compared non responder nr group end follow responder group significant reduction rv basal mid longitudinal diameter v v v respectively p together significant improvement rv systolic performance fac v tapse v v gls v p compared baseline reading gls independent predictor crt response multivariate analysis cm gls sensitivity specificity respectively prediction response crt conclusion crt induces rv reverse remodeling improves rv systolic function particularly cardiac volumetric responder rv systolic dysfunction crt implantation could identify patient might benefit crt thus helping proper patient selection optimizing crt response:0.0503432723902093",
    "4552": "background biventricular pacing proposed improve symptom exercise capacity patient advanced heart failure wide electrocardiographic wave complex study investigated effect biventricular pacing reverse remodeling underlying mechanism method result twenty five patient nyha class iii iv heart failure electrocardiographic wave complex duration m receiving biventricular pacing therapy assessed serially month pacing pacing withheld week tissue doppler echocardiography performed using basal mid segmental model assess time peak sustained systolic contraction significant improvement ejection fraction dp dt myocardial performance index decrease mitral regurgitation left ventricular lv end diastolic versus ml p end systolic volume versus ml p improved minute hall walk distance quality life score pacing month mechanism benefit follows improved lv synchrony evident homogeneous delay timing close latest usually lateral segment abolishing intersegmental difference decreasing standard deviation within left ventricle versus m p improved interventricular synchrony shortened isovolumic contraction time versus m p increased diastolic filling time benefit pacing dependent withholding pacing resulted varying speed loss cardiac improvement conclusion biventricular pacing revers lv remodeling improves cardiac function improvement lv mechanical synchrony seems predominant mechanism:0.0502392440184152",
    "180201": "background cardiac resynchronisation therapy crt standard treatment heart failure patient ventricular conduction delay benefit left ventricular lv systolic function well established effect lv diastolic mechanic remain controversial study aimed investigate interaction crt therapy lv diastolic function lv chamber stiffness method evaluated heart failure patient six month crt using two dimensional echocardiography lv volume ejection fraction ef diastolic function parameter including transmitral filling index tissue doppler e e ratio measured lv stiffness index lv si calculated using formula e e lateral end diastolic volume edv crt response defined reduction lv end systolic volume result among crt responder mean reduction lv end systolic volume median ef improvement observed diastolic function improved significantly e wave velocity downward arrow e ratio downward arrow e e ratio downward arrow medial downward arrow lateral p value lv stiffness index decreased p non responder showed significant change baseline parameter pulsed wave tissue doppler measurement well lv si showed significant difference responder non responder conclusion study demonstrates crt responder exhibited significant improvement diastolic function including measurement lv filling pressure active relaxation well reduction lv stiffness additionally lv stiffness diastolic parameter appear influence response crt:0.0497487733489152",
    "101448": "diastology study treat diastole heart transmitral flow pulmonary venous flow velocity recorded pulsed doppler echocardiography provide important information left ventricular lv diastolic dysfunction left atrial la lv coupling cardiac catheterization clinical practice however waveform influenced loading condition particularly preload early diastolic mitral annular lv wall motion index measured tissue doppler echocardiography evaluate lv relaxation abnormality filling pressure relatively preload independent addition role concomitant systolic longitudinal dysfunction well characterized asymptomatic patient patient heart failure preserved ejection fraction two dimensional speckle tracking echocardiography angle independent method potential evaluate contraction relaxation abnormality longitudinal circumferential radial direction lv myocardium well lv torsion untwisting moreover deformation la myocardium large arterial wall result new technique facilitate early detection impaired la lv arterial coupling patient occurrence overt heart failure symptom:0.0489489882970508"
  },
  "Topic 10": {
    "91737": "objective many patient severe symptomatic mitral valve regurgitation denied surgical valve replacement repair due high operative risk describe early series case transcatheter implantation cardiaq mitral valve via transapical approach method three consecutive patient society thoracic surgeon sts mortality score selected transcatheter mitral valve implantation tmvi compassionate ground patient elderly severe mitral regurgitation mr class iv heart failure deemed unsuitable mitraclip two patient functional mr setting ischaemic cardiomyopathy left ventricular ejection fraction lvef deemed remaining patient chordal rupture extensive anterior leaflet flail preserved lvef comorbidities included previous coronary artery bypass surgery n severe pulmonary hypertension n moderate severe chronic renal failure n cardiaq mitral valve implanted using fluoroscopy transoesophageal tee guidance via standard transapical approach result accurate prosthesis positioning deployment immediate elimination mr achieved case two patient made full clinical recovery discharged home post procedural tee performed day day showed good valve function stable valve position minimal lvot gradient one patient expired postoperative day due pneumonia conclusion tmvi using cardiaq device via transapical approach feasible effective:0.0725143794489582",
    "146064": "importance million people living either mitral aortic valve disease worldwide heart valve replacement surgery performed year u transcatheter valve repair emerged important therapeutic option patient candidate heart valve replacement observation transcatheter valve therapy involve multidisciplinary team interventional cardiologist cardiothoracic surgeon radiologist echocardiographers nurse social worker termed heart team determine optimal approach managing patient transcatheter aortic valve implantation tavi aortic valve replacement procedure performed percutaneously currently approved patient severe symptomatic aortic stenosis surgical risk category tavi procedure performed using balloon expandable self expanding valve low risk cohort patient partner placement aortic transcatheter valve trial rate death cause stroke rehospitalization patient receiving tavi patient undergoing surgical aortic valve replacement decision making regarding therapy choice based individual anatomy including number leaflet annular size peripheral arterial anatomy comorbidities including concomitant coronary artery disease aortopathies patient preference guide mitral transcatheter edge edge repair device approved u food drug administration high risk patient degenerative functional mitral regurgitation excellent safety efficacy population coapt cardiovascular outcome assessment mitraclip percutaneous therapy heart failure patient functional mitral regurgitation trial annualized rate hospitalization heart failure among patient underwent transcatheter edge edge repair received medical therapy compared among patient medical therapy alone group transcatheter tricuspid valve repair replacement trial ongoing show promise treatment patient tricuspid regurgitation previously limited therapeutic option multimodality imaging includes transthoracic echocardiography transesophageal echocardiography computed tomography intracardiac echocardiography important preprocedural planning device selection optimal outcome conclusion relevance approximately tavi procedure transcatheter mitral valve repair take place yearly u treat patient severe symptomatic aortic stenosis mitral regurgitation respectively transcatheter valve therapy expanded therapeutic option patient including previously viable surgical option:0.0678616080270286",
    "185213": "introduction surgical treatment patient mitral valve regurgitation advanced heart failure remains challenging order avoid peri operative low cardiac output impella x implanted electively one stage procedure may serve peri operative short term mechanical circulatory support system st mc patient undergoing mitral valve surgery method july april consecutive patient underwent high risk mitral valve surgery mitral regurgitation supported impella x system abiomed inc danvers patient discussed heart team either eligible transcatheter edge edge repair teer surgery considered favorable case indication impella x implantation made preoperative planning phase result mean age time surgery year patient presented mitral regurgitation due either ischemic n dilatative n cardiomyopathy mean ejection fraction euroscore ii uneventful mitral valve repair n replacement n performed via median sternotomy n right lateral mini thoracotomy n six patient concomitant procedure either tricuspid valve repair aortic valve replacement cabg necessary mean duration impella support day one patient successfully weaned st mc impella related complication day survival conclusion protected cardiac surgery st mc using impella x safe feasible applied high risk mitral valve surgery without st mc related complication resulting excellent outcome strategy might offer alternative comprehensive approach treatment patient mitral regurgitation advanced heart failure deemed ineligible teer need concomitant surgery:0.0668242754491603",
    "44336": "objective transcatheter aortic valve implantation considered alternative patient high risk conventional surgery direct flow medical aortic valve direct flow medical inc santa rosa calif nonmetallic tissue valve prosthesis intended treat patient severe aortic stenosis high risk surgery method thirty one patient high surgical risk enrolled trial logistic euroscore society thoracic surgeon score twenty two patient underwent successful retrograde transcatheter aortic valve implantation patient undergo implantation owing excessive calcification access issue mean preinterventional gradient effective orifice area mm hg cm respectively patient new york heart association functional class iii result mean postprocedural gradient mm hg effective orifice area cm two patient converted surgery patient died implantation myocardial infarction congestive heart failure one patient stroke day procedure patient required pacemaker month mean aortic valve gradient effective orifice area mm hg cm respectively majority patient paravalvular leak grade paravalvular leak new york heart association functional class class ii month survival respectively death patient conclusion transcatheter aortic valve implantation using study valve appears safe result promising month severe leaflet left ventricular outflow tract calcification affect procedural outcome therefore careful patient selection crucial:0.0625505624195667",
    "146410": "background transcatheter mitral valve valve tmviv valve ring tmvir replacement shown early promise patient deemed poor surgical candidate less invasive alternative conventional reoperative mitral valve mv replacement objective retrospective single center study reviewed procedural outcome tmviv tmvir procedure large tertiary referral center serving southeastern united state analysis patient safety measure also performed retrospective assessment relative procedural safety included preoperative risk stratification postoperative mortality predictor operative time average blood loss length hospital stay readmission rate method study included patient severe mv disease medical comorbidities considered high risk conventional mv replacement patient underwent tmviv tmvir edward sapien xt transcatheter valve edward lifesciences secure database patient demographic preoperative risk assessment procedural data created included technical success rate blood loss operative time intraoperative immediate postoperative complication subsequent follow patient outcome reported include collected day day year result patient study received tmviv received tmvir implantation procedure performed successfully general anesthesia via transseptal approach n transapical approach n patient requiring late operative reintervention day post op average procedural time min average blood loss ml patient successfully extubated postoperative day length intensive care unit stay day length total inpatient stay day echocardiogram collected immediately post op day day subsequently yearly interval follow demonstrated excellent prosthetic valve function low transvalvular gradient evidence valve embolization thrombosis patient follow data available year n readmission day day admission first postoperative year symptom related congestive heart failure chf conclusion tmviv tmvir safe effective patient population considered prohibitive risk conventional surgery procedure performed efficiently hybrid operating room relatively short procedural time high rate early extubation procedural complication mortality readmission rate chf day day year low high risk cohort:0.0620920766814762",
    "194398": "background management recurrent mitral regurgitation mr relevant iatrogenic mitral valve mv stenosis mitral transcatheter edge edge repair teer emerges increasingly relevant clinical issue surgery teer associated higher morbidity mortality electrosurgical leaflet laceration stabilization implant elasta clip followed transcatheter mitral valve replacement tmvr innovative less invasive treatment option patient teer failure objective author sought evaluate early result elasta clip followed transapical tmvr patient symptomatic failed teer defined persistent recurrent mr iatrogenic mv stenosis method data symptomatic patient failed teer underwent elasta clip followed compassionate use commercial transapical tmvr using abbott tendyne system retrospectively collected tertiary care center country safety efficacy procedure assessed year according mitral valve academic research consortium mvarc criterion result total patient mean age year female high surgical risk euroscore ii sts score symptomatic residual mr n iatrogenic mv stenosis n failed teer followed median period q q month elasta clip procedure transseptal transapical followed tmvr successful patient technical success according mvarc achieved patient without left ventricular outflow tract obstruction conversion sternotomy day patient paravalvular leak progression ischemic stroke occurred patient baseline mr reduced grade less patient durable result p nyha functional class significantly improved ii discharge p last follow p day patient alive three patient rehospitalized heart failure uncontrolled atrial fibrillation case underwent reintervention valve retensioning conclusion transapical tmvr elasta clip feasible less invasive option management failed teer performed acceptable result carefully selected patient population particular attention required avoid paravalvular leakage measure minimize risk periprocedural cerebrovascular event need implemented future larger scale prospective study longer term follow:0.0617744063187744",
    "75906": "valvular heart disease one frequent cause heart failure degenerative disease aortic mitral valve well dysfunctional tricuspid valve disease result worse clinical outcome severe minimal invasive surgical catheter based structural heart disease shd intervention recently seen dramatic increase transcatheter aortic valve implantation tavi severe aortic stenosis disruptive technology next generation device careful patient selection minimize limitation tavi paravalvular leak conductance disturbance ischemic stroke vascular complication indication tavi continues shift toward lower risk patient patient complex anatomy bicuspid native pure aortic regurgitation successful clinical result tavi generated considerable interest transcatheter technology targeting mitral regurgitation mr also toward tricuspid regurgitation tr efficacy safety edge edge without annuloplasty leaflet repair mimicking surgical repair confirmed technical improvement device development emerging study transcatheter mitral valve implantation might alternative strategy patient symptomatic severe mr favorable anatomy possible interventional treatment approach tr gained attention improvement development shd intervention enabled patient receive minimally invasive heart valve intervention procedure prolonged life improved quality life many patient previously considered unsuitable surgery continued technical device improvement accumulated evidence expand possibility future shd intervention:0.0617301522537679",
    "114102": "objective study report clinical echocardiographic outcome experience transapical mitral valve valve viv replacement method eleven patient mean age year underwent transapical mitral viv implantation failed bioprosthesis single institution enrolled patient considered high risk surgical intervention society thoracic surgery predicted risk mortality mean european system cardiac operative risk evaluation euroscore ii result transapical mitral viv implantation successful patient edward sapien xt sapien valve edward lifesciences corp irvine ca usa used patient respectively size valve used patient size valve used patient patient trace mitral regurgitation end procedure mean length hospital stay day survival day day year one patient died result multiorgan failure day intensive care unit stay mean mitral valve gradient across percutaneous valve mmhg mean valve area cm year follow new york heart association class patient remaining improved class ii readmission heart failure patient coumadin target international normalized ratio conclusion high risk patient transapical mitral viv implantation performed high success rate considerable improvement clinical status:0.0608755703358033",
    "157102": "background aim study report outcome patient undergoing transcatheter mitral valve implantation tendyne mitral valve system tendyne switzerland method retrospectively analyzed preoperative echocardiographic computed tomography ct data procedural finding day year follow echocardiographic clinical data patient underwent transcatheter mitral valve implantation tendyne switzerland result total patient age year male underwent transapical transcatheter mitral valve implantation tendyne june october technical success rate five patient concomitant intervention form transcatheter aortic valve implantation one patient minimally invasive direct coronary artery bypass one patient transcatheter edge edge repair three patient performed prior index procedure one device embolization two patient required valve retrieval hospital outcome included one stroke three major bleeding event none patient died within day two patient rehospitalized decompensated heart failure year follow three noncardiovascular related death conclusion transcatheter mitral valve implantation tendyne feasible treat polymorbid patient suffering complex mitral valve disease well patient previous mitral intervention perioperative risk acceptable procedural success high:0.0605737614711906",
    "108316": "background treatment hemodynamically significant mitral annular calcification mac using transcatheter approach early learning phase occurrence paravalvular leak pvl following transcatheter mitral valve mac common aim report initial experience technique percutaneous pvl closure transcatheter valve mac method series includes five consecutive patient underwent percutaneous pvl closure following transcatheter balloon expandable sapien valve mac result mean patient age year female average society thoracic surgeon score three patient single pvl defect two patient two defect located commissural site closure performed primarily heart failure four patient hemolytic anemia one patient transfemoral transseptal antegrade approach amplatz vascular plug avp ii occluders utilized patient procedure success achieved three patient one patient developed significant occluder related leaflet impingement subsequent severe prosthetic mitral regurgitation requiring second transcatheter mitral valve valve implantation procedure aborted one patient due difficulty crossing pvl defect balloon post dilatation sapien prosthesis ml additional volume hospital day mortality need emergent surgery conclusion early experience percutaneous pvl closure sapien valve mac demonstrated feasibility approach careful procedure planning monitoring sapien prosthesis leaflet impingement frame instability utmost importance increase chance procedural success:0.0599663309010428"
  },
  "Topic 11": {
    "30942": "background cardiopulmonary exercise testing cpet response heart failure preserved left ventricular ejection fraction hfpef incompletely understood aimed describe cpet response hfpef assess invasive hemodynamic determinant method result ten patient hfpef asymptomatic control underwent resting exercise right heart catheterization maximal symptom limited cpet slope minute ventilation carbon dioxide production relationship vco slope v p steeper peak oxygen consumption peak vo v ml kg min p lower heart rate recovery minute exercise termination hrr v beat min p slower hfpef compared control steeper vco slope r p lower peak vo r p slower hrr r p significantly related higher ratio change pulmonary capillary wedge pressure per change work rate measure left ventricular pressure volume relationship conclusion hfpef patient fundamental alteration cpet profile occur may part result rapid rise left ventricular filling pressure accompanies exercise patient:0.0967547366475871",
    "78471": "introduction although pulmonary arterial hypertension pah chronic heart failure chf lead exercise limitation pathophysiology different objective evaluate using right heart catheterization cardiopulmonary exercise testing difference hemodynamic parameter exercise capacity pah chf subjective symptom method studied pah mean pulmonary artery pressure mmhg mmhg chf ejection fraction patient underwent cardiopulmonary exercise testing right heart catheterization patient new york heart association functional class ii iii result peak oxygen uptake vo lower pah patient chf patient ml kg min v ml kg min p slope ventilation carbon dioxide production ratio vco higher pah patient chf patient v p despite similarity new york heart association functional class peak vo vco correlated cardiac index group important finding peak vo correlated pulmonary vascular resistance pah patient r p chf patient r p furthermore peak vo correlated pulmonary capillary wedge pressure chf patient r p pah patient r p vco slope correlated pulmonary capillary wedge pressure r p pulmonary vascular resistance r p chf patient conclusion peak vo vco slope worse pah patient chf patient despite similar subjective symptom difference might explained altered hemodynamic status:0.0928602117043191",
    "23835": "purpose study investigates relationship ventilatory expired gas cardiac parameter measured exercise testing patient heart failure method twenty five subject male female diagnosed compensated heart failure underwent symptom limited exercise testing ventilatory expired gas analysis metabolic cardiac measure interest collected testing result mean peak oxygen consumption vo minute ventilation carbon dioxide production vco slope percentage age predicted maximal heart rate achieved exercise testing apmhr peak respiratory exchange ratio ml kg min respectively vco slope significantly correlated following apmhr r p peak vo r p vo ventilatory threshold r p dead space tidal volume ratio vd vt r p ability peak vo apmhr predict vco slope significant r r p conclusion study demonstrates importance analyzing multiple exercise test parameter including metabolic measure patient heart failure:0.0910526742600510",
    "20272": "present study undertaken investigate relationship extent impaired chronotropic response cardiac output exercise exercise tolerance patient chronic heart failure subject consisted patient mean year mild chronotropic incompetence cardiopulmonary exercise testing performed patient heart rate hr anaerobic threshold maximum oxygen uptake peak vo slope regression line relating ventilatory equivalent carbon dioxide output vco slope exercise time measured cardiac output co measured thoracic bioimpedance method cardiac index ci calculated plasma norepinephrine ne measured rest immediately exercise test change hr ne ci resting state immediately exercise calculated deltahr deltane deltaci respectively deltane converted logarithmic scale deltahr log deltane used parameter hr response sympathetic nerve stimulation result follows hr ne resting state correlation peak vo deltahr log deltane correlated positively peak vo negatively co slope deltahr log deltane correlated positively peak ci deltaci deltaci exercise time data suggest one mechanism low exercise tolerance chronic heart failure patient due inadequate increase co response exercise caused impaired hr response increased ne:0.0888872445788843",
    "124350": "objective cardiopulmonary function patient chronic heart failure chf severely limited holistic integrative exercise pathophysiology still unclear method signed consent form eighty three patient severe chf october october fuwai hospital performed ramp incremental loading program cardiopulmonary exercise testing cpet normal subject served control cpet performed according standard harbor ucla mc circulatory respiratory metabolic parameter cpet measured analyzed result peak oxygen uptake peak vo chf ml min kg pred significantly lower control ml min kg pred core parameter cpet anaerobic threshold peak oxygen pulse oxygen uptake efficiency platform ouep lowest carbon dioxide output ventilation ratio lowest vco carbon dioxide output ventilation slope vco slope chf significantly different control group p core parameter lung function forced expiratory volume first second fev forced vital capacity fvc fev fvc carbon monoxide diffusion dlco significantly decreased p systolic blood pressure stage cpet chf significantly lower control group p heart rate peak recovery stage significantly lower control p minute ventilation tidal volume respiratory frequency rest warm significantly higher control p tidal volume recovery significantly higher control p vo peak recovery stage chf significantly higher control p oxygen pulse peak significantly higher control p pulse oxygen saturation stage cpet chf significantly lower control p conclusion decreased holistic functional capacity cardiogenic chf dominantly due circulatory limitation secondly due respiratory metabolic limitation:0.0886709094722879",
    "157348": "background cardiopulmonary exercise testing cpx essential assessment exercise capacity patient chronic heart failure chf respiratory gas hemodynamic parameter ventilatory efficiency vco slope peak oxygen uptake peak vo heart rate recovery established diagnostic prognostic marker clinical population previous study suggested clinical value metric related respiratory gas collected recovery peak exercise particularly recovery time peak vo current study explores metric detail recovery peak exercise chf method patient chf referred cpx healthy individual without formal diagnosis assessed inclusion subject performed cpx cycle ergometer volitional exhaustion monitored least five minute recovery cpx data analyzed overshoot respiratory exchange ratio rer vco vo ventilatory equivalent oxygen vo end tidal partial pressure oxygen peto peak vo vco result thirty two patient chf control included peak vo differed significantly patient control v ml kg min p mean left ventricular ejection fraction lvef patient chf compared control group vo vco significantly higher patient control p overshoot peto vo rer significantly lower patient control p recovery metric significantly correlated peak vo chf patient lvef conclusion patient chf significantly blunted recovery peak exercise reflected delay vo vco peto rer vo reflecting greater energy required return baseline abnormal respiratory gas kinetics chf negatively correlated peak vo baseline lvef:0.0885006194607967",
    "8931": "background various respiratory abnormality associated chronic heart failure chf however change inspiratory capacity ic breathing pattern rest exercise patient chf thoroughly investigated patient material method seventy seven male female patient clinical stable chf age year studied patient underwent pulmonary function test including measurement ic maximal inspiratory pressure pimax rest maximal cardiopulmonary exercise testing cpet treadmill cpet ic measured every min pimax measured end cpet result percent predicted forced expiratory volume fev predicted forced vital capacity fvc fev fvc predicted ic peak exercise ic lower resting v l p analysis variance weber group revealed statistically significant difference peak exercise ic p vco slope p resting pimax p post exercise pimax p rest statistically significant difference end tidal co p etco p breathing frequency p inspiratory time ti p total respiratory time tot p among weber group peak exercise statistically significant decrease minute ventilation p tidal volume vt p respiratory cycle vt ti p p etco p peak ic correlated peak vo r p anaerobic threshold r p vo slope r p post exercise pimax r p conclusion patient chf peak exercise ic reduced parallel disease severity probably due respiratory muscle dysfunction:0.0882925849306714",
    "33694": "background skeletal muscle wasting associated altered catabolic anabolic balance poor prognosis patient chronic heart failure chf study evaluated catabolic anabolic abnormality relation disease severity chf patient method forty two stable chf patient men aged year body mass index kg receiving optimal medical treatment underwent incremental symptom limited cardiopulmonary exercise testing cycle ergometer blood sample drawn within day determine serum cortisol plasma adrenocorticotropin acth serum dehydroepiandrosterone sulfate insulin like growth factor growth hormone total testosterone men result patient higher cortisol level presented impaired peak oxygen uptake vo peak v ml kg min p ventilatory response exercise carbon dioxide output vco slope v p chronotropic reserve peak heart rate hr resting hr age resting hr x v p compared lower serum cortisol cortisol inversely correlated vo peak r p correlated vco slope r p chronotropic reserve r p multivariate regression analysis cortisol independent predictor vo peak r f se p vco slope r f se p accounting age body mass index sex chf etiology creatinine left ventricular ejection fraction acth patient men cortisol dehydroepiandrosterone level independent predictor vo peak r f se p accounting also measured hormone whereas cortisol remained independent predictor vco slope r f se p conclusion enhanced catabolic status significantly associated exercise intolerance ventilatory inefficiency chronotropic incompetence chf patient suggesting significant contributing mechanism limited functional status:0.0877364537427107",
    "40426": "background autonomic dysfunction reduced exercise tolerance typical feature patient congestive heart failure chf baro chemoreflex balance organ response may common role conditioning exercise tolerance ventilation chronotropic competence patient chf hypothesis tested hypothesis relationship functional capacity chronotropic competence exercise chf method stable outpatient chf age year men nyha class ejection fraction peak vo ml kg min performed cardiopulmonary exercise testing cpx heart rate hr response exercise assessed chronotropic index cri cri calculated following formula cri peak hr rest hr age rest hr x normal value relationship cri peak oxygen consumption vo ventilation carbon dioxide production vco ratio examined group healthy control underwent cpx well result cri correlated directly peak vo r p inversely vco r p patient chf cri identified patient chf peak vo ml kg min area receiver operating curve auroc confidence interval ci cri predicted exercise hyperventilation chf auroc vco ci cri significantly related either peak vo vco control group conclusion patient mild moderate chf cri correlate functional capacity relationship add new data pathophysiologic ground support routine incorporation cri cpx interpretation:0.0868628208339304",
    "2192": "background patient chronic heart failure complain breathlessness associated increase ventilatory response carbon dioxide production vco slope yet reduction maximal ventilation achieved peak exercise analysed ventilatory capacity heart failure relation exercise capacity method analysed data patient chronic stable heart failure age year left ventricular ejection fraction control year subject undertook maximal incremental exercise testing metabolic gas exchange measurement derive peak oxygen consumption vo vco slope ventilation spirometry used measure fev fvc maximal voluntary ventilation mvv calculated fev x result peak vo lower patient ml min kg v p vco greater v p ventilation peak exercise lower patient l min v p mvv l min v p ventilation peak proportion mvv patient control inverse relation peak vo vco slope r p percentage predicted fev correlated ventilation peak r p inversely vco slope r p relation percentage mvv achieved peak vo vco slope conclusion although ventilation peak exercise lower patient heart failure normal subject ventilation proportion maximal voluntary ventilation finding suggest ventilatory capacity limit exercise capacity heart failure:0.0859284465844451"
  },
  "Topic 12": {
    "55307": "left ventricular assist device lvads emerged beneficial therapeutic strategy proven improve morbidity mortality patient advanced heart failure continuous flow rotary lvads developed hope delivering circulatory support durable manner fewer device related complication heartmate r ii continuous flow left ventricular assist system lvas thoratec corporation pleasanton ca usa become standard care heart failure patient require long term mechanical circulatory support efficacy heartmate ii demonstrated patient temporary support lvad needed suitable donor organ found transplant termed bridge transplantation well terminally ill heart failure patient candidate transplant destination therapy directly compared pulsatile lvad implantation heartmate ii lvas resulted overall improvement survival reduction number device related complication adverse event purpose article threefold describe history development continuous flow lvads describe technology heartmate ii finally review clinical outcome patient implanted device:0.0719165070003126",
    "30744": "end stage heart failure represents highly morbid condition patient limited treatment option surgical perspective treatment option effective long term survival usually limited heart transplantation heart lung transplantation implantation destination mechanical circulatory support device assuming advanced heart failure patient indeed deemed candidate transplantation patient subject shortage donor organ availability thus possible decompensation potential death awaiting transplantation various extracorporeal implantable ventricular assist device vads may able provide temporary long term circulatory support many end stage heart failure patient mechanical circulatory support option patient requiring long term biventricular support remain limited implantation total artificial heart tah currently represents one best long term surgical treatment option patient requiring biventricular mechanical circulatory support bridge transplant clinical applicability available version positive displacement pump limited size complication application continuous flow technology help solving issue currently applied research towards new generation smaller effective tahs review discus history tah development clinical application implication anaesthetic management published outcome future outlook tahs:0.0714246208108946",
    "18907": "objective levitronix centrimag ventricular assist device vad centrifugal pump designed short term extracorporeal support cardiogenic shock aim study report clinical experience levitronix centrimag uni biventricular support method july december patient supported using levitronix centrimag device nineteen male mean age range year indication support implantation cardiogenic shock included end stage heart failure ill undergo transplantation questionable neurologic status subject right ventricular failure left vad lvad implantation subject post cardiotomy status subject acute donor graft failure heart transplantation subject result post vad day survival patient mean support time day patient range day mean support time levitronix biventricular vads range day mean support time levitronix lvads range day highest survival rate levitronix support donor graft failure cardiotomy levitronix right vad rvad support long term lvad insertion incurred hospital mortality survived patient discharged home vad support remain alive date two patient bridged primary another bridged repeat heart transplantation five patient weaned recovery operation bleeding occurred patient clinical evidence cerebral thromboembolism overwhelming sepsis aortic thrombus formation clot formation tubing observed patient necessitating emergent replacement bedside successful conclusion levitronix centrimag system reliable facile temporary circulatory support system bridge decision patient refractory acute cardiogenic shock:0.0682213011774384",
    "78412": "recent outstanding clinical advance new mechanical circulatory system mc led additional strategy treatment end stage heart failure hf heart transplantation htx postponed certain patient even replaced smaller implantable left ventricular assist device lvad mechanical support failing left ventricle enables appropriate hemodynamic stabilisation recovery secondary organ failure often seen severely ill patient new device may great help bridge patient suitable cardiac allograft available also discussed definitive treatment patient qualify transplantation main indication lvad implantation bridge recovery bridge transplantation destination therapy lvad may important tool patient expected prolonged period waiting list instance blood group b body weight kg potentially reversible secondary organ failure pulmonary artery hypertension however lvad implantation mean additional heart operation inherent peri operative risk complication waiting period finally cardiac transplantation patient prior implantation lvad represents surgical challenge review summarises current knowledge lvad continuous flow device especially since latter increasingly used worldwide recent year review also based institutional experience berne university hospital apart short term device impella cardiac assist deltastream ecmo used approximately case pulsatile long term lvad rvad bi vad non pulsatile lvad mainly heartmateii heartware implanted initial learning curve one year mortality dropped last patient:0.0678111605847865",
    "135161": "total artificial heart tah form mechanical circulatory support involves resection native ventricle followed placement device restore total pulmonary systemic flow given increasing burden congestive heart failure cardiovascular disease number people need cardiac replacement therapy continue grow despite aggressive effort expand donor pool number heart transplant united state u plateaued less per year addition increasing recognition long term complication current generation left ventricular assist device progressive aortic insufficiency complication related blood trauma early delayed right ventricular failure factor may serve expand role tah treatment patient end stage heart failure particularly new generation device developed durable improved safety profile totally implantable purpose review review role current evidence use tah management advanced heart failure discus development recent tahs may impact field near future recent finding many patient receive heart transplant bridged mechanical support device commonly left ventricular assist device lvad however small subset patient profound biventricular bv failure structural abnormality preclude lvad placement require support biventricular assist device bivad tah numerous study showing efficacy tah bridging transplantation also recent study shown equal rate bridging transplantation patient receiving tah compared bivad however bivad support higher incidence stroke addition complication related native heart arrhythmia valve dysfunction currently multiple new generation artificial heart preclinical development clinical trial bridge transplant destination therapy tah shown effective circulatory support select patient end stage heart failure current lvads associated significant long term complication related retention native heart pump design many complication may addressed increased use cardiac replacement therapy e total artificial heart multiple generation pulsatile advanced design continuous flow tah development potential expand role tahs:0.0676380095909940",
    "107302": "cardiogenic shock c continues high mortality morbidity despite advance pharmacological mechanical reperfusion approach treatment c refractory medical therapy percutaneous mechanical circulatory support mc considered acute mc device ranging intra aortic balloon pump iabps percutaneous temporary ventricular assist device vad extracorporeal membrane oxygenation ecmo aid restore maintain appropriate tissue perfusion development irreversible end organ damage technology improved patient survival recovery c patient cardiac recovery occur acute mc effectively utilized bridge long term mc device heart transplantation heart transplantation limited donor heart availability leading greater role left ventricular assist device lvad support patient biventricular failure ineligible lvad implantation advancement total artificial heart tah may allow improved survival compared medical therapy alone review discus current state acute durable mc ongoing advance lvads tah device improved method durable mc implantation patient selection future mc development dynamic field may allow optimization hf treatment:0.0675291666184112",
    "73038": "background heart transplantation gained recognition gold standard therapy advanced heart failure scarcity donor organ become important concern evolution surgical alternative ventricular assist device vads allow recovery myocardium ensure patient survival heart transplantation becomes possible report elaborates role vads bridge heart transplantation infant child year old end stage heart failure method retrospective review medical record heart transplant recipient may september identified child mean age year old iqr year advanced heart failure supported vad left vad lvad biventricular vad bvad bridge heart transplantation fourteen patient less year old child cardiac arrest underwent cardiopulmonary resuscitation patient also requiring extracorporeal membrane oxygenation ecmo support prior implantation vad aetiology heart failure primarily cardiomyopathy dilative restrictive endocardial fibrosis idiopathic toxic induced reported patient vads employed primarily berlin heart excor r n heartware n berlin heart incor r n toyobo n result mean duration vad support day range day iqr day donor heart became available primary complication encountered patient bridged transplant mediastinal bleeding main indication pump exchange thrombus formation valve incidence technical failure blood pump driving system component skin infection around cannulae occurred adverse neurological symptom thromboembolism cerebral haemorrhage occurred permanent neurological sequela could detected clinical examination study mean duration follow year iqr year cumulative survival rate patient bridged transplantation vad day year respectively statistically significant difference p survival rate patient bridged heart transplantation vad compared underwent primary heart transplantation post transplant survival rate stratified according type vad implanted number ventricle supported statistically different p respectively addition post transplant survival rate significantly different age gender diagnosis adjusted furthermore statistically significant difference found post transplant survival rate child episode rejection compared episode rejection conclusion result series demonstrate vads satisfactorily support paediatric patient advanced heart failure variety aetiology heart transplantation data suggests patient bridged vads comparable long term post transplant survival undergoing primary heart transplantation:0.0663573864028577",
    "86265": "recent outstanding clinical advance new mechanical circulatory system led additional strategy treatment end stage heart failure heart transplantation postponed certain patient even replaced smaller implantable left ventricular assist device lvads mechanical support failing left ventricle enables appropriate haemodynamic stabilization recovery secondary organ failure often seen severely ill patient new device may great help bridge patient suitable cardiac allograft available also discussed definitive treatment patient qualify transplantation main indication lvad implantation bridge recovery bridge transplantation destination therapy lvad may important tool patient expected prolonged period waiting list instance blood group b high low body weight potentially reversible secondary organ failure pulmonary artery hypertension however lvad implantation mean additional heart operation inherent perioperative risk complication waiting period finally cardiac transplantation patient prior implantation lvad represents surgical challenge care patient implantation miniaturized lvads heartware r system seems easier following pulsatile device explantation device time transplantation technically comfortable heartmate ii implantation:0.0643765731358634",
    "130305": "purpose review durable mechanical circulatory support mc technology changed time device evolved pulsatile continuous flow support review discus recent data substantial change current practice pertains subject current era durable left ventricular assist device lvads bridge heart transplantation recent finding result heart transplantation patient bridged durable lvad support satisfactory even prolonged duration support report recent experience lvad related infection suggest complication limited impact post transplant outcome important sex related disparity continue exist following durable lvad implantation recent change united network organ sharing donor heart allocation policy resulted drastic decline use durable lvad support bridge transplant united state summary durable mc form lvad btt strategy continues evolve time optimization role treatment end stage heart failure particularly female need focus future research:0.0640307004474935",
    "80594": "child heart failure unresponsive medical therapy left option survival ventricular assist device vads life saving option patient allowing bridge transplantation cardiac recovery retrospective review case may october undertaken fourteen patient underwent implantation vads refractory heart failure mean age year range year weight kg range kg indication support end stage cardiomyopathy n myocarditis n univentricular failure n congenital heart disease postcardiotomy n level limitation time implant included critical cardiogenic shock six progressive decline eight extracorporeal membrane oxygenation used bridge vad five patient preimplant variable patient requiring mechanical ventilation mean day hyperbilirubinemia acute renal insufficiency device selection systemic vad biventricular assist device three berlin heart excor used eight patient six patient received thoratec implantable vad paracorporeal vad mean duration support day range day overall survival ten patient successfully bridged transplantation three died device one remains support patient weaned vad child supported single ventricle heart failure survival none currently bridged transplantation complication included bleeding requiring reoperation n stroke n driveline infection n two patient total six pump exchange performed thrombus formation survival pediatric patient age excellent using current device technology majority patient successfully bridged transplantation morbidity acceptably low considering severity illness significant challenge exist long term extracorporeal support due lack donor availability high incidence preformed alloantibody especially failing single ventricle:0.0640159253642239"
  },
  "Topic 13": {
    "113645": "background puerarin show inhibitory effect inflammation chronic heart failure chf efficacy coronary heart disease chd remained vague method rat chd model constructed serum parameter determined using blood liquid biochemical analyzer also content creatine kinase ck creatine kinase mb isoenzyme ck mb lactate dehydrogenase ldh cardiac troponin ctnt measured using colorimetry histological examination conducted hematoxylin eosin h e staining cardiac function assessed echocardiography cell apoptosis detected using terminal deoxynucleotidyl transferase mediated dutp nick end labeling tunel assay relative expression measured using quantitative real time polymerase chain reaction qrt pcr western blot needed result chd rat level tc ldl tg expression matrix metalloproteinase mmp cd ligand cd l tumor necrosis factor alpha tnf alpha c reactive protein crp increased hdl level decreased accompanied inflammatory cell infiltration cardiac malfunction also content ck ck mb ldh ctnt percentage apoptotic cell expression bcl associated x protein bax cleaved caspase tnf alpha interleukin beta il beta il lipoprotein associated phospholipase lp pla expression level oxidized ox ldl malondialdehyde mda upregulated level super oxidase dismutase sod expression b cell lymphoma bcl vascular endothelial growth factor vegf downregulated however puerarin ameliorated effect chd model construction suppressed nuclear factor nf kappab expression enhanced expression farnesoid x receptor fxr phosphorylated akt p akt phosphorylated signal transducer activator transcription p stat conclusion puerarin alleviated chd rat via inhibiting inflammation providing possible method chd treatment:0.0627066681189842",
    "196818": "ethnopharmacological significance therapeutic efficacy ershen zhenwu decoction eszwd famous formulation xin patient chronic heart failure heart kidney yang deficiency chf hkyd well established still underlying molecular mechanism clear aim study study investigated mechanism eszwd suppresses cardiac pathology including myocardial fibrosis chf hkyd model rat ang ii stimulated cardiac fibroblast cf material method component eszwd analyzed ultra high performance liquid chromatography coupled quadrupole time flight mass spectrometry uhplc q tof m chf hkyd model established male sprague dawley rat bilateral thyroidectomy intraperitoneal administration doxorubicin dox twice weekly week subsequently chf hkyd model rat randomly categorized model eszwd l g kg eszwd eszwd g kg eszwd eszwd h g kg eszwd sac val mg kg sacubitril valsartan group treated daily week control sham surgery group sham used primary cardiac fibroblast cf categorized control model eszwd sac val group cf stimulated ang ii eszwd sac val group incubated different concentration drug containing serum effect cf viability assessed via cck assay eszwd sac val group received drug containing serum concentration determined cck assay result cardioprotective effect eszwd determined using echocardiography hematoxylin eosin h e staining masson staining sirius red staining enzyme linked immunosorbent assay elisa eszwd effect ra homolog gene family member rhoa rho associated coiled coil kinase rock signaling pathway myocardial fibrosis assessed western blotting quantitative real time pcr qrt pcr analysis immunofluorescence used observe fibrotic marker cf result eszwd treatment improved cardiac function chf hkyd rat significantly reducing myocardial fibrosis ventricular remodeling eszwd treatment increased rat body temperature b h urine volume left ventricular ejection fraction lvef lv fractional shortening lvfs decreased lv internal systolic diameter lvids lv internal diastolic diameter lvidd heart weight body weight hw bw compared model group comparison model rat eszwd treatment decreased serum level b type natriuretic peptide precursor nt probnp tumor necrosis factor alpha tnf alpha interleukin il il eszwd treatment significantly regulated protein mrna expression level collagen alpha sma rhoa rock rock heart tissue chf hkyd rat ang ii stimulated cf conclusion eszwd significantly improved cardiac function attenuated myocardial fibrosis inflammation chf hkyd rat inhibiting rhoa rock signaling pathway:0.0624232088903696",
    "73318": "background aim study investigate effect sulforaphane sfn natural isothiocyanate compound rabbit ascending aortic cerclage model chronic heart failure chf material method thirty new zealand white rabbit divided sham operation group n chf group n chf sfn group n treated subcutaneous sfn mg kg five day per week week week echocardiography biometric analysis performed followed examination rabbit heart enzyme linked immunosorbent assay elisa western blot used detect level inflammatory cytokine superoxide dismutase sod malondialdehyde mda result chf group compared sham operation group increase heart weight body weight ratio hw bw left ventricular weight body weight ratio lvw bw left ventricular end diastolic diameter lvedd left ventricular end systolic diameter lvesd plasma brain natriuretic peptide bnp atrial natriuretic peptide anp level cardiac collagen volume fraction cvf apoptotic index expression level collagen collagen iii tumor necrosis factor alpha tnf alpha interleukin il malondialdehyde mda myocardial tissue decrease left ventricular shortening fraction lvfs left ventricular ejection fraction lvef cardiac superoxide dismutase sod activity change corrected sfn treated group conclusion rabbit model chf treatment sfn improved cardiac function remodeling inhibiting oxidative stress inflammation:0.0601664592234543",
    "185724": "objective aim study investigate protective effect mechanism action moa qiliqiangxin capsule ql deoxycorticosterone acetate doca salt induced rat heart failure preserved ejection fraction hfpef model material method nono nephrectomy sixty sprague dawley sd rat received doca salt injection saline drinking water week randomly divided four group average model group n sac val group sacubitril valsartan g kg n ql l group qiliqiangxin g kg n ql h group qiliqiangxin g kg n another normal group set n blood pressure n terminal pro brain natriuretic peptide nt probnp cardiac index echocardiography hemodynamics measured evaluate heart function masson wheat germ agglutinin wga staining performed observe fibrosis deposition cross sectional area csa cardiomyocytes concentration level serum cytokine including tumor necrosis factor alpha tnf alpha interleukin il il il inflammatory factor detected elisa matrix metalloproteinase mmp matrix metalloproteinase mmp transforming growth factor beta tgf beta nuclear factor kappab nf kappab smad homologue smad smad homologue smad expression detected western blot result compared model group ql treatment significantly ameliorated heart function doca salt induced rat hfpef model showing decrease cardiac index increase ef e ratio reduction left ventricular anterior posterior wall lvaw lvpw time contraction isovolumic diastolic time ivrt dp dt max tau decrease serum nt probnp masson wga staining indicated ql inhibited fibrosis deposition myocardial hypertrophy compared model group consistent reducing protein expression level cardiac remodeling tgf beta mmp mmp smad smad moreover ql treatment inhibited expression nf kappab heart tissue decreased serum concentration pro inflammatory cytokine tnf alpha il instead increasing il concentration conclusion ql improved cardiac function inhibited myocardial fibrosis doca salt induced rat hfpef improving diastolic dysfunction preventing left ventricular hypertrophy ameliorating inflammatory response model doca salt induced rat hfpef model:0.0589989011242695",
    "34885": "others previously demonstrated heme oxygenase ho induction acute hemin administration exerts cardioprotective effect developed rat model heart failure investigate whether long term induction ho chronic hemin administration exerted protective effect sprague dawley rat underwent permanent ligation left coronary artery closely monitored survival rate analysis sacrificed day post operation administration hemin mg kg body weight every day week induced massive increase ho expression activity shown increased level two main metabolic product heme degradation bilirubin carbon monoxide co effect associated significant improvement survival reduced extension myocardial damage ischemic heart hemin treated animal displayed reduced oxidative stress apoptosis comparison non treated rat shown decreased level lipid peroxidation free radical induced dna damage caspase activity bax expression besides chronic ho activation suppressed elevated level myeloperoxidase mpo activity interleukin beta il beta production tumor necrosis factor alpha tnfalpha production evoked ischemic injury increased plasma level anti inflammatory cytokine il interestingly ho inhibitor zinc protoporphyrin ix znpp ix mg kg lowered bilirubin co concentration control value thus abolishing cardioprotective effect hemin conclusion result demonstrate chronic ho activation prolonged administration hemin improves survival exerts protective effect rat model myocardial ischemia exerting potent antioxidant activity disrupting multiple level apoptotic inflammatory cascade:0.0570112031682266",
    "73982": "objective observe therapeutic effect mechanism dunhuang liaofengxushouruo decoction lxd traditional chinese medicine chronic heart failure chf rat method forty eight male wistar rat randomly divided normal group n model group captopril group lxd traditional chinese medicine high medium low dose group except normal group rat intravenous injected adriamycin mg kg one day week captopril rat intragastric administrated captopril mg kg lxd high medium low dose group intragastric administrated lxd g kg consecutive week rat breathing coat color activity body weight bw time exhaustive swimming measured heart rate mean arterial pressure map left ventricular systolic pressure lvsp left ventricular end diastolic pressure lvedp maximal rate left ventricular pressure dp dtmax dp dtmax rat examined power lab level interleukin il tumor necrosis factor alpha tnf alpha measured rat sacrificed heart removed separation left right ventricle antioxidant activity ventricular mass index measured left ventricular myocardium administrated paraformaldehyde staining morphological change observed microscope result body weight group decreased time exhaustive swimming decreased modeling p day administration bw high middle dose lxd group increased swimming time rat lxd high dose group increased p day bw lxd group increased exhaustive swimming time high middle dose lxd prolonged p map decreased lvsp dp dtmax dp dtmax increased lxd high middle group lvedp decreased high dose lxd group p p level creatine kinase ck aspartate aminotransferase ast middle low dose lxd group decreased p p serum level il tnf alpha malondialdehyde mda serum lxd high middle dose group lower activity superoxide dismutase sod serum increased lxd group lvmi rvmi decreased high middle dose lxd group p p pathological result showed myocardial fiber arrangement myocardial interstitial edema phenomenon obviously improved high dose lxd group cmd decreased conclusion therapeutic effect lxd chf doxorubicin induced rat confirmed mechanism associated improved hemodynamics myocardial tissue:0.0552763105916853",
    "69649": "objective evaluate effect oltipraz opz isoproterenol induced heart failure hf heart function also explore underlying molecular mechanism opz material method rat randomly divided four group including normal control group isoproterenol iso group iso mg kg opz group opz group hemodynamic parameter left ventricular systolic pressure statistically analyzed besides plasma level brain natriuretic peptide bnp pro inflammatory cytokine antioxidant marker assessed using enzyme linked immunosorbent assay elisa moreover histopathological examination applied assess degree cardiac interstitial fibrosis result opz could statistically improve hemodynamic parameter heart function could also obviously attenuate cardiac interstitial fibrosis iso induced hf rat compared iso group besides plasma level bnp iso mg kg opz group dramatically decreased comparison iso group moreover compared iso group opz treatment significantly reduced level pro inflammatory cytokine tumor necrosis factor alpha tnf alpha interleukin beta il beta moreover opz treatment remarkably increased level antioxidant marker superoxide dismutase sod glutathione peroxidase gpx iso induced hf rat conclusion opz administration may provide experimental evidence possible effect opz isoproterenol induced heart failure rat moreover opz administration may potential utility treatment heart failure:0.0550466108362470",
    "149810": "alleviating cardiac dysfunction improves prognosis heart failure patient lycorine alkaloid several beneficial biological property used mouse evaluate effect lycorine cardiac dysfunction elicited isoproterenol mouse divided four group control lycorine isoproterenol isoproterenol lycorine mouse combined group treated daily mg kg isoproterenol intraperitoneally week mg kg lycorine given simultaneously intraperitoneally week cardiac structure function assessed echocardiography hematoxylin eosin staining masson trichrome staining isoproterenol induced cardiac dysfunction histopathological injury significantly improved treatment lycorine western blotting quantitative real time polymerase chain reaction used explore molecular mechanism effect level inflammatory cytokine interleukin il beta il tumor necrosis factor alpha increased treatment isoproterenol increase significantly reduced lycorine involvement nf kappab signaling pathway fibrotic factor collagen collagen iii increased isoproterenol decreased treatment lycorine inhibiting activation smad signaling pathway addition lycorine alleviated oxidative stress evidenced reduction total reactive oxygen specie isoproterenol lycorine group compared isoproterenol group lycorine exerted anti apoptotic effect evidenced upregulating bcl downregulating bax overall finding demonstrate lycorine protects cardiac dysfunction induced isoproterenol inhibiting inflammation fibrosis oxidative stress apoptosis:0.0543945424738728",
    "165392": "investigate effect luhong yixin granule myocardial fibrosis rat heart failure possible mechanism total male wistar rat randomly divided control group model group low medium high dose luhong yixin granule group rat group except control group rat group induced intraperitoneal injection doxorubicin dox rat model luhong yixin granule dissolved amount normal saline given gavage low medium high dos g kg control group model group given amount normal saline gavage day end dosing echocardiography used measure left ventricular ejection fraction lvef left ventricular fractional shortening lvfs rat body weight bw heart weight hw calculated hw bw enzyme linked immunosorbent assay used measure level interleukin il interleukin il tumor necrosis factor alpha tnf alpha transforming growth factor beta tgf beta growth stimulation expressed gene protein st n terminal pro b type natriuretic peptide nt probnp galectin gal creatine kinase isoenzyme ck mb serum hematoxylin eosin staining masson staining used observe pathological morphology myocardial tissue western blot quantitative real time polymerase chain reaction used detect protein mrna expression level il il tnf alpha tgf beta smad smad alpha smooth muscle actin alpha sma collagen col respectively result showed compared control group lvef lvfs hw bw model group decreased p lt level il il tnf alpha tgf beta st nt probnp gal ck mb increased p lt staining showed inflammatory change myocardial tissue masson staining showed decrease cross sectional area ventricular cavity area heart myocardial fibrosis varying degree p lt protein mrna expression il il tnf alpha tgf beta smad alpha sma col increased p lt protein mrna expression smad protein decreased p lt compared model group lvef lvfs hw bw low medium high dose luhong yixin granule group increased p lt level il il tnf alpha tgf beta st nt probnp gal ck mb decreased p lt staining showed gradually reduced inflammatory change myocardial tissue masson staining showed increased cross sectional area ventricular cavity area heart decreased area myocardial fibrosis p lt protein mrna expression level il il tnf alpha tgf beta smad alpha sma col decreased p lt protein mrna expression level smad increased p lt luhong yixin granule may great value treatment heart failure regulating tgf beta smads signaling pathway inhibiting expression inflammation related protein reducing deposition extracellular matrix alleviating myocardial fibrosis:0.0541498257999551",
    "14813": "ghrelin novel growth hormone releasing peptide shown exert beneficial cardiac effect chronic heart failure chf recently study attempted investigate mechanism effect ghrelin ventricular remodeling following acute myocardial infarction mi ligation coronary artery used create mi rat one week mi ghrelin microg kg saline injected subcutaneously twice day week compared sham group ghrelin administration significantly decreased left ventricular lv remodeling post mi rat indicated increased lv maximum rate pressure lv fractional shortening scar thickness decreased lv end diastolic pressure lv end systolic diameter lv end diastolic diameter cardiocytocytes apoptosis moreover ghrelin inhibited inflammatory response shown decreased mrna protein level interleukin il beta tumor necrosis factor alpha tnf alpha subsequently expression matrix metalloproteinase mmp mmp also inhibited ghrelin injection ghrelin alleviates lv dysfunction ventricular remodeling post mi rat suggests beneficial effect ghrelin chf may result inhibition inflammatory response:0.0539168715107287"
  },
  "Topic 14": {
    "130454": "background left bundle branch area pacing lbbap emerged promising technique deliver cardiac resynchronization therapy crt however safety efficacy ventricular arrhythmia sensing via left bundle implantable cardioverter defibrillator icd recipient remain unclear sought evaluate feasibility single lbbap lead connected dual chamber icd patient indicated crt implantation method cross left pilot study prospectively included consecutive patient reduced ejection fraction complete left bundle branch block indicated prophylactic crt df lead implanted right ventricular rv apex lbbap lead interventricular septum ventricular fibrillation induced implantation conventional rv left bundle branch area sensing configuration latter final sensing configuration patient implanted dual chamber df icd connected atrial lead ra port lbbap lead rv port defibrillation lead rv df port pin capped atrioventricular delay optimized ensure fusion lbbap native conduction right bundle patient followed month result difference configuration observed regarding r wave sensing sinus rhythm p ventricular fibrillation median interval detection p total induced episode duration p lbbap resulted significant reduction median qrs width m p median ventricular sensing significantly improved implantation mv month p median lvef also significantly improved month p conclusion ventricular arrhythmia sensing defibrillation performed via single lbbap lead connected dual chamber icd associated significant electromechanical reverse remodeling clinical trial registration number nct patient presenting left bundle branch block left ventricular systolic dysfunction left bundle branch area pacing lead connected df dual chamber implantable cardioverter defibrillator provides safe ventricular arrhythmia sensing efficient electro mechanical resynchronization:0.0581048644605000",
    "83666": "multisite pacing treatment heart failure added new dimension electrocardiographic evaluation device function left ventricular lv pacing appropriate site coronary venous system correctly positioned lead v register right bundle branch block pattern exception biventricular stimulation associated right ventricular rv apical pacing qrs often positive lead v frontal plane qrs axis usually right superior quadrant occasionally left superior quadrant barring incorrect placement lead v high chest lack lv capture lv lead displacement marked latency exit block delay stimulation site ventricular fusion spontaneous qrs complex negative qrs complex lead v biventricular pacing involving rv apex probably reflects different activation heterogeneous biventricular substrate ischemia scar purkinje participation view varying pattern lv activation spontaneous left bundle branch block necessarily indicate poor electrical mechanical contribution lv stimulation situation imperative rule presence coronary venous pacing via middle cardiac vein even unintended placement two lead rv biventricular pacing rv lead outflow tract paced qrs lead v often negative frontal plane paced qrs axis often directed right inferior quadrant right axis deviation patient sinus rhythm relatively short pr interval ventricular fusion competing native conduction biventricular pacing may cause misinterpretation ecg narrowing paced qrs complex simulates appropriate biventricular capture represents common pitfall device follow elimination ventricular fusion shortening av delay often associated clinical improvement anodal stimulation may complicate threshold testing misinterpreted pacemaker malfunction one must cognizant various disturbance disrupt atrial tracking cause loss ventricular resynchronization upper rate response upper rate response biventricular pacemaker differs traditional wenckebach upper rate response conventional antibradycardia pacemaker heart failure patient generally sinus bradycardia av junctional conduction delay programmed upper rate sufficiently fast avoid loss resynchronization situation associated sinus tachycardia programmed upper rate may caused variety event especially ventricular premature complex favored presence first degree av block alter timing sensed paced event case atrial event become trapped postventricular atrial refractory period atrial rate programmed upper rate presence spontaneous av conduction algorithm available restore resynchronization automatic temporary abbreviation postventricular atrial refractory period:0.0577639302935086",
    "35409": "bundle branch reentrant bbr tachycardia uncommon form ventricular tachycardia vt incorporating bundle branch reentry circuit arrhythmia usually seen patient acquired heart disease significant conduction system impairment although patient structurally normal heart described surface ecg sinus rhythm sr characteristically show intraventricular conduction defect patient typically present presyncope syncope sudden death vt fast rate frequently beat per minute qrs morphology vt typical bundle branch block pattern usually left bundle branch block may identical sr prolonged ventricular h v interval sr found majority patient bbr vt although patient may h v interval within normal limit diagnosis bbr vt based electrophysiological finding pacing maneuver prove participation purkinje system tachycardia mechanism radiofrequency catheter ablation bundle branch cure bbr vt currently regarded first line therapy technique choice ablation right bundle reported incidence clinically significant conduction system impairment requiring implantation permanent pacemaker varies long term outcome depends underlying cardiac disease patient poor systolic left ventricular function risk sudden death death progressive heart failure despite successful bbr vt ablation considered implantable cardiovertor defibrillator:0.0564334853578652",
    "186343": "background electrocardiographic ecg feature left bundle branch lbb block lbbb observed patient suffering heart failure reduced ejection fraction however predicting lbbb patient benefit cardiac resynchronization therapy crt conduction system pacing remains challenging study aimed establish translational model lbbb enhance understanding pathophysiology improve therapeutic approach method fourteen male pig underwent radiofrequency catheter ablation proximal lbb fluoroscopy ecg guidance comprehensive clinical assessment lead ecg bloodsampling echocardiography electroanatomical mapping conducted lbbb induction day three pig received crt pacemaker day lbb ablation assess resynchronization feasibility result following proximal lbb ablation ecg displayed characteristic lbbb feature including qrs widening slurring left lateral lead qrs axis change qrs duration increased m m r wave peak time v extended m m echocardiography confirmed cardiac electromechanical dyssynchrony septal flash appearance prolonged septal posterior wall motion delay extended ventricular electromechanical delay electroanatomical mapping revealed left ventricular breakthrough site shift significantly prolonged left ventricular activation time rf induced lbbb persisted week crt reduced qrs duration m demonstrating successful resynchronization conclusion porcine model accurately replicates electrical electromechanical characteristic lbbb observed patient provides practical cost effective reproducible platform investigate molecular translational aspect cardiac electromechanical dyssynchrony controlled clinically relevant setting:0.0561630398507343",
    "99529": "background novel metric electrical dyssynchrony based multi electrode mapping ecg based marker fusion better predictor cardiac resynchronization therapy crt response qrs duration objective describe new methodology measuring electrical synchrony based wavefront fusion electrocardiographic cancellation patient crt potential crt optimization method patient left bundle branch block lbbb type conduction crt n studied multiple device setting using ecg belt anterior posterior electrode area combination anterior posterior curve auc calculated cardiac resynchronization index cri defined percent change auc compared lbbb result patient complete heart block atrial fibrillation cri optimal ventriculo ventricular delay vvd m significantly higher simultaneous biventricular pacing bivp v p patient paced lv lv paced wavefront ahead native wavefront short atrio ventricular delay avd cri increased increase avd peaked decreased optimal cri lv pacing significantly better optimal cri simultaneous bivp v p occurred avd m less atrial rv sensed interval sequential bivp best cri lv preactivation m best cri setting markedly better cri standard setting v p conclusion describe novel non invasive investigational tool quantifies wavefront fusion electrical dyssynchrony may allow individualized crt optimization:0.0542092017858833",
    "35941": "aim malignant ventricular arrhythmia arise subset congestive heart failure chf patient undergo cardiac resynchronization therapy crt thus counteracting haemodynamic benefit typically associated biventricular pacing study seek assess whether alteration ventricular transmural repolarization conduction due reversal depolarization sequence epicardial biventricular pacing facilitate development ventricular arrhythmia method result ecg monophasic action potential map recorded programmed stimulation right ventricle rv endocardium rv endo left ventricle lv epicardium lv epi biventricular bi v individual without structural heart disease patient severe chf crt n ecg collected rv endo lv epi bi v pacing map duration intracardiac electrogram qt jt peak end interval ecg different pacing site measured compared subject without structural heart disease compared rv endo pacing lv epi bi v pacing resulted longer jt m lv epi m bi v v m rv endo chf individual p peak end interval m lv epi m bi v v m rv endo normal heart subject p m lv epi m bi v v m rv endo chf patient p addition prolonged myocardial repolarization time delayed endocardial activation follow sudden death arrhythmia storm occurred two chf patient crt conclusion epicardial biventricular pacing prolong time increase dispersion myocardial repolarization delay transmural conduction considered potential arrhythmogenic factor chf patient receive crt:0.0539267376583962",
    "6269": "background cardiac resynchronization therapy crt improves hemodynamics decrease heart failure symptom however potential crt bring electrical remodeling heart investigated method result studied patient nonischemic cardiomyopathy ischemic cardiomyopathy left bundle branch block lbbb right bundle branch block rbbb nonspecific intraventricular conduction delay routine device clinic visit patient chronic biventricular pacing month reprogrammed vvi allow native conduction resume minute native rhythm surface electrocardiogram ecg recorded previous device setting restored ecg compared preimplant ecg preimplant mean ejection fraction range follow mean ejection fraction mean time implant follow ecg month range qrs interval prior crt m shortened m p qrs axis shifted p significant change pr qtc interval heart rate conclusion crt lead decrease surface qrs duration without affecting surface ecg parameter reduced electrical activation time may reflect change specialized conduction system intramyocardial impulse transmission:0.0538904135761627",
    "185137": "left bundle branch area pacing lbbap emerged promising physiological pacing modality study designed investigate acute impact atrioventricular delay avd cardiac electrical characteristic identify optimal range avds lbbap achieve electrical atrioventricular interventricular synchrony patient indicated ventricular biventricular pacing studied routine follow ups least month lbbap implantation patient excluded complete av block persistent atrial fibrillation avd programed m intrinsic conduction occurred optimal avd determined electrocardiography criterion including qrs duration reduced r wave lead v reduced notching slurring lateral lead desirable precordial qrs transition total patient age year male dual chamber pacemaker cardiac resynchronization therapy device average follow period month included fusion lbbap intrinsic right ventricular conduction occurred patient corresponding optimal avd determined great proportion approximately optimal avds ranged observed atrium left bundle branch sensing lbbs interval linear correlation optimal avd corresponding lbbs interval optimal avd x lbss interval m produced r p conclusion avd selection lbbap greatly impacted ventricular electrical characteristic optimal avd linearly correlated corresponding lbbs interval:0.0536492565523821",
    "112246": "cardiac pacing effective therapy treating patient bradycardia due sinus node dysfunction atrioventricular block however traditional right ventricular apical pacing rvap cause electric mechanical dyssynchrony associated increased risk atrial arrhythmia heart failure therefore need develop physiological pacing approach activates normal cardiac conduction provides synchronized contraction ventricle although bundle pacing hbp widely used physiological pacing modality limited challenging implantation technique unsatisfactory success rate patient wide qrs wave high pacing capture threshold early battery depletion recently left bundle branch pacing lbbp defined capture left bundle branch lbb via transventricular septal approach emerged newly physiological pacing modality result early clinical study demonstrated lbbp feasibility safety rare complication high success rate overall approach found provide physiological pacing guarantee electrical synchrony left ventricle low pacing threshold previously specifically characterized narrow paced qrs duration large r wave fast synchronized left ventricular activation correction left bundle branch block therefore lbbp may potential alternative pacing modality rvap cardiac resynchronization therapy hbp biventricular pacing bvp however technique widespread adaptation need validation ascertain safety efficacy randomized clinical trial review discus current knowledge lbbp:0.0531012628294004",
    "142021": "cardiac resynchronization therapy crt proven efficacious reducing even eliminating cardiac dyssynchrony thus improving heart failure symptom however quantification mechanical dyssynchrony still difficult identification crt candidate currently based morphology width qrs complex standard lead ecg brings limited information pattern ventricular activation aimed study change produced different pacing mode body surface potential map bspm total crt recipient symptomatic heart failure nyha ii iv sinus rhythm qrs width m healthy control studied mapping system biosemi unipolar electrode used bspm acquisition maximum qrs duration longest shortest activation time atmax atmin dispersion qt interval qtd measured calculated spontaneous rhythm single site right left ventricular pacing biventricular pacing echo optimized av delay moreover studied impact crt location early late activated region heart average value spontaneous rhythm group patient dyssynchrony qrs m atmax m atmin m qtd m significantly differed measured control group qrs m atmax m atmin m qtd m right ventricular pacing rvp improved significantly atmax m p measured parameter left ventricular pacing lvp succeeded improvement parameter qrs m p atmax m p atmin m p qtd m p biventricular pacing bvp showed also beneficial effect parameter qrs m p atmax m p atmin m p qtd m p result proved beneficial outcome lvp bvp evaluated parameter seems important particularly case activation time revealed complete return activation time normal distribution using crt modality:0.0525794109759879"
  },
  "Topic 15": {
    "188879": "primary treatment autoimmune diabetes mellitus type diabetes mellitus dm insulin therapy unfortunately multitude clinical case demonstrated use insulin sole therapeutic intervention fails address issue comprehensively therefore non insulin adjunct treatment investigated shown successful result clinical trial various hypoglycemia inducing drug metformin glucagon like peptide glp receptor agonist dipeptidyl peptidase dpp inhibitor amylin analog sodium glucose cotransporters sglt inhibitor developed good outcome patient dm currently sglt inhibitor remarkably improved treatment patient diabetes preventing cardiovascular event heart failure hospitalization progression renal disease however pharmacological potential explored enough thus substantial interest sglt inhibitor sglt underline present review begin overview carrier mediated cellular glucose uptake evidencing insulin independent transport system contribution glucose homeostasis essential role sodium glucose cotransporters pharmacological property sglt detailed leading potential application treating dm patient automated insulin delivery aid system result several study demonstrated improvement glycemic control increase time range tir decrease glycemic variability reduced daily insulin requirement without increasing hyperglycemic event benefit weight management however advantage counterbalanced increased risk particularly concerning diabetic ketoacidosis dka several clinical trial reported higher incidence dka patient dm received sglt inhibitor sotagliflozin empagliflozin hand patient dm body mass index bmi kg treated dapagliflozin showed similar reduction hyperglycemia body weight insignificantly increased dka incidence compared overall trial population additional multicenter randomized study required establish safer effective long term strategy based patient selection education continuous ketone body monitoring optimal integration sglt inhibitor dm therapeutic protocol:0.0740030331839190",
    "144234": "pharmacotherapy type diabetes mellitus dm markedly evolved last two decade classical antidiabetic agent sulphonylureas metformin insulin competition new glucose lowering medication alpha glucosidase inhibitor thiazolidinediones glitazones able replace older agent insufficient efficacy poor tolerability safety contrast incretin based therapy dipeptidyl peptidase inhibitor dpp gliptins oral agent glucagon like peptide receptor agonist glp ra subcutaneous injection major breakthrough management dm associated hypoglycaemia weight gain dpp tend replace sulphonylureas add metformin glp ra tend replace basal insulin therapy failure oral therapy furthermore placebo controlled cardiovascular outcome trial demonstrated neutrality dpp cardiovascular protection glp ra patient dm high cardiovascular risk recently sodium glucose cotransporter inhibitor sglt gliflozins oral agent also showed cardiovascular protection especially reduction hospitalization heart failure well renal protection patient without dm high cardiovascular risk established heart failure chronic kidney disease thus glp ra sglt considered preferred drug dm patient high risk atherosclerotic cardiovascular disease whereas sglt specifically recommended patient risk heart failure renal albuminuric disease management dm moving glucocentric approach broader strategy focusing risk factor including overweight obesity organ disease targeted personalized approach:0.0722045741893206",
    "185318": "cardiovascular complication renal disease growing cause mortality patient diabetes subversive complication diabetes hyperglycemia hyperlipidemia insulin resistance lead increase risk myocardial infarction mi stroke heart failure hf well chronic kidney disease ckd among commercially available anti hyperglycemic agent incretin based medication appear safe effective treatment type diabetes mellitus dm associated cardiovascular renal disease glucagon like peptide receptor agonist glp ra shown fruitful reducing hba c blood glucose lipid profile body weight diabetic patient several preclinical clinical study revealed safety efficacy preventive advantage glp ra diabetes induced cardiovascular kidney disease data cardio renal outcome trial highlighted glp ra protected people established ckd significant cardiovascular disease lowered likelihood hospitalization heart failure hhf lowered cause mortality also positive effect people end stage renal disease esrd ckd beside clinical outcome glp ra reduced oxidative stress inflammation fibrosis improved lipid profile pre clinically diabetic model cardiomyopathy nephropathy demonstrated cardio protective reno protective effect glp ra review focused recent clinical preclinical outcome glp ra cardio protective reno protective agent glp ra medication demonstrated effective treating dm diabetes induced cardiovascular renal disease currently available treatment clinic without inducing hypoglycemia weight gain:0.0713391311892368",
    "145593": "type diabetes leading cause chronic kidney disease worldwide continues increase prevalence turn significant implication healthcare provision economy recent year multiple advance glucose lowering agent available treatment diabetes modify disease also important benefit term associated cardiovascular outcome cardiovascular outcome trial agent glucagon like peptide receptor agonist glp ra sodium glucose cotransporter inhibitor sglt demonstrated significant benefit reducing major adverse cardiovascular event admission heart failure case mortality secondary analysis trial also indicated significant renoprotective benefit canagliflozin renal outcome type diabetes mellitus nephropathy credence renal specific trial shown major benefit canagliflozin renal outcome diabetic kidney disease similar trial sglt inhibitor either underway awaiting analysis article review current goal treatment diabetes implication advancing renal impairment choice treatment area discussed include diagnosis diabetic kidney disease current treatment strategy diabetic kidney disease ranging lifestyle modification glycaemic control review focus role glp ra sglt inhibitor treating diabetes chronic kidney disease illustrative case clear agent considered first choice combination metformin diabetes increased cardiovascular risk reduced renal function preference class dipeptidyl peptidase dpp inhibitor sulphonylureas:0.0708797187861199",
    "67327": "randomized controlled trial rcts intensive glucose control patient type diabetes lead modest reduction major cardiovascular event mace associated reduction kidney event reduction eye event fda issued guidance led conduct numerous cardiovascular outcome cvot trial assess cardiovascular safety new antihyperglycemic therapy patient type diabetes result trial show insulin glargine three different dipeptidyl peptidase dpp inhibitor saxagliptin alogliptin sitagliptin lixisenatide glucagon like peptide receptor agonist produce significant difference cvot compared usual care placebo trial newer diabetes drug including empagliflozin canagliflozin two sodium glucose co transporter inhibitor liraglutide semaglutide two glp receptor agonist succeeded demonstrating cv benefit people type diabetes last two decade equation diabetes equal myocardial infarction contributed development preventive therapy risk factor diabetes primary secondary prevention diabetic patient high rate statin aspirin treatment improved cv outcome compared non user drug used reduce glucose level patient type diabetes seem important ultimate cardiovascular outcome combination intensive glycemic control safely attainable newer diabetes drug empagliflozin canagliflozin liraglutide semaglutide may decrease incidence mace nephropathy retinopathy moreover depending drug used cv mortality heart failure may also reduced:0.0704926825645883",
    "139535": "diabetes mellitus group metabolic disorder result deficiency insulin secretion sensitivity type diabetes mellitus range predominant insulin resistance relative insulin secretory deficiency insulin resistance predominant insulin secretory deficiency disease progress several risk factor type diabetes including history pre diabetes usually defined impaired fasting glucose mmol l impaired glucose tolerance noted oral glucose tolerance test result mmol l elevated glycated hemoglobin c level estimated canadian confidence interval ci newly diagnosed type diabetes raising national burden disease estimated ci prevalent case furthermore estimated total canadian death ci attributable type diabetes translates estimated year life lost ci goal therapy type diabetes aimed achieving stringent glycemic control within normal range early possible addition diet lifestyle measure several class antidiabetic agent approved canada insulin sulphonylureas sus alpha glucosidase inhibitor biguanides glucagon like peptide glp receptor agonist meglitinides meg thiazolidinediones tzds sodium glucose cotransporter inhibitor dipeptidyl peptidase dpp inhibitor combination may often necessary optimal treatment report focus particular drug tzd class pioglitazone pio often considered therapeutic option glycemic target achieved first line drug metformin pio work binding peroxisome proliferator activated receptor gamma primarily located adipose vascular cell increasing insulin sensitivity addition hypoglycemic effect pio shown favourable effect reducing major adverse cardiovascular event e g cause mortality non fatal myocardial infarction mi stroke nevertheless case drug therapy benefit associated pio ought weighed possible risk patient previously reported concern adverse event aes bladder cancer heart failure hf edema fracture weight gain ovulation anovulatory woman remains uncertainty around overall safety profile pio previous cadth report topic include comparison safety pio rosiglitazone ro patient type diabetes objective present report investigate clinical evidence regarding safety pio patient pre diabetes type diabetes:0.0696771857915225",
    "175302": "importance type diabetes involves progressive loss insulin secretion pancreatic beta cell setting insulin resistance manifest clinically hyperglycemia type diabetes account case diabetes globally estimate ranging million million people worldwide u type diabetes affect approximately adult observation risk factor type diabetes include older age family history overweight obesity physical inactivity gestational diabetes hispanic ethnicity american indian alaska native asian black race diabetes diagnosed fasting plasma glucose greater equal mg dl hemoglobin c greater equal hour glucose g oral glucose tolerance testing greater equal mg dl approximately one third adult type diabetes cardiovascular disease severe vision difficulty blindness prevalence type diabetes among patient kidney failure although weight management important component treatment type diabetes specific diet proven effective improving health outcome physical activity reduce hemoglobin c improve cardiovascular risk factor ie hypertension dyslipidemia randomized clinical trial reported absolute reduction microvascular disease retinopathy nephropathy myocardial infarction mortality intensive glucose lowering strategy hemoglobin c v conventional treatment decade trial completion first line medication type diabetes include metformin patient cardiovascular kidney comorbidities high cardiovascular risk glucagon like peptide receptor agonist glp ra sodium glucose cotransporter inhibitor sglt common add medication include dual glucose dependent insulinotropic polypeptide gip glp ra dipeptidyl peptidase inhibitor sulfonylurea thiazolidinediones approximately one third patient type diabetes require treatment insulin lifetime several randomized clinical trial demonstrated benefit specific sglt glp ra medication compared placebo atherosclerotic cardiovascular disease risk reduction heart failure risk reduction kidney disease risk reduction year trial participant type diabetes taking metformin high potency glp ra dual gip glp ra medication result weight loss greater individual type diabetes weight loss may exceed conclusion type diabetes affect global population associated preventable long term complication cardiovascular disease kidney failure vision loss increased mortality addition lifestyle modification including diet exercise weight management metformin generally first line therapy attainment hemoglobin c target individual type diabetes cardiovascular kidney disease high cardiovascular risk guideline recommend early treatment sglt glp ra medication:0.0689650399269032",
    "157768": "cardiovascular disease cvd leading cause morbidity mortality individual diabetes mellitus dm although benefit attributed strict control hyperglycemia traditional antidiabetic treatment novel antidiabetic medication demonstrated cardiovascular cv safety benefit reducing major adverse cardiac event improving heart failure hf decreasing cvd related mortality emerging data underline interrelation diabetes metabolic disorder inflammation endothelial dysfunction oxidative stress pathogenesis microvascular macrovascular complication conventional glucose lowering medication demonstrate controversial cv effect dipeptidyl peptidase inhibitor failed prove beneficial patient coronary artery disease also safety questionable treatment patient cvd however metformin first line option type dm dm show cvd protective property dm induced atherosclerotic macrovascular complication thiazolidinedione sulfonylurea questionable effect evidence large study show reduction risk cv event death increased rate hospitalization hf moreover several study revealed insulin monotherapy dm treatment increase risk major cv event death hf compared metformin although may reduce risk myocardial infarction finally review aimed summarize mechanism action novel antidiabetic drug acting glucagon like peptide receptor agonist sodium glucose co transporter inhibitor show favorable effect blood pressure lipid level inflammation leading reduced cvd risk dm patient:0.0686168787879578",
    "156051": "cardiovascular microvascular disorder serious complication diabetes intensive glucose control believed hinder pathological progression complication review focus risk diabetic retinopathy dr intensive treatment recently introduced glucose lowering drug including glucagon like peptide receptor agonist glp ra sodium glucose co transporter sglt inhibitor dipeptidyl peptidase dpp inhibitor glp ra suitable patient diabetes risk established cardiovascular complication sglt inhibitor appropriate complication heart failure chronic renal disease accumulating evidence indicates glp ra may provide greater reduction risk dr patient diabetes compared dpp inhibitor sulfonylurea insulin glp ra may ideal antihyperglycemic drug direct benefit retina since glp r expressed photoreceptors topical administration glp ra induces direct retinal neuroprotection dr multiple mechanism preventing neurodysfunction retinal neurodegeneration relieving disruption blood retinal barrier associated vascular leakage inhibiting oxidative stress inflammatory action neuronal apoptosis hence seems reasonable utilize strategy treat patient diabetes early stage dr rather exclusively using neuroprotective agent:0.0670234284214565",
    "112665": "cardiovascular complication type diabetes mellitus dm including myocardial infarction heart failure peripheral vascular disease stroke retinopathy nephropathy neuropathy microvascular complication newer therapy like glitazones even dipeptidyl peptidase iv dpp iv inhibitor increase risk therapy glucagon like peptide receptor agonist glp ra reported suitable alternate glp ra reduce major adverse cardiovascular event mace anti atherogenic potential possess pleiotropic activity glp ra found improve neuroprotection enhance neuronal growth reduce incidence stroke improve central insulin resistance glp ra beneficial improving glycemic profile preventing macroalbuminuria reducing decline egfr enhancing renal protection renal benefit add therapy glp ra sglt inhibitor composite renal outcome suppression inflammatory pathway improvement natriuresis diuresis found nephroprotective improvement glycemic control reduction body weight intraglomerular pressure prevention tubular injury make glp ra suitable add therapy improving cardiorenal outcome obesity important contributor insulin resistance reduction weight essential therapeutic option addressing diabetic obesity also reduces damage blood retinal barrier thus beneficial halting development diabetic retinopathy diabetic complication glycemic control addressing insulin resistance weight loss controlling atherosclerosis anti inflammatory effect cardio renal neuro protection make glp ra suitable therapeutic strategy long term treatment dm review discusses role glp ra diabetes dosage mono combination therapy antidiabetic long term treatment effect uncontrolled diabetes:0.0669654916368186"
  },
  "Topic 16": {
    "170232": "incidence heart failure hf india estimated case per people per year approximately million new case detected every year despite high rate mortality associated hf patient receive maximal guideline directed medical therapy gdmt current guideline advocate early multidrug combination therapy four class drug namely beta blocker bb mineralocorticoid receptor antagonist mras angiotensin receptor neprilysin inhibitor arnis sodium glucose transport protein inhibitor sglt particularly patient heart failure reduced ejection fraction hfref arnis reduce cardiac morbidity mortality patient hfref however recent data indicated patient hfref receive arni india hence national consensus hf meeting cardiology expert india formulated national consensus use arni hf based current evidence guideline consensus state arni used early hf particularly de novo patient hfref acute decompensated heart failure adhf irrespective presence low systolic blood pressure sbp diabetes moreover hfref renin angiotensin aldosterone system raas inhibitor switched arni reduce risk repeated hospitalization hf worsening hf cardiac death improve quality life qol starting arni first hospitalization preferable safe effective across dos arnis also used secondary benefit patient preserved ejection fraction heart failure preserved ejection fraction hfpef hf mildly reduced ef heart failure mildly reduced ejection fraction hfmref:0.0565117436587672",
    "153678": "aim half heart failure hf patient chronic kidney disease ckd complicating pharmacological management evaluated physician patient pattern use evidence based medical therapy hf across ckd stage method result studied hf patient reduced hfref mildly reduced hfmref ejection fraction enrolled swedish heart failure registry investigated likelihood physician prescribe guideline recommended therapy patient ckd patient fill prescription within day incident hf initiating therapy adhere proportion day covered persist continued use treatment first year therapy identified patient hfref median age year ckd proportion receiving prescription angiotensin converting enzyme inhibitor angiotensin receptor blocker angiotensin receptor neprilysin inhibitor acei arb arni estimated glomerular filtration rate egfr ml min respectively beta blocker mineralocorticoid receptor antagonist mras triple therapy combination acei arb arni beta blocker mra patient ckd less likely initiate medication less likely adhere persist acei arb arni mra triple therapy among stopper ckd patient less likely restart medication result consistent multivariable adjustment patient hfmref n conclusion patient hf ckd less likely prescribed fill prescription evidence based therapy showing lower adherence persistence even egfr category therapy recommended shown efficacy clinical trial:0.0550515282179558",
    "154672": "aim heart failure hf increasing concern worldwide rising hf burden expected due prospected future demographic change aging population consequently long term follow treatment performed increasingly primary care physician future contemporary data hf patient primary care needed plan ensure effective safe follow future patient method result electronic patient journal primary care clinic denmark searched standardized manner identify patient hf code k international classification primary care second edition prespecified variable including demographic information clinical variable co morbidity prescribed medication setting follow recorded total patient included study mean timepoint hf diagnosis august case diagnosis hf made specialized setting echocardiogram data used phenotyping available patient hf reduced ejection fraction hfref present recovered hfref hf mildly reduced hfmref preserved ejection fraction hfpef patient hfref recovered hfref fundamental treatment prescribed angiotensin converting enzyme inhibitor acei angiotensin receptor blocker arb angiotensin receptor neprilysin inhibitor arni beta blocker mineralocorticoid receptor antagonist mra sodium glucose co transporter inhibitor sglt older patient treated significantly lesser extent young patient drug class odds ratio point estimate p value patient hfmref hfpef acei arb arni prescribed beta blocker mra sglt significantly lower probability treatment compared patient hfref recovered hfref point estimate p value setting follow available patient irrespective hf phenotype follow performed solely primary care patient generally treated lesser extent hf therapy compared patient follow included specialized care yet difference generally small conclusion hfref common phenotype hf primary care followed recovered hfref fundamental therapy markedly underutilized initiative increase use recommended therapy needed improve future care patient hf:0.0542783387724166",
    "199684": "aim central eastern europe cee quality care centre qcc survey evaluated implementation guideline directed medical therapy gdmt device use discharge heart failure hf hospitalization cee gdmt underutilization remains concern method result march january patient mean age year male enrolled discharge centre across cee country patient population included hf reduced ejection fraction hfref hf mildly reduced ejection fraction hf preserved ejection fraction total population admission discharge increase use angiotensin receptor neprilysin inhibitor arni beta blocker mineralocorticoid receptor antagonist mra sodium glucose co transporter inhibitor sglt reduction angiotensin converting enzyme inhibitor acei use p similar trend observed across hf phenotype including hfref increased use arni beta blocker mra sglt lower acei use p discharge patient received quadruple therapy hfref target dos titratable drug achieved hfref predictor gdmt underuse included older age lower education living alone non ischaemic hf higher ejection fraction chronic kidney disease hypotension hyperkalaemia prolonged hospitalization residual oedema among eligible hfref patient discharged referred implantable cardioverter defibrillator cardiac resynchronization therapy conclusion cee qcc survey highlight substantial hospital gdmt implementation titration though device use remains limited targeted strategy needed enhance guideline implementation ensure optimal hf care across cee region:0.0528559007280701",
    "160263": "introduction chronic heart failure hf high rate mortality hospitalization patient advanced chronic kidney disease ackd however randomized clinical trial systematically excluded ackd population investigated current hf therapy patient receiving clinical care specialized ackd unit method heart kidney audit haka cross sectional retrospective real world study including outpatient ackd hf spanish center objective evaluate treatment hf patient ackd complied recommendation european society cardiology guideline diagnosis treatment hf especially regarding foundational drug renin angiotensin system inhibitor rasi angiotensin receptor blocker neprilysin inhibitor arni beta blocker bb mineralocorticoid receptor antagonist mras sodium glucose cotransporter inhibitor sglt result among ackd patient diagnosis hf reduced ejection fraction hfref mildly reduced ef hfmref preserved ef hfpef patient hfref receiving quadruple therapy rasi arni bb mra sglt majority maximum recommended dos none patient hfref ckd g received quadruple therapy among hfmref patient approximately half two third receiving rasi bb respectively less received arni mra sglt less patient hfpef receiving sglt conclusion real world condition hf ackd patient sub optimally treated increased awareness current guideline pragmatic trial specifically enrolling patient represent unmet medical need:0.0516688552597743",
    "74669": "background guideline strongly recommend patient heart failure reduced ejection fraction hfref treated multiple medication proven improve clinical outcome tolerated degree gap medication use dosing persist contemporary outpatient practice unclear objective study sought characterize pattern factor associated use dose hfref medication current practice method champ hf change management patient heart failure registry included outpatient united state chronic hfref receiving least oral medication management hf patient characterized baseline use dose angiotensin converting enzyme inhibitor acei angiotensin ii receptor blocker arb angiotensin receptor neprilysin inhibitor arni beta blocker mineralocorticoid receptor antagonist mra patient level factor associated medication use examined result overall patient primary care cardiology practice included mean age year female mean ef among eligible patient prescribed acei arb arni beta blocker mra therapy respectively medication prescribed patient receiving target dos acei arb arni beta blocker whereas patient receiving target dos mra therapy among patient eligible class medication simultaneously receiving target dos ace arb arni beta blocker mra adjusted model older age lower blood pressure severe functional class renal insufficiency recent hf hospitalization generally favored lower medication utilization dose social economic characteristic independently associated medication use dose conclusion contemporary outpatient hfref registry significant gap use dose guideline directed medical therapy remain multiple clinical factor associated medication use dose prescribed strategy improve guideline directed use hfref medication remain urgently needed finding may inform targeted approach optimize outpatient medical therapy:0.0511625328079115",
    "196026": "heart failure hf chronic disease associated high morbidity mortality rate renin angiotensin aldosterone system blocker including angiotensin receptor neprilysin inhibitor beta blocker mineralocorticoid receptor blocker remain mainstay pharmacotherapy hf reduced ejection fraction hfref however despite use guideline directed medical therapy mortality hfref remains high hf preserved ejection fraction hfpef comprises approximately half total incident hf case however unlike hfref proven therapy condition sodium glucose cotransporter inhibitor sglt represent new class pharmacological agent approved diabetes mellitus dm inhibit sglt receptor kidney serendipitous finding seminal trial sglt dm significant improvement renal cardiovascular cv outcome importantly improvement hf hospitalization hhf cv outcome trial sglt striking multiple mechanism proposed pleiotropic effect sglt beyond glycemic control however patient hf included trial considered primary intervention subsequently two landmark study sglt patient hfref namely empagliflozin outcome trial patient chronic hf reduced ejection fraction emperor reduced dapagliflozin prevention adverse outcome hf dapa hf demonstrated significant improvement hhf cv mortality regardless presence dm impressive result pitchforked drug class indication patient hfref across major guideline thereafter empagliflozin outcome trial patient chronic hf preserved ejection fraction emperor preserved dapagliflozin evaluation improve life patient preserved ejection fraction hf deliver trial successively confirmed sglt also benefit patient hfpef without dm result represent watershed constitute first clinically meaningful therapy hfpef past three decade evolution hf management emerging positive data use sglt acute hf post myocardial infarction scenario strengthened pivotal role agent realm hf short span time class drug captivated entire scenario hf:0.0496087942674005",
    "188558": "introduction although several guideline recommend patient heart failure reduced ejection fraction hfref treated angiotensin converting enzyme inhibitor angiotensin ii receptor blocker aceis arb angiotensin receptor neprilysin inhibitor arnis beta blocker mineralocorticoid receptor antagonist mras sodium glucose cotransporter inhibitor sglt still several gap prescription dosage colombia study aimed describe use pattern hfref treatment colombian heart failure registry recolfaca method patient hfref enrolled recolfaca included heart failure hf medication prescription daily dose assessed using absolute number proportion therapeutic scheme patient treated internal medicine specialist compared treated cardiologist result patient registry hfref among individual prescribed beta blocker acei arb mras arnis moreover less third total patient reached target dos recommended european hf guideline significant difference therapeutic scheme target dos observed patient treated internal medicine specialist cardiologist conclusion prescription rate target dose achievement suboptimal colombia nevertheless recolfaca one highest prescription rate beta blocker mras compared recent hf registry however arnis remain underprescribed continuous registry update improve identification patient suitable arni sglt therapy promote use clinical practice:0.0495577293100507",
    "181273": "aim persistent symptom despite guideline directed medical therapy gdmt poor tolerance gdmt hallmark patient advanced heart failure hf reduced ejection fraction hfref however real world data gdmt use dose prognostic implication lacking method result included consecutive patient hfref least one need help marker advanced hf enrolled multicentre registry beta blocker bb administered patient angiotensin converting enzyme inhibitor angiotensin receptor blocker angiotensin receptor neprilysin inhibitor acei arb arni administered patient received mineralocorticoid receptor antagonist mra overall target dos reached patient bb acei arb arni mra respectively hypotension bradycardia kidney dysfunction hyperkalaemia main cause underprescription underdosing half patient receive target dos unknown cause bb acei arb arni mra respectively proportion patient receiving bb acei arb arni lower among fulfilling hfa esc criterion advanced hf treatment bb acei arb arni associated lower risk death hf hospitalization adjusted hazard ratio hr confidence interval ci hr ci respectively conclusion large real world contemporary cohort patient severe hfref least one marker advanced hf prescription uptitration gdmt remained limited significant proportion patient undertreated due unknown reason suggesting potential role clinical inertia either prescribing healthcare professional patient treatment bb acei arb arni associated lower mortality morbidity:0.0495338898477100",
    "179053": "introduction optimization guideline directed medical therapy gdmt improve prognosis patient heart failure hf one main goal chronic care objective aimed assess implementation recommendation regarding gdmt optimization hf patient undergoing scheduled hospitalization particular emphasis patient reduced left ventricular ejection fraction lvef patient method analysis included patient known lvef mean sd age men admitted elective hospitalization representing subset participant hero study heart failure observational study polish cardiac society recruitment across polish center took place april may result mean sd lvef study group patient hf reduced lvef hfref constituted n whole group subgroup use angiotensin receptor neprilysin inhibitor arni angiotensin converting enzyme inhibitor acei angiotensin receptor blocker arb increased patient admission discharge beta blocker mineralocorticoid receptor antagonist mra sodium glucose cotransporter inhibitor sglt arni acei arb therapy optimized participant rate optimization beta blocker mra sglt respectively however patient attained pillar gdmt sglt arni acei arb beta blocker mra dos equal target dose conclusion polish multicenter hero registry patient hfref discharged pillar gdmt nevertheless attainment target high dose gdmt remained suboptimal finding provide new insight variability gdmt implementation national level underline need strategy improve dosing optimization:0.0481382375012144"
  },
  "Topic 17": {
    "1184": "background aim present study assess early clinical outcome following primary coronary angioplasty elderly patient aged year compared younger patient year method study population included consecutive patient mean age year acute st elevation myocardial infarction mi underwent primary percutaneous coronary intervention pci within hour symptom onset elderly patient accounted patient primary pci performed using balloon coronary stent well glycoprotein iib iiia inhibitor primary endpoint hospital incidence major adverse cardiac event including death stroke reinfarction target vessel revascularization new onset heart failure result elderly patient frequently female v p comorbid disease prior stroke v p extensive cardiovascular disease previous acute mi v p multivessel disease v p significantly lower ejection fraction v p despite similar rate timi flow presentation v p n similar use stent v p glycoprotein iib iiia inhibitor infusion v p comparable angiographic residual stenosis v p n final rate timi flow significantly lower elderly population v p although hospital ischemic event rate age significantly different hospital mortality higher elderly compared younger patient v p even patient cardiogenic shock time admission excluded v p furthermore patient aged hospital heart failure v p whole population multivariate analysis identified baseline killip class iii iv independent predictor event elderly patient multivariate analysis identified baseline killip class iii iv time onset chest pain pci independent predictor event conclusion data suggest elderly patient acute st elevation mi primary pci yield positive result successful reperfusion achieved high proportion elderly patient mortality rate lower reported non pci registry high killip class late reperfusion therapy predict unfavorable outcome elderly patient treated primary pci:0.0634122832019470",
    "156009": "objective goal retrospective study reveal prevalence angiographic characteristic clinical presentation long term outcome non st segment elevation myocardial infarction nstemi patient wellens syndrome background procedural result percutaneous coronary intervention pci acute coronary syndrome ac improved recent year however still paucity available clinical trial data wellens syndrome even though well known high risk ac method among total patient ac underwent angioplasty cardiovascular center beijing friendship hospital nstemi patient culprit left anterior descending lad vessel enrolled study according electrocardiographic criterion wellens syndrome patient divided wellens group n non wellens group n primary endpoint cardiac death secondary endpoint main adverse cardiovascular cerebrovascular event macces composite cause death cardiac death heart failure target lesion revascularization recurrent myocardial infarction stroke medical follow data obtained institutional database result incidence wellens syndrome ac patient among patient wellens syndrome nstemi proportion significant decrease percentage preexisting coronary heart disease chd prior myocardial infarction previous pci p wellens group compared non wellens group coronary angiography single vessel lesion common wellens group v p almost patient received drug eluting stent notably wellens group higher proportion early pci non wellens group v p month statistically significant difference cardiac death p two group macces comparable wellens v non wellens p age year largest independent risk factor adverse prognosis conclusion early recognition aggressive intervention wellens syndrome longer risk factor adverse prognosis patient nstemi current pci era:0.0620946107465243",
    "188045": "background contemporary management spontaneous coronary artery dissection scad still controversial systematic review literature aim explore outcome patient treated conservative management v invasive strategy method prisma preferred reporting item systematic review meta analysis guideline followed extensively searched three electronic database pubmed sciencedirect web science study compared conservative v invasive revascularization treatment outcome patient scad outcome interest cause death major adverse cardiovascular event mace including acute coronary syndrome ac heart failure hf need additional revascularization target vessel revascularization tvr scad recurrence stroke result systematic review included observational study evaluating patient scad overall mean age female overall prevalence arterial hypertension hyperlipidemia smoking diabetes approximately patient diagnosed non st elevated myocardial infarction nstemi st elevated myocardial infarction stemi unstable angina stable angina diagnosed various type arrhythmia left anterior descending artery lad common culprit lesion patient initially conservatively treated patient v underwent percutaneous coronary intervention pci underwent coronary artery bypass graft cabg scad pci revascularization associated variable range pci failure common complication hematoma extension iatrogenic dissection scad pci revascularization frequently required three stent residual area dissection overall reported hospital follow mortality rate respectively follow range across study month author reported variable prevalence mace recurrent scad ac tvr repeat revascularization ua hf stroke conclusion result highlight conservative treatment preferred method treatment patient scad pci revascularization associated high prevalence periprocedural complication scad pose considerable risk mace mainly associated tvr ac recurrent scad:0.0614808059366604",
    "178491": "background aimed compare clinical outcome immediate staged complete revascularization primary percutaneous coronary intervention pci treating st segment elevation myocardial infarction stemi multivessel disease mvd method total patient enrolled prospective randomized multicenter registry immediate revascularization defined one time pci culprit non culprit lesion initial procedure staged revascularization defined pci non culprit lesion later date mean day interquartile range following initial culprit revascularization end point major adverse cardiovascular event mace composite total death recurrent myocardial infarction revascularization individual component mace cardiac death stent thrombosis stroke month result follow year mace occurred patient immediate revascularization group patient staged revascularization group hazard ratio hr confidence interval ci incidence total death numerically higher immediate group staged group v hr ci significant difference group risk individual component mace cardiac death stroke hospital complication need transfusion bleeding acute renal failure acute heart failure study prematurely terminated due halt production everolimus eluting stent manufactured promus element boston scientific natick massachusetts conclusion due limited power definite conclusion drawn regarding complete revascularization strategy present study large randomized clinical trial would warranted confirm optimal timing complete revascularization patient stemi mvd:0.0597722053522800",
    "175571": "background aim beneficial effect pre treatment unfractionated heparin ufh first medical contact fmc primary percutaneous coronary intervention ppci comer st elevation myocardial infarction stemi remains uncertain method help pci investigator initiated randomized controlled trial conducted clinical centre china patient stemi presenting h symptom onset undergoing ppci randomly assigned intravenous administration ufh u kg fmc cath lab catheter sheath primary endpoint thrombolysis myocardial infarction flow grade tfg infarct related artery ira diagnostic angiography ppci secondary outcome complete epicardial myocardial reperfusion ppci major adverse cardiac cerebrovascular event macce defined composite cause death cardiac death heart failure hospitalization infarction stent thrombosis unplanned revascularization stroke month safety outcome day bleeding academic research consortium barc type bleeding result total patient stemi undergoing ppci randomly assigned receive either ufh administration fmc n cath lab n pre treated population fmc showed higher frequency tfg ira compared cath lab group v odds ratio confidence interval p significant difference secondary endpoint safety endpoint including month macce complete epicardial myocardial reperfusion major bleeding conclusion pre treatment loading dose ufh fmc associated improvement spontaneous reperfusion ira without increasing risk major bleeding:0.0596342391448371",
    "149481": "background one promising biomarker received substantial interest evaluation suspected acute coronary syndrome ac copeptin therefore goal assess additive value copeptin early diagnosis prognosis non st segment acute coronary syndrome nste ac method study included ninety patient suspected ac patient typical ischemic chest pain within six hour symptom onset without st segment elevation electrocardiograph ecg included addition cardiac troponin ctni copeptin assayed venous blood sample obtained admission followed serial troponin measurement six twelve hour later one year follow performed major adverse cardiac event mace including cardiac death infarction hospitalization ischemic event heart failure stroke target lesion revascularization tlr result seventy nine patient included final analysis forty diagnosed unstable angina ua thirty nine non st elevation myocardial infarction nstemi copeptin level admission significantly higher among nstemi patient ua regard correlation analysis copeptin positively correlated global registry acute coronary event grace thrombolysis myocardial infarction timi synergy percutaneous coronary intervention taxus cardiac surgery syntax score sensitivity negative predictive value npv combination admission copeptin ctn respectively versus respectively admission ctn alone area curve auc combination copeptin ctn p significantly higher auc ctn alone p admission copeptin independent predictor mace multiple regression analysis ci p high value copeptin highest rate mace coronary revascularization one year follow conclusion combination copeptin conventional troponin aid early rule nstemi virtually independent chest pain onset cpo high npv patient presenting within three hour chest pain onset excellent prognostic value risk stratification prediction mace:0.0595397238136154",
    "77513": "objective aimed assess sex difference invasive parameter acute microvascular reperfusion injury infarct characteristic cardiac mri st segment elevation myocardial infarction stemi method patient stemi undergoing emergency percutaneous coronary intervention pci prospectively enrolled index microcirculatory resistance imr coronary flow reserve cfr measured culprit artery post pci contrast enhanced mri used assess infarct characteristic microvascular obstruction myocardial haemorrhage day month post stemi prespecified outcome follows cause death first heart failure hospitalisation ii cardiac death non fatal myocardial infarction urgent coronary revascularisation major adverse cardiovascular event mace year median follow result patient stemi woman mean age year men mean age year woman anterior stemi less often fewer prescription beta blocker discharge higher baseline n terminal pro b type natriuretic peptide level p following emergency pci fewer woman men thrombolysis myocardial infarction timi myocardial perfusion grade v p woman lower corrected timi frame count v p however imr cfr microvascular obstruction myocardial haemorrhage infarct size myocardial salvage index left ventricular remodelling ejection fraction differ significantly sex female sex associated mace cause death first heart failure hospitalisation conclusion sex difference microvascular pathology patient acute stemi woman less anterior infarct men beta blocker therapy discharge prescribed less often woman trial registration number nct:0.0594525671597047",
    "119133": "background patient presenting st elevation myocardial infarction stemi complicated cardiogenic shock c extremely high mortality rate objective sought assess impact prior revascularization either coronary artery bypass graft surgery cabg percutaneous coronary intervention pci hospital month outcome compare revascularization naive patient method result total consecutive patient admitted institution stemi c defined new york state percutaneous coronary intervention reporting system pcirs underwent primary pci baseline clinical angiographic procedural characteristic well hospital outcome prospectively collected among patient undergoing primary pci part new york state pcirs data collection patient history prior bypass graft surgery older history heart failure hypertension dyslipidemia diabetes left anterior descending coronary artery usually culprit vessel post pci revascularization naive patient whereas vein graft patient prior history surgical bypass hospital mortality rate different three group significant difference major adverse cardiac cerebrovascular event rate among three group p notably revascularization naive patient higher rate major bleeding complication p multivariable analysis age ci prior history congestive heart failure ci dyslipidemia ci independent predictor month mortality prior revascularization impact rate stroke death macce conclusion patient acute stemi c similar hospital one year mortality stroke major adverse cardiac cerebrovascular event rate irrespective prior revascularization status:0.0590389069236122",
    "81667": "objective study sought assess whether intracoronary adenosine nitroprusside following thrombus aspiration ta superior ta alone prevention microvascular obstruction mvo st segment elevation myocardial infarction stemi patient undergoing percutaneous coronary intervention pci background mvo due multifactorial pathogenesis still occurs ta sizeable portion patient method performed placebo controlled randomized open label blind examination multicenter trial total stemi patient thrombolysis myocardial infarction timi flow grade randomly allocated receive adenosine n nitroprusside n saline n given distal occluded site ta primary endpoint incidence st segment resolution str surface electrocardiogram min pci secondary endpoint angiographic mvo incidence timi flow grade myocardial blush grade major adverse cardiac event mace rate day composite cardiac death myocardial infarction target lesion revascularization heart failure requiring hospitalization result str occurred adenosine treated patient nitroprusside treated patient saline treated patient p p respectively v saline angiographic mvo occurred adenosine treated patient nitroprusside treated patient saline treated patient p p respectively v saline mace occurred patient respectively p p v saline conclusion stemi patient treated pci ta additional intracoronary administration adenosine nitroprusside result significant improvement mvo assessed str:0.0587160209975588",
    "33814": "aim primary percutaneous coronary intervention ppci preferred strategy acute st segment elevation myocardial infarction stemi evidence improved clinical outcome compared fibrinolytic therapy however consensus best manage multivessel coronary disease detected time ppci little robust data best management angiographically significant stenosis detected non infarct related n ira coronary artery cvlprit determine optimal management n ira lesion detected ppci method result cvlprit complete versus culprit lesion primary pci trial open label prospective randomised multicentre trial stemi patient undergo verbal assent presentation patient included angiographic mvd detected randomised culprit ira pci n patient complete multivessel pci n cumulative major adverse cardiac event mace cause mortality recurrent mi heart failure need revascularisation pci cabg recorded month secondary endpoint include safety endpoint confirmed ischaemic stroke intracranial haemorrhage major non intracranial bleeding repair vascular complication cardiac magnetic resonance cmr substudy provide mechanistic data infarct size myocardial salvage index microvascular obstruction cost efficacy analysis undertaken conclusion management multivessel coronary artery disease setting ppci stemi including timing perform non culprit artery revascularisation undertaken remains unresolved cvlprit yield mechanistic insight myocardial consequence n ira intervention undertaken peri infarct period:0.0584962691001132"
  },
  "Topic 18": {
    "112375": "importance rehospitalization major surgery common represents significant cost health care system little known regarding cause readmission degree may preventable objective evaluate degree readmission major surgery potentially preventable design setting participant retrospective cohort study used weighted sample patient national readmission database evaluate adult inpatient hospitalization common major surgical procedure statistical analysis performed january november main outcome measure study calculated day readmission rate well rate readmission considered potentially preventable potentially preventable readmission pprs defined primary diagnosis code superficial surgical site infection acute kidney injury aspiration pneumonitis agency healthcare research quality defined ambulatory care sensitive condition multivariable logistic regression used identify factor associated pprs result total weighted sample patient woman mean age year ci year underwent surgical procedure experienced readmission within day potentially preventable readmission accounted day readmission estimated total cost u health care system approximately million common reason pprs congestive heart failure exacerbation pneumonia acute kidney injury multivariable model adult aged year patient public health insurance medicare medicaid twice odds ppr compared private insurance adjusted odds ratio ci among patient aged year older patient private insured lower odds ppr compared patient medicare primary payer adjusted odds ratio ci conclusion relevance study suggests nearly readmission surgery potentially preventable account nearly million cost addition better inpatient care improved access ambulatory care may represent opportunity reduce costly readmission among surgical patient:0.0699360031908736",
    "86911": "importance center medicare medicaid service recently identified day readmission discharge inpatient rehabilitation facility national quality indicator research needed determine rate factor related readmission patient population objective determine day readmission rate factor related readmission patient receiving postacute inpatient rehabilitation design setting patient retrospective cohort study record medicare fee service beneficiary mean age sd year discharged inpatient rehabilitation facility community sixty three percent patient woman non hispanic white main outcome measure thirty day readmission rate largest diagnostic impairment category receiving inpatient rehabilitation included stroke lower extremity fracture lower extremity joint replacement debility neurologic disorder brain dysfunction result mean rehabilitation length stay sd day overall day readmission rate ci rate ranged ci patient lower extremity joint replacement ci patient debility rate highest men ci v ci woman non hispanic black ci v ci white ci hispanic ci race ethnicity beneficiary dual eligibility ci v ci dual eligibility patient tier comorbidities ci v ci tier ci tier ci tier comorbidities higher motor cognitive functional status associated lower hospital readmission rate across impairment category adjusted readmission rate state ranged approximately patient rehospitalized within day period readmitted within day discharge medicare severity diagnosis related group code heart failure urinary tract infection pneumonia septicemia nutritional metabolic disorder esophagitis gastroenteritis digestive disorder common reason readmission conclusion relevance among postacute rehabilitation facility providing service medicare fee service beneficiary day readmission rate ranged selected impairment group research needed understand cause readmission:0.0646121348726222",
    "69545": "background readmission hospital cardiopulmonary resuscitation icpr common contribute increased health care utilization cost study aimed estimate burden pattern day readmission icpr u nationwide readmission database nrd method using international classification disease ninth revision clinical modification code patient underwent icpr nrd included incidence predictor cause cost day readmission analyzed discharge weight obtain national estimate result among index admission survived hospital discharge icpr readmitted within day length stay los day index hospitalization chronic pulmonary disease congestive heart failure renal failure discharge teaching metropolitan hospital medicare insurance depression diabetes independent predictor day readmission common cause readmission among case sepsis heart failure respiratory failure estimated median cost readmission interquartile range accounted total episode care index readmission median los readmission day conclusion thirty day readmission icpr associated patient comorbidities significant cost burden recognition predictor individualization care would allow provision appropriate intervention reduce readmission healthcare cost:0.0640250545063215",
    "138009": "background early readmission important indicator quality care limited data exist describing hospital readmission acute diverticulitis study aimed describe unplanned day readmission among adult acute diverticulitis patient assess readmission predictor method analyzed united state national readmission database identified acute diverticulitis admission using administrative code adult patient older year age primary outcome day unplanned readmission rate used chi square test test wilcoxon rank sum test descriptive analysis survey logistic regression calculate adjusted odds ratio aors confidence interval association readmission adjusting confounders result cohort hospitalization acute diverticulitis primary diagnosis index admission least one unplanned day readmission sixty percent readmission occurred within first week index admission common reason unplanned day readmission due diverticulitis colon postoperative infection septicemia intestinal infection due clostridium difficile digestive system complication bleeding fistula multivariable analysis showed advance age year discharge medical advice comorbidities renal failure coronary artery disease atrial fibrillation congestive heart failure hypertension diabetes obesity weight loss chronic lung disease malignancy blood transfusion medicare medicaid insurance increased length stay day associated significantly higher odds readmission patient undergone abdominal surgery index admission less likely get readmitted conclusion national level hospitalization acute diverticulitis followed unplanned readmission within day admission occurring first week multiple modifiable non modifiable factor influencing readmission rate noted study examine strategy address predictor decrease readmission:0.0635926558931827",
    "110845": "study examined rate cause short term readmission among adult across age insurance type compared rate characteristic cost day readmission cause hospitalization across insurance type u retrospectively evaluated alive patient year old discharged cause non federal hospital state nationwide readmission database primary stratification variable interest primary insurance comorbid condition assessed based elixhauser comorbidities defined administrative billing code additional measure included diagnosis index hospitalization leading rehospitalization hierarchical multivariable logistic regression model hospital site random effect used calculate adjusted odds day readmission age group insurance category cost discharge estimate weighted per nrd procedure reflect nationally representative sample diagnosis index hospitalization leading rehospitalization determined among discharge resulted readmission within day medicaid insurance associated highest adjusted odds ratio aor readmission year old aor ci p aor ci p medicare group medicare v private insurance aor ci p discharge psychiatric substance abuse disorder septicemia heart failure accounted largest number readmission readmission rate respectively total cost readmission billion usd highest medicare billion usd non medicare cost exceeding billion usd medicare readmission account half total burden readmission cost non medicare readmission nonetheless substantial medicaid patient highest odds readmission individual older age commonly due hospitalization psychiatric illness substance abuse disorder medicaid patient represent population uniquely high risk readmission:0.0624517009223749",
    "66993": "background readmission within day copd hospitalization common measure performance copd care however study copd readmission risk constrained single data source private payer claim medicare claim data making difficult generalize result study population purpose study examine risk readmission within day time discharge patient copd using healthcare cost utilization project hcup state inpatient database california year statewide dataset allows u consider readmission copd regardless age payer status method total dataset included visit among patient hospital identified patient hospitalization primary diagnosis related copd age older discharged alive found hospitalization matched definition included information covariates comorbidities age insurance status characterize joint association covariates readmission within day used generalized linear model result patient aged likely readmitted hospital within day copd related hospitalization patient older effect persists adjustment patient severity comorbidities payer demographic model featured interaction age insurance type found younger patient aged public insurance highest readmission rate medicare medicaid however younger patient private insurance lowest readmission rate additional significant covariates included whether patient left medical advice diagnosis congestive heart failure diabetes addition found although admission copd highest winter true copd readmission peak summer also inpatient mortality patient admitted copd decreased approximately study period conclusion result demonstrate many risk factor readmission may dependent data source used furthermore many strongest predictor clearly related patient observation may help explain prior program reduce readmission limited success:0.0619588527342806",
    "136137": "importance emergency general surgery egs represents hospitalization almost half hospitalized patient older adult older adult high rate mortality readmission egs yet little known outcome compare acute medical condition target quality improvement objective examine whether medicare beneficiary undergo egs experience similar year outcome compared patient admitted acute medical condition design setting participant population based retrospective cohort study using medicare claim data january december included adult year older least year medicare claim urgent emergency admission highest burden egs procedure partial colectomy small bowel resection peptic ulcer disease surgery lysis adhesion laparotomy primary diagnosis acute medical condition pneumonia heart failure acute myocardial infarction patient undergoing egs acute medical condition matched step algorithm exact match hospital propensity score match age sex race ethnicity charlson comorbidity index individual comorbid condition claim based frailty index year admission intensive care unit stay data analysis performed july november exposure partial colectomy small bowel resection peptic ulcer disease surgery lysis adhesion laparotomy primary diagnosis pneumonia heart failure acute myocardial infarction main outcome measure one year mortality postdischarge health care utilization emergency department visit additional hospitalization intensive care unit stay total hospital encounter day home year result total matched pair mean sd age year female adequate covariate balance included study patient undergoing egs experienced higher day mortality v p yet lower year mortality v p compared medical patient among pair survived discharge medical patient experienced higher rate total hospital encounter year discharge v per person year incidence rate ratio ci similar mean day home compared patient undergoing egs v day incident rate ratio ci conclusion relevance study older patient undergoing egs similarly high year rate mortality hospital use day away home acutely ill medical patient finding suggest egs also targeted national quality improvement program:0.0618915354580153",
    "102357": "background context atlantoaxial fusion used correct atlantoaxial instability often secondary traumatic fracture syndrome rheumatoid arthritis effect age comorbidities outcome following atlantoaxial fusion unknown purpose study aimed better understand trend predictor outcome charge following atlantoaxial fusion identify confounding variable included future prospective study study design retrospective analysis data nationwide inpatient sample ni nationally representative payer database inpatient diagnosis procedure united state patient sample included patient underwent atlantoaxial fusion international classification disease ninth revision clinical modification code year older time admission outcome measure outcome measure included hospital charge hospital length stay los hospital mortality discharge disposition method predictor outcome following atlantoaxial fusion assessed using series univariable analysis predictor p value less included final multivariable model independent predictor outcome significant alpha level following inclusion final multivariable model logistic regression used determine predictor hospital mortality discharge disposition whereas linear regression used determine predictor hospital charge los discharge weight used produce generalizable result result hospitalization recorded wherein atlantoaxial fusion performed inpatient hospital stay hospitalization met inclusion criterion study sample white majority patient either insured medicare private health insurance common comorbidity defined ni elixhauser comorbidity index hypertension hospital mortality rate study population median los day median total charge inflation adjusted per hospitalization patient discharged home significant predictor hospital mortality included increased age emergent urgent admission weekend admission congestive heart failure coagulopathy depression electrolyte disorder metastatic cancer neurologic disorder paralysis non bleeding peptic ulcer many variable also found predictor los hospital charge discharge disposition conclusion study found older patient greater comorbidity burden greater odds postoperative mortality discharged another care facility longer hospital los incurred greater hospital charge following atlantoaxial fusion:0.0615484965718426",
    "96017": "background obstetrical health care disparity documented different aspect maternal care outcome prior epidemiological study shown labor analgesia underused african american hispanic group mean may inadequate labor pain control group difference usage attributed primarily insurance educational level perceptional influence fear paralysis chronic low back pain cesarean section delivery race ethnicity affect choice anesthesia considered race ethnicity affect maternal outcome cesarean section epidural placement generally unexplored disparity health care utilization shown contribute disparity health outcome method retrospective analysis using data agency healthcare research quality healthcare cost utilization project ahrq hcup national inpatient sample ni database january december stratified sample nonfederal hospital united state woman undergoing cesarean section international classification disease th revision clinical modification icd cm procedure code perioperative epidural catheter placement icd cm procedure code included analysis result final cohort used analysis included patient significant difference distribution patient characteristic across race group majority health care coverage caucasian asian private insurance african american hispanic native american medicare medicaid almost examined comorbid condition statistically significant highest african american group including hypertension obesity diabetes renal failure except congestive heart failure highest asian group cesarean section took place mostly urban teaching hospital across group discharge home predominant destination recovery mean cost hospitalization dollar per stay mean length stay day cohort adverse event rate small finding indicate racial difference comorbidities occurred often minority adverse maternal outcome hematoma blood transfusion cardiac arrest ventricular fibrillation occurred frequently minority group undergoing cesarean section epidural catheter placement throughout period conclusion using ni database finding indicate racial difference comorbidities occurred often minority adverse maternal outcome hematoma blood transfusion cardiac arrest ventricular fibrillation occurred frequently minority group undergoing cesarean section epidural catheter placement throughout period population study warranted determine biological perception etiology contributing disparity:0.0614568061369300",
    "140440": "importance center medicare medicaid service cm day risk standardized mortality rate rsmr risk standardized readmission rate rsrr model adjust resuscitate dnr status hospitalized patient may bias hospital readmission reduction program hrrp financial penalty overall hospital quality star rating objective identify association hospital level dnr prevalence condition specific day rsmr rsrr implication association hrrp financial penalty design setting participant cross sectional study obtained patient level data medicare limited data set inpatient standard analytical file hospital level data cm hospital compare website consecutive medicare inpatient encounter july june u hospital hospitalized patient principal diagnosis acute myocardial infarction ami heart failure hf stroke pneumonia chronic obstructive pulmonary disease copd incoming acute care transfer discharge medical advice patient coming discharged hospice among excluded analysis exposure present admission poa dnr status defined international classification disease ninth revision diagnosis code v october international statistical classification disease related health problem tenth revision diagnosis code z beginning october hospital level prevalence poa dnr status calculated condition main outcome measure hospital level day rsmrs rsrrs condition specific cohort mortality cohort ami hf stroke pneumonia copd readmission cohort ami hf pneumonia copd hrrp financial penalty status yes result included study inpatient encounter across condition specific day mortality cohort patient mean sd age year woman inpatient encounter across condition specific day readmission cohort patient mean sd age year woman hospital level median interquartile range iqr prevalence poa dnr status mortality cohort varied ami hf stroke pneumonia copd readmission cohort hospital level median iqr poa dnr prevalence ami hf pneumonia copd day rsmrs significantly higher hospital highest quintiles v lowest quintiles dnr prevalence eg ami ci v ci p inverse true among readmission cohort highest quintiles dnr prevalence exhibiting lowest rsrrs eg ami ci v ci p absolute increase risk adjusted hospital level dnr prevalence associated greater odds avoiding hrrp financial penalty odds ratio ci p conclusion relevance cross sectional study found lack adjustment cm day rsmr rsrr model poa dnr status hospitalized patient may associated biased readmission penalization hospital level performance:0.0612921091474448"
  },
  "Topic 19": {
    "174929": "importance atherosclerotic cardiovascular disease remains leading cause global morbidity mortality identifying early marker subclinical atherosclerosis critical predicting major adverse cardiovascular event mace improving prevention strategy carotid intima medium thickness cimt well established surrogate marker atherosclerosis impact cardiometabolic risk factor burden cimt future mace risk fully understood objective assess association cimt risk mace evaluate relationship composite cardiometabolic risk biomarker index cimt well future mace risk design prospective cohort study using data uk biobank median follow year setting population based study participant uk biobank participant men woman aged year n free cardiovascular disease baseline exclusion made prior coronary heart disease myocardial infarction heart failure exposure carotid intima medium thickness cimt measured baseline composite cardiometabolic risk biomarker index crbi developed using hba c total cholesterol ratio blood pressure main outcome measure primary outcome risk mace including coronary heart disease chd myocardial infarction mi heart failure hf association cimt crbi risk event evaluated using hazard ratio hr adjusted confounders result higher cimt value microm predictive increased risk chd hr microm ci mi hr microm ci cumulative burden cardiometabolic risk factor measured crbi score significantly associated increased cimt beta microm high crbi score ci p future mi risk hr high crbi score ci lifestyle factor smoking physical activity also correlated higher cimt particularly male conclusion carotid intima medium thickness strong predictor coronary heart disease myocardial infarction cumulative cardiometabolic risk biomarker index offer additional predictive value subclinical atherosclerosis future cardiovascular event finding underscore importance comprehensive cardiometabolic health cvd prevention strategy:0.0552183657416194",
    "58551": "background depression associated coronary heart disease stroke association range pathologically diverse cardiovascular disease well understood examine risk cardiovascular disease according depression status history new onset method cohort study adult men woman free cardiovascular disease baseline using linked uk electronic health record exposure new onset depression new gp diagnosis depression prescription antidepressant one year baseline history gp diagnosed depression baseline primary endpoint initial presentation cardiovascular disease baseline used disease specific cox proportional hazard model multiple imputation adjusting cardiovascular risk factor age sex socioeconomic status smoking blood pressure diabetes cholesterol result median iqr year follow history depression incident cardiovascular event occurred adjustment cardiovascular risk factor history depression associated stable angina hazard ratio ci unstable angina myocardial infarction unheralded coronary death heart failure cardiac arrest transient ischemic attack ischemic stroke subarachnoid haemorrhage intracerebral haemorrhage peripheral arterial disease abdominal aortic aneurysm new onset depression developed people among cardiovascular event occurred new onset depression similarly associated disease evidence stronger association compared history depression strength association depression cardiovascular disease differ woman men conclusion depression prospectively associated cardiac cerebrovascular peripheral disease evidence disease specificity research needed understanding specific pathophysiology heart vascular disease triggered depression healthy population:0.0516917391734367",
    "30723": "introduction growing prevalence gout u worldwide gout recognized risk factor cardiovascular disease cvd unclear whether risk factor cvd also associated increased risk gout anemia one cvd risk factor study evaluated relationship anemia gout tested whether anemia associated incident gout independent comorbid condition atherosclerosis risk community method population based cohort recruited individual four u community contained nine year follow anemia defined hemoglobin g dl men g dl woman using cox proportional hazard model estimated hazard ratio hr confidence interval ci incident gout baseline anemia adjusted confounders sex race estimated glomerular filtration rate body mass index alcohol intake clinical factor coronary heart disease congestive heart failure diabetes hypertension diuretic use serum urate level result among participant anemia baseline case incident gout patient anemia two fold increased risk developing gout nine year hr ci anemia associated incident gout independent known gout risk factor confounders clinical risk factor hr ci association persisted additionally adjusting serum urate level hr ci conclusion identified anemia novel risk factor gout anemia associated approximately two fold increased risk gout independent kidney function serum urate finding suggest anemia risk factor gout par chronic condition obesity diabetes biological mechanism linking anemia gout remains unclear:0.0507789868429107",
    "91253": "context epidemiologic study suggest endogenous testosterone level male may implicated cardiovascular disease cvd however clarification needed objective assessed cross sectional relationship endogenous plasma mean carotid intima medium thickness cimt longitudinal relationship incident clinical cvd event cardiac mortality cause mortality using male participant atherosclerosis risk community aric study design study involved subset men visit aric study setting study conducted community based cohort participant male provided morning blood sample excluding taking androgen therapy prevalent coronary heart disease chd stroke heart failure hf n intervention none main outcome measure plasma liquid chromatography mass spectrometry carotid imt using high resolution b mode ultrasound obtained visit incident chd hf cardiac mortality cause mortality identified surveillance median year result lower significantly associated higher body mass index greater waist circumference diabetes hypertension lower hdl never smoking p associated mean cimt unadjusted adjusted analysis following multivariable adjustment association quartile q incident chd hazard ratio hr ci q ci q ci q compared reference q incident hf hr ci q ci q ci q compared reference q similarly association q mortality cardiac associated mortality conclusion low male plasma cross sectionally associated key cvd risk factor adjustment association mean cimt incident cardiac event mortality result reassuring neither high low level directly predict atherosclerosis marker cardiovascular risk factor:0.0505299485641438",
    "18576": "background separate multivariable risk algorithm commonly used assess risk specific atherosclerotic cardiovascular disease cvd event ie coronary heart disease cerebrovascular disease peripheral vascular disease heart failure present report present single multivariable risk function predicts risk developing cvd constituent method result used cox proportional hazard regression evaluate risk developing first cvd event framingham study participant mean age year woman attended routine examination year age free cvd sex specific multivariable risk function general cvd algorithm derived incorporated age total high density lipoprotein cholesterol systolic blood pressure treatment hypertension smoking diabetes status assessed performance general cvd algorithm predicting individual cvd event coronary heart disease stroke peripheral artery disease heart failure year follow participant woman developed first cvd event traditional risk factor evaluated predicted cvd risk multivariable adjusted p general cvd algorithm demonstrated good discrimination c statistic men woman calibration simple adjustment general cvd risk algorithm allowed estimation risk cvd component two simple risk score presented based traditional risk factor based non laboratory based predictor conclusion sex specific multivariable risk factor algorithm conveniently used assess general cvd risk risk individual cvd event coronary cerebrovascular peripheral arterial disease heart failure estimated absolute cvd event rate used quantify risk guide preventive care:0.0504334426309002",
    "131150": "background aim psychologic wellbeing impact cardiovascular health aimed evaluate joint association multiple psychologic wellbeing factor cardiovascular disease cvd examine whether association modified genetic susceptibility method uk biobank participant free cvd coronary heart disease chd stroke heart failure hf baseline completed questionnaire psychological factor included psychological wellbeing score calculated four factor happiness life satisfaction broad depression neuroticism cox proportional hazard model used assess association psychological wellbeing score cvd risk result median follow year participant newly diagnosed cvds low life satisfaction presence depression neuroticism score significantly associated increased risk cvd multivariable adjusted model decreasing psychological wellbeing score significant increasing linear trend risk cvd chd stroke hf p trend participant lowest psychological wellbeing score highest risk cvd hr ci woman susceptible worse psychological wellbeing status cvd men p interaction association psychological wellbeing score cvd consistent across genetic risk p interaction considered jointly participant exposed high risk psychological wellbeing genetic status fold ci risk chd conclusion joint exposure multiple psychological wellbeing factor associated increased risk incident cvd additive manner regardless genetic susceptibility:0.0496320409314505",
    "66748": "objective study examined association aldosterone plasma renin activity pra incident cardiovascular disease cvd using composite endpoint coronary heart disease stroke heart failure mortality among african american jackson heart study background paucity data association aldosterone pra incident cvd cause mortality among community dwelling african american method total african american adult year age followed year aldosterone pra cardiovascular risk factor collected baseline incident event included coronary heart disease stroke assessed heart failure assessed cox model used estimate hazard ratio hr incident cvd mortality adjusting age sex education occupation current smoking physical activity dietary intake body mass index result among participant without prevalent cvd median follow year incident cvd case adjusted analysis u sd increase log aldosterone log pra associated hr confidence interval ci ci incident cvd respectively median year death occurred among participant adjusted analysis u sd increase log aldosterone log pra associated hr ci ci mortality respectively conclusion elevated aldosterone pra may play significant role development cvd cause mortality among african american:0.0493534690083888",
    "64247": "functional biomarkers like large artery elasticity lae small artery elasticity sae may predict cardiovascular disease cvd event beyond blood pressure author examined prognostic value lae sae clinical cvd event among multi ethnic study atherosclerosis participant initially aged year without symptomatic cvd lae sae derived diastolic pulse contour analysis median year follow adjudicated cvd event occurred including case coronary heart disease chd stroke heart failure multiple diagnosis possible adjustment age race ethnicity sex clinic height heart rate body mass index systolic diastolic blood pressure use antihypertensive cholesterol lowering medication smoking total cholesterol high density lipoprotein cholesterol triglyceride diabetes high sensitivity c reactive protein hazard ratio cvd per standard deviation increase sae confidence interval p lowest stiffest sae quartile hazard ratio confidence interval versus highest elastic quartile net reclassification index conditional base risk sae significantly associated future chd stroke heart failure adjustment lae significantly related cvd asymptomatic participant free overt cvd lower sae added prognostic information cvd chd stroke heart failure event:0.0491238541741212",
    "137877": "background goal striving stress gss stress striving goal associated poor health less known association cardiovascular disease cvd method result used data jhs jackson heart study study cvd among black year old participant free cvd baseline included analysis n gss examined category low moderate high sd unit incident cvd defined fatal nonfatal stroke coronary heart disease chd heart failure used cox proportional hazard regression estimate hazard ratio hr confidence interval ci incident cvd level gss adjusting demographic socioeconomic status health behavior risk factor perceived stress distribution gss category follows low moderate high average year incident stroke event chd event heart failure event full adjustment high versus low gss associated lower risk stroke hr ci higher risk chd hr ci among woman standard deviation unit increase gss associated increased risk chd hr ci among woman conclusion higher gss may risk factor developing chd among woman however appears protective stroke among woman analysis replicated sample black individual:0.0487047627935707",
    "42441": "background parental history widely accepted risk factor offspring cardiovascular event although mechanism remain unclear examined contribution conventional novel risk factor explaining excess risk cardiovascular event offspring positive parental history ph method result collected conventional blood pressure cholesterol adiposity lifestyle novel c reactive protein crp risk factor baseline participant scottish health survey n men aged year followed average year cardiovascular disease cvd event composite fatal nonfatal event incorporating acute myocardial infarction coronary artery bypass surgery percutaneous coronary angioplasty stroke heart failure younger ph participant year higher risk incident cvd event age adjusted sex adjusted hazard ratio confidence interval ci compared ph despite association ph blood pressure total high density lipoprotein cholesterol crp physical activity less excess risk explained conventional novel risk factor however greatest risk cvd observed ph participant elevated crp mg l hazard ratio ci hypertension hazard ratio ci conclusion small amount excess cvd risk associated ph accounted conventional novel mechanism however combination elevated crp hypertension ph substantially increase risk cvd:0.0484519797397160"
  },
  "Topic 20": {
    "62081": "aim patient heart failure hf commonly suffer severe impairment quality life qol one main goal hf treatment improvement qol physical well essential component qol enable assessment physical well hf patient validated questionnaire prospective study patient cardiac insufficiency bisoprolol study elderly method result hf patient age year male new york heart association class ii left ventricular ejection fraction measured physical well qol item short form health survey sf depressive symptom prime md patient health questionnaire german short version depression phq baseline two follow visit correlated score qol data clinical parameter mean score baseline month year assessed data quality scale assumption construct validity reliability cronbach alpha subscales resilience ability enjoy vitality inner peace total score intraclass correlation coefficient icc ci icc pearson correlation sf phq significant six minute walking distance heart rate correlated significantly total score conclusion showed good reliability internal consistency intraclass correlation score correlated well psychological physical well sf clinical marker exercise tolerance min walk test heart rate result indicate strong correlation self reported physical well psychological factor value baseline predicted development several aspect qol beta blocker titration:0.0825562985577974",
    "2273": "objective create valid sensitive disease specific health status measure patient congestive heart failure chf background quantifying health status becoming increasingly important chf kansa city cardiomyopathy questionnaire kccq new self administered item questionnaire quantifies physical limitation symptom self efficacy social interference quality life method establish performance characteristic kccq two distinct patient cohort recruited stable decompensated chf patient ejection fraction upon entry study patient administered kccq minnesota living heart failure questionnaire short form sf questionnaire repeated three month later result convergent validity kccq domain documented comparison available criterion standard r p among stable chf remained stable predefined criterion n minimal change kccq domain detected three month observation mean change point p n contrast large change score observed among patient whose decompensated chf improved three month later n mean change point p sensitivity kccqwas substantially greater minnesota living heart failure sf questionnaire conclusion kccqis valid reliable responsive health status measure patient chf may serve clinically meaningful outcome cardiovascular research patient management quality assessment:0.0817648140553928",
    "171754": "introduction kansa city cardiomyopathy questionnaire kccq one widely used instrument measuring health related quality life patient heart failure hf however item version kccq sufficiently tested european population invariance patient reduced midrange preserved ejection fraction never assessed aim purpose study examine validity reliability kccq large cohort italian patient hf assess measurement invariance across level ejection fraction method total patient mean age year male completed kccq alongside measure depression anxiety quality life hf symptom burden construct validity assessed mean confirmatory factor analysis testing association kccq score clinical parameter ie ejection fraction mortality month well measure anxiety depression symptom burden general quality life multigroup confirmatory factor analysis implemented investigate invariance property across reduced midrange preserved ejection fraction omega model based internal consistency coefficient computed investigate internal consistency reliability result confirmatory factor analysis specified according original factor model ie physical social limitation symptom frequency quality life yielded satisfactory fit index root mean square error approximation comparative fit index moderate high correlation found kccq mental physical component score short form well conceptually related construct indicating adequate facet construct validity multigroup confirmatory factor analysis tested across patient different ejection fraction group established kccq invariant partial scalar level omega model based internal consistency coefficient adequate ranging subscales whole scale confirming strong internal consistency reliability conclusion kccq demonstrated satisfactory psychometric property european sample patient hf providing evidence support use practice research:0.0795620198988039",
    "12983": "background heart failure hf increasingly common condition affecting patient health related quality life hrql however little literature comparing hf specific instrument aim evaluate compare data conceptual model metric property reliability validity responsiveness hf specific hrql instrument performing systematic review meta analysis method result article initially identified full text reviewed ninety four reported data five questionnaire minnesota living heart failure questionnaire mlhfq chronic heart failure questionnaire chfq quality life questionnaire severe heart failure qlq shf kansa city cardiomyopathy questionnaire kccq left ventricular dysfunction lvd questionnaire metric property reliability validity responsiveness summarised using meta analysis pool five estimate cronbach alpha coefficient generally high overall score scale measuring physical health association four validity criterion new york heart association nyha class six minute walk test mwt short form sf physical social functioning moderate strong except two chfq domain fatigue dyspnoea nyha pooled estimate change eight meta analysis showed mlhfq highly responsive change overall score ranging confidence interval ci placebo ci pacing device chfq kccq also showed good sensitivity change conclusion questionnaire studied met minimum psychometric criterion though current evidence would primarily support use mlhfq followed kccq chfq:0.0787984003980345",
    "59762": "objective compare psychometric property heart failure hf specific quality life questionnaire medical outcome study item short form health survey sf patient hf design methodological study based month follow data evaluating psychometric property health related quality life hrqol questionnaire setting cardiac rehabilitation center cardiovascular research institute participant eligible patient hf n intervention exercise training cardiac rehabilitation main outcome measure sf macnew heart disease questionnaire minnesota living heart failure questionnaire mlhfq new york heart association functional classification result item mlhfq macnew questionnaire acceptable correlation r p internal consistency test retest reliability adequate mlhfq subscales correlation mlhfq macnew sf similar item ranged respectively similar scale macnew mlhfq showed strong correlation baseline follow supporting convergent validity improvement hrqol significant mlhfq subscales p macnew emotional p social p subscales mlhfq demonstrated responsiveness change discriminated disease severity best follow score mlhfq macnew subscales significantly greater patient improved compared showed change deteriorated conclusion mlhfq responsive change hrqol macnew questionnaire time patient hf macnew questionnaire responsive change sf:0.0778706495816188",
    "129452": "background health related quality life hrqol known impaired individual coronary artery disease cad especially recent acute coronary syndrome ac heart failure hf common burden population significantly contributes worsening hrqol accurately measure level hrqol individual cad ac disease specific scale minnesota living heart failure questionnaire mlhfq recommended nevertheless date study would comprehensively evaluate psychometric property mlhfq large sample individual cad ac debate regarding internal structure mlhfq also still present hence study aimed translate mlhfq evaluate internal structure reliability precision validity individual cad following ac lithuania method cross sectional study participant men age sd evaluated sociodemographic clinical characteristic hrqol measured using mlhfq short form health survey sf addition exercise capacity ec also evaluated study patient using standardized computer driven bicycle ergometer result internal consistency mlhfq subscales found good confirmatory factor analysis cfa provided support three factor model physical domain social domain emotional domain mlhfq showed acceptable fit comparative fit index cfi goodness fit gfi non normal fit index nfi root mean square error approximation rmsea regarding convergent evidence significant association found mlhfq domain sf domain ec r range conclusion current study completed cultural validation provided information psychometric characteristic mlhfq lithuania suggesting mlhfq valid reliable instrument measure hrqol lithuanian version mlhfq best described three factor solution measuring physical social emotional dimension hrqol among individual cad following ac:0.0772826095477669",
    "172528": "background coronavirus disease covid pandemic significantly worsened health quality life vulnerable population particularly elderly patient heart failure study aimed assess effect covid infection quality life elderly patient heart failure pandemic method retrospective case control study included elderly heart failure patient admitted second people hospital lanzhou december december diagnosed ongoing covid pandemic patient underwent covid nucleic acid testing upon admission among heart failure patient tested positive covid tested negative multiple validated instrument used assess physical mental health quality life instrument included minnesota living heart failure questionnaire mlhfq item short form health survey physical component summary score sf pc minute walking test mwt geriatric depression scale gd self rating anxiety scale sa total pittsburgh sleep quality index psqi mini nutritional assessment short form mna sf fatigue resistance ambulation illness loss weight frail scale result heart failure patient tested positive covid exhibited significantly lower blood pressure sf score mwt distance compared tested negative p additionally covid positive group higher mlhfq score older average age greater proportion patient nyha class iii iv frequent electrolyte imbalance elevated dimer c reactive protein crp n terminal pro brain natriuretic peptide nt probnp level longer hospital stay p patient also exhibited higher level anxiety sa total poorer sleep quality psqi greater frailty frail scale compared covid negative counterpart p addition heart failure patient covid infection reported severe symptom dyspnea fatigue p age covid infection identified significant factor negatively affecting quality life patient population conclusion covid infection significantly exacerbates decline quality life elderly patient heart failure highlight urgent need strengthened comprehensive treatment targeted mental health support vulnerable group:0.0764802907835756",
    "198381": "introduction objective pragmatic validated instrument needed assess quality life qol real world care heart failure hf patient study aimed validate minnesota living heart failure questionnaire mlhfq european portuguese search association patient reported outcome pro method single center prospective study two sample hf patient used mlhfq translation cultural adaptation validation validation sample included patient managed multidisciplinary hf clinic february february result validation sample included hf patient median age year female sex reduced left ventricle ejection fraction lvef preserved lvef principal component analysis identified three component representing three group question mlhfq related one domain subscore physical emotional social validated version showed reliable general factor good internal consistency mlhfq total score associated variable studied score strongly associated nyha functional class association found physical score borg fatigue score six minute walking distance emotional score associated anxiety depression score hospital anxiety depression scale conclusion study validated mlhfq portuguese revealed existence three subscores enables pragmatic assessment qol portuguese hf patient particularly preserved lvef future research concerning pro:0.0762097546475068",
    "51352": "background assessment health related quality life widely recommended european health agency relevant research study well clinical care aim validate french version macnew heart disease health related quality life questionnaire method part international heartqol project french speaking patient ischaemic heart disease angina n myocardial infarction mi n heart failure n mean age year recruited seven cardiac rehabilitation centre patient completed french version macnew questionnaire short form health survey sf hospital anxiety depression scale evaluate psychometric property french version macnew instrument result mean macnew global scale score patient angina mi heart failure respectively p mi versus angina observed minimal missing item ceiling effect floor effect factor analysis confirmed three factorial structure explaining observed variance internal consistency reliability cronbach alpha ranged test retest reliability ranged convergent validity confirmed total group diagnosis although correlation macnew physical subscale sf mental component summary higher expected discriminative validity partially confirmed sf health transition item fully confirmed anxiety depression predictor variable conclusion french version macnew questionnaire recommended assessing health related quality life french speaking patient ischaemic heart disease:0.0752682592155908",
    "85565": "breathlessness cardinal symptom pulmonary arterial hypertension pah yet breathlessness instrument previously tested reliability validity population using cross sectional design tested psychometric property dyspnoea assessment breathlessness pah pearson correlation world health organization functional class fc minnesota living heart failure pulmonary hypertension modified version mlhf ph hospital anxiety depression scale hads minute walk distance test mwd conducted participant n mostly female mean age year diagnosed idiopathic pah congenital heart disease connective tissue disease fc ii iii showed excellent internal consistency total two component score physical emotional cronbach alpha respectively total score significantly associated mlhf ph r hads anxiety r depression r fc r mwd r patient pah short patient reported measure breathlessness severity tap physical emotional component reliable valid instrument:0.0746210702090671"
  },
  "Topic 21": {
    "107551": "observational study investigate efficacy safety nonvitamin k antagonist oral anticoagulant noacs atrial fibrillation af patient bioprosthetic valve prior surgical valve repair clinical practice total patient mean age female bioprosthetic heart valve surgical valve repair af treated noacs included analysis mean cha d vasc congestive heart failure hypertension age year diabetes mellitus prior stroke transient ischemic attack vascular disease bled hypertension abnormal renal liver function stroke bleeding labile inr international normalized ratio elderly drug alcohol score value respectively total study population taking apixaban mg twice daily bid apixaban mg bid dabigatran mg bid dabigatran mg bid rivaroxaban mg daily qd rivaroxaban mg qd also study population previously warfarin replaced noacs due lack compliance labile inr control time therapeutic range noac therapy af started average day bioprosthetic heart valve implantation surgical repair average duration day study population included patient bioprosthetic mitral valve patient bioprosthetic aortic valve patient previous surgical mitral repair patient previous surgical aortic repair concomitant use noacs patient evaluated thromboembolic event ischemic stroke transient ischemic attack systemic embolism well major bleeding event follow period study population recorded low mean annual incidence thromboembolism major bleeding according data anticoagulation therapy noacs seems effective safe treatment strategy nonvalvular af patient bioprosthetic valve prior surgical valve repair:0.0658000343368253",
    "73123": "background management atrial fibrillation af evolved development direct oral anticoagulant doacs data clinical effectiveness safety outside clinical trial setting limited method raffine registry observational multicenter prospective registry japanese patient af designed follow clinical event year patient enrollment conducted university hospital general hospital private clinic ensure inclusion broad spectrum representative af patient primary outcome event study ischemic stroke systemic embolism major bleeding result enrolled ambulatory patient af university hospital general hospital clinic japan mean patient age year male type af paroxysmal persistent permanent major coexisting disease hypertension diabetes mellitus congestive heart failure history ischemic stroke transient ischemic attack coronary artery disease entire cohort treated warfarin treated doacs prescription doacs exceeded warfarin general hospital clinic risk score chad score cha d vasc score bled score higher patient university hospital patient general hospital clinic conclusion raffine registry baseline described current status anticoagulation therapy japan long term follow data identify outcome vary stratified group patient af doac era umin clinical trial registry umin:0.0622243820255841",
    "136850": "background atrial fibrillation af chronic kidney disease ckd associated increased risk ischemic stroke aim study compare clinical characteristic incidence left atrial appendage laa thrombus predictor spontaneous echo contrast sec population patient af depending estimated glomerular filtration rate egfr value method study included patient underwent transesophageal echocardiographic examination prior cardioversion ablation year three cardiac center result quarter af patient decreased egfr ml min characterized high risk population comorbidities higher thromboembolic bleeding risk compared normal renal function oral anticoagulation oac prescribed patient decreased normal egfr respectively higher prevalence prescribed non vitamin k antagonist oral anticoagulant noacs incidence laa thrombus sec increase simultaneously decrease egfr ml min respectively among patient prescribed reduced dos noac decreased egfr often observed laa thrombus v non paroxysmal af heart failure previous bleeding predictor laa thrombus irrespective egfr value ckd predictor laa thrombus patient including non paroxysmal af male without diabetes without hypertension cha d vasc conclusion despite oac patient concomitant af ckd remain high risk laa thrombus formation:0.0607300757342515",
    "168319": "importance u approximately million adult atrial fibrillation af af associated significantly increased risk stroke heart failure myocardial infarction dementia chronic kidney disease mortality observation symptom af include palpitation dyspnea chest pain presyncope exertional intolerance fatigue although approximately people af asymptomatic af detected incidentally clinical encounter wearable device interrogation cardiac implanted electronic device patient presenting ischemic stroke without diagnosed af implantable loop recorder ie subcutaneous telemetry device evaluate patient intermittent af american college cardiology acc american heart association aha american college clinical pharmacy accp heart rhythm society hr guideline writing group proposed stage af evolution stage risk defined patient af associated risk factor eg obesity hypertension stage pre af sign atrial pathology electrocardiogram imaging without af stage presence paroxysmal recurrent af episode lasting day persistent continuous af episode lasting day af subtypes stage permanent af lifestyle risk factor modification including weight loss exercise prevent af onset recurrence complication recommended stage patient estimated risk stroke thromboembolic event greater per year anticoagulation vitamin k antagonist direct oral anticoagulant reduces stroke risk compared placebo patient direct oral anticoagulant apixaban rivaroxaban edoxaban recommended warfarin lower bleeding risk compared anticoagulation aspirin associated poorer efficacy recommended stroke prevention early rhythm control antiarrhythmic drug catheter ablation restore maintain sinus rhythm recommended acc aha accp hr guideline patient af catheter ablation first line therapy patient symptomatic paroxysmal af improve symptom slow progression persistent af catheter ablation also recommended patient af heart failure reduced ejection fraction hfref improve quality life left ventricular systolic function cardiovascular outcome rate mortality heart failure hospitalization conclusion relevance af associated increased rate stroke heart failure mortality lifestyle risk factor modification recommended prevent af onset recurrence complication oral anticoagulant recommended estimated risk stroke thromboembolic event greater per year early rhythm control using antiarrhythmic drug catheter ablation recommended select patient af experiencing symptomatic paroxysmal af hfref:0.0607103474877809",
    "729": "atrial fibrillation af common cardiac arrhythmia af paroxysmal persistent becomes permanent convert sinus rhythm spontaneously attempted cardioversion fails prevalence af general population increase age octogenarian men age adjusted prevalence generally higher woman af synchronous mechanical atrial activity disturbed resulting haemodynamic impairment give rise thrombus formation embolism systemic circulation thrombus associated af arises frequently left atrial appendage cerebrovascular embolus af patient often manifest transient ischaemic attack ischaemic stroke overall rate ischaemic stroke among patient nonrheumatic af average per year rate increase age patient af higher risk cerebrovascular event cause stroke one every six occurs patient af including transient ischaemic attack silent stroke detected radiographically overall rate cerebrovascular event af patient rise per year although approximately one third due cause secondarily incidentally associated af related anticoagulant therapy antiarrhythmic therapy useful improve cardiac rate function af however reduce first recurrent embolus antithrombotic therapy paramount importance result several randomized clinical trial antithrombotic therapy shown adjusted dose warfarin reduces first recurrent stroke compared placebo patient nonvalvular af anticoagulated odds ischaemic stroke intracranial bleeding favour inr acetylsalicylic acid less efficacious warfarin af patient reducing risk stroke therefore antiplatelet agent used af patient low risk anticoagulation current treatment modality af patient high intermediate risk e patient history transient ischaemic attack stroke aged year history hypertension diabetes heart failure structural heart disease valvular disease significant systolic dysfunction benefit dual antiplatelet regimen af patient unknown combining antiplatelet agent different mechanism action important topic future investigation:0.0598416375239941",
    "17902": "atrial fibrillation af common sustained cardiac rhythm disturbance found clinical practice increasing prevalence age af often associated structural heart disease although significant proportion detectable heart disease last decade increase hospitalization af extremely costly public health problem af associated increased long term risk stroke heart failure cause mortality fact mortality rate patient af double patient normal sinus rhythm antithrombotic therapy recommended patient af prevent thromboembolism except lone af contraindication selection antithrombotic agent based upon absolute risk stroke bleeding relative risk benefit given patient however despite oral anticoagulation vitamin k antagonist warfarin acenocoumarol patient still thromboembolic event furthermore majority patient international normalized ratio inr monitoring may inconvenience new anticoagulant direct thrombin inhibitor investigated result ly trial recently published study population patient af dabigatran mg b associated stroke systemic embolism rate similar associated warfarin lower rate major hemorrhage however dabigatran administered dose mg lower rate stroke systemic embolism similar rate major hemorrhage found compared warfarin aim review update information prevention thromboembolic event patient af dabigatran may change daily clinical practice:0.0597327852611638",
    "142208": "objective identified factor associated thromboembolic bleeding event two contemporary cohort anticoagulated patient atrial fibrillation af treated either vitamin k antagonist vka non vka oral anticoagulant noacs design prospective multicentre observational study setting centre seven european country participant patient receiving vka prevention thromboembolic event european registry atrial fibrillation prefer af derivation cohort patient receiving noac prefer af prolongation validation cohort stroke prevention af outcome measure risk factor thromboembolic event ischaemic stroke systemic embolism major bleeding gastrointestinal bleeding intracerebral haemorrhage life threatening bleeding result mean age patient enrolled prefer af registry year female mean cha d vasc score incidence thromboembolic major bleeding event ci ci year follow respectively abnormal liver function prior stroke transient ischaemic attack labile international normalised ratio inr concomitant therapy antiplatelet non steroidal anti inflammatory drug heart failure older age year independently associated thromboembolic major bleeding event exception unstable inr value risk factor validated patient treated noacs prefer af prolongation study year female cha d vasc single point decrease modifiable bleeding risk scale observed lower risk major bleeding event ci p lower rate thromboembolic event ci p conclusion attending modifiable risk factor important treatment target anticoagulated af patient reduce thromboembolic bleeding event initiation anticoagulation risk stroke prevented elevated bleeding risk score:0.0597079645399223",
    "114284": "objective study sought investigate clinical outcome associated left atrial appendage occlusion laao versus direct oral anticoagulant doacs patient high risk atrial fibrillation af background laao shown noninferior warfarin stroke prevention af however anticoagulation doacs preferred warfarin thromboprophylaxis af method patient af enrolled amulet observational registry n successful laao amplatzer amulet device n compared propensity score matched control cohort incident af patient n treated doacs identified danish national patient registry propensity score matching based covariates cha d vasc congestive heart failure hypertension age year diabetes mellitus prior stroke transient ischemic attack thromboembolism vascular disease age year sex category bled hypertension abnormal renal liver function stroke bleeding labile international normalized ratio elderly drug alcohol score predicting stroke bleeding primary outcome composite ischemic stroke major bleeding bleeding academic research consortium cause mortality follow year result af patient treated laao significantly lower risk primary composite outcome compared patient treated doacs hazard ratio hr confidence interval ci total event event rate per patient year laao v doacs v v respectively risk ischemic stroke comparable group hr ci risk major bleeding hr ci cause mortality hr ci significantly lower patient treated laao conclusion among high risk af patient laao comparison doacs may similar stroke prevention efficacy lower risk major bleeding mortality:0.0589558727676403",
    "45914": "atrial fibrillation af common arrhythmia prevalence increase markedly increasing age presence af implication management future stroke risk patient pulse irregular electrocardiogram ordered key management decision whether adopt rhythm control rate control strategy whether initiate anticoagulation primary aim rhythm control strategy improved symptom control af ablation may considered younger patient aged year paroxysmal early persistent af af increase risk stroke anticoagulation considered basis stroke risk clearly indicated chad score congestive heart failure hypertension age year diabetes point previous stroke transient ischaemic attack point independent type af patient af benefit stroke reduction systemic anticoagulation outweigh bleeding risk anticoagulant antiplatelet agent increase risk bleeding however new oral anticoagulant tend improved safety profile particularly regard intracranial bleeding least effective warfarin stroke prevention:0.0575632666741478",
    "95416": "atrial fibrillation af frequent arrhythmia prevalence near general population mexico one half million people affected af need considered public health problem af independent risk factor associated mortality due embolic event heart failure sudden death early diagnosis utmost importance unstable patient recent onset af electrical cardioversion practiced stable patient thromboembolic measure taken necessary assess whether reasonable administer antiarrhythmic drug restore sinus rhythm performed electrical cardioversion recidivating case paroxysmal persistent presentation effective strategy performed pulmonary vein isolation either radiofrequency cryoballoon energy permanent af recovery sinus rhythm possible distinguishing feature phase uncontrollable variability ventricular frequency could treated pharmacologically atrioventricular av nodal blocker vvir pacemaker plus av nodal ablation presence af long associated development cerebral systemic pulmonary limb coronary renal visceral embolism prevention embolism valvular af perform vitamin k antagonist vka patient af associated mitral stenosis mechanical valve prosthesis choice made anticoagulant drug vka direct oral anticoagulant antiplatelet agent weakest effect preventing embolism:0.0573589083331033"
  },
  "Topic 22": {
    "135125": "objective study sought determine whether risk atrial fibrillation af estimated accurately using routinely ascertained feature electronic health record ehr whether af risk associated stroke background early diagnosis af treatment anticoagulation may prevent stroke method using multi institutional ehr study identified individual year age without prevalent af prediction model derived validated year af risk using split sample validation model performance compared method af risk assessment result within year individual developed af derivation sample af event total optimal risk model included sex age race smoking height weight diastolic blood pressure hypertension hyperlipidemia heart failure coronary heart disease valvular disease prior stroke peripheral arterial disease chronic kidney disease hypothyroidism quadratic term height weight age validation sample af event total af risk model demonstrated good discrimination c statistic confidence interval ci calibration ci model discrimination calibration superior charge af cohort heart aging research genomic epidemiology af c statistic ci calibration slope ci c hest coronary artery disease chronic obstructive pulmonary disease hypertension elderly age year systolic heart failure thyroid disease hyperthyroidism c statistic ci calibration slope ci cha d vasc congestive heart failure hypertension age year diabetes mellitus prior stroke transient ischemic attack tia thromboembolism vascular disease age year sex category female score c statistic ci calibration slope ci af risk discriminated incident stroke n c statistic ci stroke within day incident af n c statistic ci conclusion model developed real world ehr database predicted af accurately stratified stroke risk incorporating af prediction ehrs may enable risk guided screening af:0.0672728874177514",
    "137541": "background gout associated higher risk coronary heart disease chd stroke prior study study assessed association gout incident heart failure hf method analyzed data black white men woman year age population based reason geographic racial difference stroke regard cohort study medicare coverage without history hf chd stroke baseline gout defined hospitalization outpatient visit diagnosis code gout medicare claim prior participant baseline study examination regard study participant followed hf hospitalization chd stroke cause mortality separate outcome december analysis replicated random sample patient year age medicare coverage january june followed december result among regard study participant included current analysis mean age baseline year men black gout median follow year incidence rate per person year among participant without gout hf hospitalization chd stroke cause mortality respectively multivariable adjustment sociodemographic variable cardiovascular risk factor hazard ratio ci comparing participant versus without gout hf hospitalization chd stroke cause mortality multivariable adjusted hazard ratio hf hospitalization reduced preserved left ventricular ejection fraction among participant versus without gout ci ci respectively multivariable adjusted hazard ratio heart failure hospitalization associated gout among medicare beneficiary ci conclusion among older adult gout associated increased risk incident hf incident chd incident stroke cause mortality:0.0656813964154318",
    "144740": "importance individual bipolar disorder schizophrenia higher risk adverse outcome cardiovascular disease oral anticoagulation therapy oat patient atrial fibrillation af needed stroke prevention whether patient bipolar disorder schizophrenia face disparity receiving therapy unknown objective assess whether bipolar disorder schizophrenia associated lower rate oat initiation patient incident af lower prevalence oat prevalent af design setting participant nationwide cohort study danish patient af conducted january december data analyzed january june data national registry included information redeemed prescription hospital contact patient incident prevalent af age year increased risk status defined cha d vasc congestive heart failure hypertension age year diabetes stroke transient ischemic attack vascular disease age year sex category risk score greater equal exposure hospital diagnosis bipolar disorder schizophrenia main outcome measure adjusted proportion difference oat initiation oat prevalence comparing individual without bipolar disorder schizophrenia result patient included incident af n mean sd age year woman bipolar disorder schizophrenia accounting age sex calendar time bipolar disorder schizophrenia associated significantly lower frequency oat initiation within day incident af bipolar disorder ci schizophrenia ci lower oat prevalence patient prevalent af bipolar disorder ci schizophrenia ci adjusting socioeconomic factor comorbid condition attenuated association particularly patient bipolar disorder however schizophrenia continued associated lower rate oat initiation ci ci lower oat prevalence association also present introduction non vitamin k antagonist adjusted proportion difference ci initiation ci prevalence conclusion relevance study patient bipolar disorder schizophrenia less likely receive oat setting af patient bipolar disorder deficit largely associated socioeconomic factor comorbidities especially toward end study period patient schizophrenia disparity stroke prevention therapy persistently exceeded could explained patient characteristic:0.0647350153384853",
    "135233": "importance warfarin prescribed patient atrial fibrillation af prevention cardioembolic complication whether warfarin adversely affect bone health controversial availability alternate direct oral anticoagulant doac option make possible evaluate comparative safety warfarin association fracture risk objective test hypothesis among patient nonvalvular af use doacs v warfarin associated lower risk incident fracture design setting participant comparative effectiveness cohort study used marketscan administrative claim database identify patient nonvalvular af prescribed oral anticoagulant january september reduce confounding patient matched age sex cha d vasc congestive heart failure hypertension age year point year point diabetes previous stroke transient ischemic attack point vascular disease score high dimensional propensity score final analysis included patient af data analyzed february september exposure warfarin doacs dabigatran etexilate rivaroxaban apixaban main outcome measure incident hip fracture fracture requiring hospitalization clinical fracture identified using inpatient outpatient claim defined international classification disease ninth revision clinical modification code result study population patient af woman men mean sd age year total hip fracture hospitalized fracture total fracture occurred mean sd follow month multivariable adjusted propensity score matched cox proportional hazard regression model relative new user warfarin new user doacs tended lower risk fracture requiring hospitalization hazard ratio hr ci clinical fracture hr ci whereas association hip fracture hr ci statistically significant comparing individual doacs warfarin strongest finding apixaban hr hip fracture ci hr fracture requiring hospitalization ci hr clinical fracture ci subgroup analysis doacs appeared beneficial among patient af also diagnosis osteoporosis among without diagnosis osteoporosis conclusion relevance real world population patient af use doacs particularly apixaban compared warfarin use associated lower fracture risk association pronounced among patient diagnosis osteoporosis given potential adverse effect warfarin bone health finding suggest caution used prescribing warfarin patient af high risk fracture:0.0636910746572265",
    "168127": "importance health disparity among racial ethnic minoritized population particularly cancer mortality rate remain major public health concern men underrepresented background black hispanic men specifically face pervasive effect discrimination daily life also contribute complex association among allostatic load marker chronic stress educational opportunity elevated risk cancer mortality objective elucidate association among educational attainment allostatic load cancer mortality risk among men design setting participant retrospective cohort analysis data national health nutrition examination survey nationally representative sample approximately people across u linked data national death index served follow data cohort available december participant included men aged year older data analyzed june october exposure allostatic load data stratified educational attainment level categorized less high school education high school graduate allostatic load score calculated sum total abnormal biomarkers health measure total participant considered high allostatic load score main outcome measure primary outcome cancer death weighted cox proportional hazard model fitted estimate adjusted hazard ratio hr cancer death educational attainment allostatic load adjusted age income smoking status result among men mean se age year high al less high school educational attainment greater fold increased risk cancer mortality unadjusted hr ci compared low allostatic load college degree higher similarly black men hr ci white men hr ci high allostatic load less high school educational attainment higher risk cancer death compared race specific counterpart college education low allostatic load adjustment age poverty income ratio smoking status history cancer ever congestive heart failure heart attack association attenuated men hr ci white men hr ci still greater increased risk cancer death compared men college education low allostatic load conclusion relevance study highlight detrimental association attaining high school degree combined high allostatic load marker chronic stress cancer mortality effort promote educational attainment address underlying social determinant health imperative reducing cancer disparity population:0.0620805465802715",
    "63561": "introduction lifestyle change program implemented within healthcare system could reach many american impact cardiovascular disease cvd remains unclear move program largest lifestyle change program implemented healthcare setting u study aimed determine whether move participation associated reduced cvd incidence method retrospective cohort study analyzed used national veteran health administration database identify move participant eligible non participant comparison patient eligible move obese overweight weight related health condition baseline cvd examined n move participant patient male white mean age year bmi main outcome incidence cvd icd procedure code coronary artery disease cerebrovascular disease peripheral vascular disease heart failure result adjusting age race sex bmi statin use baseline comorbidities mean year follow move participation associated lower incidence total cvd hazard ratio hr ci coronary artery disease hr ci cerebrovascular disease hr ci peripheral vascular disease hr ci heart failure hr ci association move participation cvd incidence remained significant examined across category race ethnicity bmi diabetes hypertension smoking status statin use conclusion although participation limited move associated reduced cvd incidence nationwide healthcare setting:0.0619695416418400",
    "191207": "aim study prevalence cardiovascular disease cvd associated risk factor among different race ethnicity across different income group method retrospective analysis included data national health nutrition examination survey adult year identified non hispanic nh white nh black hispanic included family income poverty ratio pir calculated dividing family income poverty guideline specific survey year divided four quartile weighted logistic regression performed estimate adjusted odds ratio determine association race ethnicity cvd pir quartile model adjusted age sex race health insurance marital status citizenship status education level pir result included adult corresponded approximately million weighted nationally representative participant participant belonged st nd rd th quartile respectively prevalence diabetes mellitus dm hypertension coronary artery disease cad congestive heart failure chf stroke decreased successive pir quartile nh black participant higher prevalence odds dm hypertension obesity chf stroke compared nh white participant difference prevalence odds nh white adult nh black adult greater obesity p interaction dm p interaction stroke p interaction th pir quartile highest income compared st pir quartile lowest income conclusion racial ethnic disparity risk cvd persists across income level greater difference prevalence select cvd risk factor nh black nh white participant highest income quartile compared lowest income quartile:0.0615270869824208",
    "175873": "background kidney disease known independent driver cardiovascular disease dietary sodium potassium intake approximated via urinary excretion known cardiac risk factor general population role prevention person kidney disease unclear thus studied relationship ratio urinary sodium potassium excretion incident cardiovascular disease individual chronic kidney disease method included adult chronic kidney disease enrolled chronic renal insufficiency cohort free cardiovascular disease study entry urinary sodium potassium measured via hour urine collection baseline visit primary study outcome included atrial fibrillation af heart failure overall reduced ejection fraction hfref preserved ejection fraction hfpef myocardial infarction mi incidence rate confidence interval calculated per person year nested model created using cox regression adjusted sociodemographic data age sex race ethnicity lifestyle habit body mass index cigarette smoking medication use medical comorbidities renal characteristic result among study population mean sd age year mean estimated glomerular filtrate rate ml min highest quartile versus lowest quartile urinary sodium potassium ratio associated fold increased risk overall hf hr ci fold increased risk hfref hr ci fold increased risk af hr ci adjustment covariates find association incident mi hr ci hfpef hr ci conclusion higher ratio urinary sodium potassium excretion associated incident af hf particularly hfref mi person chronic kidney disease dietary sodium potassium represent possible modifiable risk factor cardiovascular disease prevention individual kidney disease:0.0598343600740692",
    "166930": "background aim numerous study linked air pollution cardiovascular disease fewer study examined association low concentration level assessed potential modifier investigation examined hospitalization miss incident case study aim address gap nationwide cohort study medicare enrollee method study cohort comprise medicare enrollee year old continuously enrolled fee service program medicare part b across contiguous u examined association population weighted zip code level annual average pm warm season may october first diagnosis atrial fibrillation af congestive heart failure chf stroke fit multi pollutant cox proportional hazard model adjusted individual demographic characteristic area level covariates examined association low pollutant concentration level potential effect modification race ethnicity comorbidities diabetes hypertension hyperlipidemia result elevated pm level associated increased incidence af chf stroke mug increase annual pm hazard ratio hr ci ci ci respectively ppb increase annual hr ci ci ci respectively warm season ppb increase associated increased incidence chf hr ci stroke hr ci larger magnitude hr observed restricted pollutant level lower naaqs standard generally higher risk observed black people diabetic conclusion long term exposure pm warm season associated increased incidence cardiovascular disease even low pollutant concentration level black people people diabetes found vulnerable population:0.0598143460451933",
    "162920": "objective study aim examine whether greater frequency depressive symptom associate increased risk incident heart failure hf background depressive symptom associate adverse prognosis patient prevalent hf association incident hf less studied particularly low income minority individual method studied black white southern community cohort study participant median age year black woman enrolled without prevalent hf receiving center medicare medicaid service coverage cox model adjusted traditional hf risk factor socioeconomic behavioral factor social support antidepressant medication used quantify association depressive symptom assessed enrollment via center epidemiologic study depression scale cesd incident hf ascertained center medicare medicaid service international classification disease th revision icd code x icd code code december result median cesd score iqr median year follow participant developed hf strongest correlate cesd score antidepressant medication use age socioeconomic factor rather traditional hf risk factor greater frequency depressive symptom associated increased incident hf risk per u higher cesd hr ci p without variation race sex association depressive symptom incident hf varied antidepressant use interaction p increased risk among individual taking antidepressant conclusion high risk low income cohort predominantly black participant greater frequency depressive symptom significantly associate higher risk incident hf:0.0594734232174974"
  },
  "Topic 23": {
    "2079": "context result recent study effect beta blockade patient heart failure demonstrated reduction total mortality however effect beta blockade frequency hospitalization symptom quality life patient heart failure fully explored objective examine effect beta blocker controlled release extended release metoprolol succinate metoprolol cr xl mortality hospitalization symptom quality life patient heart failure design randomized double blind controlled trial preceded week single blind placebo run period conducted february october mean follow year setting three hundred thirteen site country participant patient n chronic heart failure new york heart association nyha functional class ii iv ejection fraction less stabilized optimum standard therapy intervention patient randomized metoprolol cr xl mg per day nyha class ii mg per day nyha class iii iv titrated week target dosage mg per day n matching placebo n main outcome measure total mortality hospitalization time first event number hospitalization worsening heart failure change nyha class intervention group quality life assessed substudy patient result incidence predefined end point lower metoprolol cr xl group placebo group including total mortality cause hospitalization prespecified second primary end point v event risk reduction confidence interval ci p total mortality hospitalization due worsening heart failure v event risk reduction ci p number hospitalization due worsening heart failure v p number day hospital due worsening heart failure v day p nyha functional class assessed physician mcmaster overall treatment evaluation score assessed patient improved metoprolol cr xl group compared placebo group p p respectively conclusion study patient symptomatic heartfailure metoprolol cr xl improved survival reduced need hospitalization due worsening heart failure improved nyha functional class beneficial effect patient well:0.0604600751282600",
    "117340": "objective lorcaserin selective serotonin c receptor agonist effective pharmacologic weight loss therapy improves several cardiovascular risk factor long term clinical cardiovascular metabolic safety efficacy patient elevated cardiovascular risk unknown research design method camellia timi nct randomized double blind placebo controlled multinational clinical trial designed evaluate safety efficacy lorcaserin regard major adverse cardiovascular event progression diabetes overweight obese patient high cardiovascular risk overweight obese patient either established cardiovascular disease diabetes least cardiovascular risk factor randomized ratio lorcaserin mg twice daily matching placebo primary safety objective assess noninferiority lorcaserin composite end point cardiovascular death myocardial infarction stroke major adverse cardiovascular event mace noninferiority defined upper bound sided ci excluding hazard ratio compared placebo assessed interim analysis adjudicated event efficacy objective assessed study completion evaluate superiority lorcaserin primary composite end point cardiovascular death myocardial infarction stroke hospitalization unstable angina heart failure coronary revascularization mace key secondary end point conversion diabetes recruitment began january completed november resulting total population patient trial planned continue least adjudicated mace event accrued median treatment duration exceeds year conclusion camellia timi investigating safety efficacy lorcaserin mace conversion diabetes overweight obese patient established cardiovascular disease multiple cardiovascular risk factor:0.0545449244209599",
    "20641": "background patient chronic heart failure chf high risk cardiovascular death recurrent hospital admission aimed find whether use angiotensin receptor blocker could reduce mortality morbidity method parallel randomised double blind controlled clinical trial compared candesartan placebo three distinct population studied patient left ventricular ejection fraction lvef less receiving angiotensin converting enzyme inhibitor previous intolerance currently receiving angiotensin converting enzyme inhibitor patient lvef higher overall patient data randomly assigned candesartan n titrated mg daily matching placebo n followed least year primary outcome overall programme cause mortality component trial cardiovascular death hospital admission chf analysis intention treat finding median follow month patient candesartan placebo group died unadjusted hazard ratio ci p covariate adjusted p fewer cardiovascular death v unadjusted p covariate adjusted p hospital admission chf v p candesartan group significant heterogeneity candesartan result across component trial patient discontinued candesartan placebo concern renal function hypotension hyperkalaemia interpretation candesartan generally well tolerated significantly reduced cardiovascular death hospital admission heart failure ejection fraction treatment baseline alter effect:0.0538005862443036",
    "18072": "background chronic heart failure associated high mortality morbidity raised resting heart rate risk factor adverse outcome aimed assess effect heart rate reduction selective sinus node inhibitor ivabradine outcome heart failure method patient eligible participation randomised double blind placebo controlled parallel group study symptomatic heart failure left ventricular ejection fraction lower sinus rhythm heart rate beat per min higher admitted hospital heart failure within previous year stable background treatment including beta blocker tolerated patient randomly assigned computer generated allocation schedule ivabradine titrated maximum mg twice daily matching placebo patient investigator masked treatment allocation primary endpoint composite cardiovascular death hospital admission worsening heart failure analysis intention treat trial registered number isrctn finding patient randomly assigned treatment group ivabradine placebo data available analysis patient ivabradine group patient allocated placebo median follow iqr month patient ivabradine group taking placebo primary endpoint event hr ci p effect driven mainly hospital admission worsening heart failure placebo v ivabradine hr p death due heart failure v hr p fewer serious adverse event occurred ivabradine group event placebo group p ivabradine patient symptomatic bradycardia compared placebo group p visual side effect phosphenes reported patient ivabradine placebo p interpretation result support importance heart rate reduction ivabradine improvement clinical outcome heart failure confirm important role heart rate pathophysiology disorder funding servier france:0.0534139737847130",
    "184750": "presence systemic right ventricle srv biventricular physiology biv associated increased patient morbidity mortality date pharmacologic therapy heart failure proven effective patient systolic dysfunction srv biv designed randomized double blind placebo controlled crossover trial compare sacubitril valsartan treatment placebo adult aged year moderate severe srv biv dysfunction new york heart association functional class ii iii symptom two primary efficacy endpoint assessed trial exercise capacity submaximal exercise duration neurohormonal activation n terminal prohormone brain natriuretic peptide secondary objective include assessing change kansa city cardiomyopathy questionnaire score evaluating safety tolerance sacubitril valsartan week open run phase identifies maximum tolerated dose sacubitril valsartan mg mg twice daily week washout period patient randomized sacubitril valsartan treatment v placebo week phase followed another week washout period subsequent crossover alternative treatment arm additional week phase data assess primary secondary endpoint collected baseline end phase total patient required provide power detect difference distance walked n terminal prohormone brain natriuretic peptide level sacubitril valsartan treatment v placebo sided p value summary prospective comparison angiotensin receptor neprilysin inhibitor v placebo patient congenital systemic right ventricular heart failure trial paracys rv determine role sacubitril valsartan treating heart failure patient srv biv carry potential alter management patient population:0.0533492737524370",
    "23718": "background beta blocking agent reduce risk hospitalization death patient mild moderate heart failure little known effect severe heart failure method evaluated patient symptom heart failure rest minimal exertion clinically euvolemic ejection fraction less percent double blind fashion randomly assigned patient placebo patient treatment carvedilol mean period month standard therapy heart failure continued patient required intensive care marked fluid retention receiving intravenous vasodilator positive inotropic drug excluded result death placebo group death carvedilol group difference reflected percent decrease risk death carvedilol percent confidence interval percent p unadjusted p adjusted interim analysis total patient died hospitalized placebo group compared carvedilol group difference reflected percent decrease combined risk death hospitalization carvedilol percent confidence interval percent p favorable effect end point seen consistently subgroup examined including patient history recent recurrent cardiac decompensation fewer patient carvedilol group placebo group withdrew adverse effect reason p conclusion previously reported benefit carvedilol regard morbidity mortality patient mild moderate heart failure also apparent patient severe heart failure evaluated trial:0.0530382401952818",
    "194176": "background finerenone selective nonsteroidal mineralocorticoid receptor antagonist sodium glucose cotransporter inhibitor sglt reduce chronic kidney disease ckd progression improve kidney cardiovascular cv outcome confidence combination effect finerenone empagliflozin participant chronic kidney disease type diabetes using uacr endpoint study nct eudract hypothesis early combination finerenone empagliflozin sglt superior either drug alone reducing urine albumin creatinine ratio uacr month method confidence ongoing fully enrolled randomized controlled double blind multicentre phase clinical trial adult year age ckd type diabetes estimated glomerular filtration rate egfr ml min uacr mg g participant taking clinically maximum tolerated dose renin angiotensin system inhibitor month screening eligible participant randomized daily finerenone plus empagliflozin finerenone plus placebo empagliflozin plus placebo dos mg daily empagliflozin mg daily finerenone depending egfr baseline randomization stratified egfr ml min uacr mg g primary efficacy outcome relative change uacr baseline day result participant randomized across site country july august mean standard deviation egfr ml min median interquartile range uacr mg g mean standard deviation hba c mean systolic diastolic blood pressure mmhg glucagon like peptide receptor agonist insulin used participant respectively atherosclerotic cv disease diabetic retinopathy history heart failure present participant respectively conclusion confidence trial enrolled diverse population ckd determine impact simultaneous initiation combination finerenone sglt versus individual therapy potentially mitigating progression ckd people trial registration number clinicaltrials gov nct eudract:0.0523403813739241",
    "160973": "background empagliflozin improves cardiovascular outcome patient heart failure patient type diabetes high cardiovascular risk patient chronic kidney disease safety efficacy empagliflozin patient acute myocardial infarction unknown method event driven double blind randomized placebo controlled trial assigned ratio patient hospitalized acute myocardial infarction risk heart failure receive empagliflozin dose mg daily placebo addition standard care within day admission primary end point composite hospitalization heart failure death cause assessed time first event analysis result total patient assigned receive empagliflozin receive placebo median follow month first hospitalization heart failure death cause occurred patient empagliflozin group patient placebo group incidence rate event respectively per patient year hazard ratio confidence interval ci p respect individual component primary end point first hospitalization heart failure occurred patient empagliflozin group patient placebo group hazard ratio ci death cause occurred respectively hazard ratio ci adverse event consistent known safety profile empagliflozin similar two trial group conclusion among patient increased risk heart failure acute myocardial infarction treatment empagliflozin lead significantly lower risk first hospitalization heart failure death cause placebo funded boehringer ingelheim eli lilly empact mi clinicaltrials gov number nct:0.0519368960515789",
    "53422": "background ivabradine specifically inhibits f current sinoatrial node lower heart rate without affecting aspect cardiac function aimed test whether lowering heart rate ivabradine reduces cardiovascular death morbidity patient coronary artery disease left ventricular systolic dysfunction method december december screened patient centre country enrolled eligible patient coronary artery disease left ventricular ejection fraction less randomised double blind placebo controlled parallel group trial patient received mg ivabradine intention increasing target dose mg twice day received matched placebo addition appropriate cardiovascular medication primary endpoint composite cardiovascular death admission hospital acute myocardial infarction admission hospital new onset worsening heart failure analysed patient intention treat study registered clinicaltrials gov number nct finding mean heart rate baseline sd beat per minute bpm median follow month iqr ivabradine reduced heart rate bpm se month corrected placebo patient receiving beta blocker addition study drug safety concern identified ivabradine affect primary composite endpoint hazard ratio ci p patient ivabradine group serious adverse event compared control p prespecified subgroup patient heart rate bpm greater ivabradine treatment affect primary composite outcome hazard ratio ci p cardiovascular death admission hospital new onset worsening heart failure however reduce secondary endpoint admission hospital fatal non fatal myocardial infarction ci p coronary revascularisation ci p interpretation reduction heart rate ivabradine improve cardiac outcome patient stable coronary artery disease left ventricular systolic dysfunction could used reduce incidence coronary artery disease outcome subgroup patient heart rate bpm greater:0.0509964845789785",
    "5803": "context vasopressin mediates fluid retention heart failure tolvaptan vasopressin v receptor blocker show promise management heart failure objective investigate effect tolvaptan initiated patient hospitalized heart failure design setting participant efficacy vasopressin antagonism heart failure outcome study tolvaptan everest event driven randomized double blind placebo controlled study outcome trial comprised patient within short term clinical status study hospitalized heart failure randomized north american south american european site october february followed long term treatment intervention within hour admission patient randomly assigned receive oral tolvaptan mg per day n placebo n minimum day addition standard therapy main outcome measure dual primary end point cause mortality superiority noninferiority cardiovascular death hospitalization heart failure superiority secondary end point included change dyspnea body weight edema result median follow month patient tolvaptan group placebo group died hazard ratio confidence interval ci p upper confidence limit mortality difference within prespecified noninferiority margin p composite cardiovascular death hospitalization heart failure occurred tolvaptan group patient placebo group patient hazard ratio ci p secondary end point cardiovascular mortality cardiovascular death hospitalization worsening heart failure also different tolvaptan significantly improved secondary end point day patient assessed dyspnea day body weight day edema patient hyponatremia serum sodium level significantly increased kansa city cardiomyopathy questionnaire overall summary score improved outpatient week body weight serum sodium effect persisted long discharge tolvaptan caused increased thirst dry mouth frequency major adverse event similar group conclusion tolvaptan initiated acute treatment patient hospitalized heart failure effect long term mortality heart failure related morbidity trial registration clinicaltrials gov identifier nct:0.0509555829921142"
  },
  "Topic 24": {
    "54088": "objective report first case pathologically confirmed myocarditis patient receiving treatment lenalidomide non hodgkin lymphoma case summary year old woman recurrent follicular lymphoma treated lenalidomide mg daily low dose dexamethasone mg weekly clinical trial past medical history hypertension breast cancer within day starting lenalidomide dexamethasone developed symptom sign congestive heart failure despite aggressive supportive care progressive refractory multiorgan failure died postmortem examination heart confirmed absence coronary artery disease histopathological examination myocardium revealed diffuse lymphocytic eosinophilic inflammatory infiltrate associated acute chronic myocardial injury affecting chamber heart consistent myocarditis discussion lenalidomide immunomodulatory agent derived thalidomide approved treatment multiple myeloma myelodysplastic syndrome efficacy lenalidomide reported b cell malignancy common toxicity myelosuppression fatigue diarrhea skin rash venous thromboembolism peripheral neuropathy tumor flare reaction cardiovascular toxicity limited atrial fibrillation increased risk venous thromboembolism autoimmune hemolytic anemia pneumonitis dermatitis described lenalidomide propose immunological mechanism myocarditis based predominantly cell infiltration myocardium conclusion finding suggest lenalidomide may cause drug induced myocarditis patient treated lenalidomide present sign symptom heart failure absence obvious cause lenalidomide hypersensitivity considered differential diagnosis myocardial biopsy considered common cause heart failure excluded reasonable management approach drug discontinuation early institution corticosteroid therapy objective causality assessment using naranjo probability scale revealed adverse drug event probable:0.0637046656502419",
    "86628": "tnf alpha blocker side effect vary according frequency severity mainly include immunogenicity ability cause immune reaction infection malignancy heart failure demyelinating disease others treatment tnf alpha blocker may result formation autoantibody rarely development lupus like syndrome administered patient experienced severe hypersensitivity reaction urticaria dyspnea hypotension occur tnf alpha inhibitor administration serious infusion reaction including anaphylaxis infrequent patient treated tnf alpha blocker increased risk developing serious infection active tuberculosis including reactivation latent tb invasive fungal infection bacterial viral also infection due opportunistic pathogen therefore patient screened systemic localized infection starting therapy patient positive screening tb treated isoniazid least week starting tnf alpha blocker therapy tnf alpha blocker may associated non hodgkin lymphoma cancer especially combined immunosuppressive drug monotherapy showed effect patient cited personal history malignant disease therefore caution needed tnf alpha blocker contraindicated patient moderate severe congestive heart failure nyha class iii iv tnf alpha blocker associated reactivation hepatitis b virus hbv infection patient chronic carrier patient tested hbv infection treatment patient test positive monitored closely reactivation hbv infection following termination therapy patient negative serology vaccinated severe hepatic reaction including acute liver failure jaundice hepatitis cholestasis reported patient symptom sign liver dysfunction evaluated evidence liver injury case leucopenia neutropenia thrombocytopenia pancytopenia reported tnf alpha blocker associated rare case cns manifestation systemic vasculitis new onset exacerbation cns peripheral demyelinating disorder including multiple sclerosis guillain barre syndrome:0.0612017175308500",
    "67164": "dear editor year old woman developed yellow brownish infiltrates nodule tumor mimicking xanthoma mostly involving periorbital chest area within three month figure abnormality serum cholesterol triglyceride level detailed laboratory analysis revealed presence mild monoclonal gammopathy presence immunoglobulin g igg kappa light chain however according hematologist consultation require medical intervention imaging assessment ultrasound examination show specific involvement internal organ skin biopsy demonstrated necrobiotic area alternated focus xanthogranulomatous infiltration throughout reticular dermis extension subcutaneous tissue granulomatous infiltrate composed epithelioid foamy histiocyte addition conspicuous giant cell touton type foreign body type well variable number lymphocyte plasma cell neutrophile lipid vacuole seen within focus necrobiosis xanthogranulomatous infiltration figure two month first admission department first sign necrosis within lesion noted massive necrosis skin lesion occurred following month figure based clinical manifestation histological laboratory finding diagnosis necrobiotic xanthogranuloma nxg established patient extremely late onset disease aggressive course absence malignant hematological disorder remarkable general condition improved local treatment low dose prednisone however patient anamnesis revealed myocardial infarction past congestive heart failure atrial fibrillation eventually patient died due acute heart failure alkylating agent could administered consider patient death unrelated nxg nxg rare chronic granulomatous disorder first described kossard winkelmann currently less one hundred fifty case syndrome reported literature worldwide disease occurs adulthood slightly frequently woman usually age year although youngest reported patient year old disease initially manifest xanthoma like eruption yellowish red orange papule nodule coalesce indurated plaque size lesion typically increase time next recurrence comparison hyperlipemic normolipemic xanthoma lesion firmer prominent polymorphic superficial telangiectasias sometimes erythematous violaceous border atrophy ulceration lesion observed patient tended extensive progressive skin lesion nxg occur anywhere body however two third patient periorbital involvement particularly upper lower eyelid elsewhere face second commonly affected site trunk predominantly chest however many skin lesion first appear trunk extremity subsequently involve periorbital area one body area affected published case individual case occurrence nxg noted within scar trauma previously x ray irradiated area lesion may asymptomatic however half patient asked reported various symptom predominantly itching also burning tenderness even pain periorbital skin lesion often accompanied ophthalmic manifestation mainly scleritis choroiditis conjunctivitis complication blepharoptosis restricted ocular motility proptosis extracutaneous lesion commonly seen respiratory tract including lung larynx followed myocardium oral cavity skeletal muscle kidney ovary intestine site extracutaneous involvement reported less case frequency seems increased recent year regarding laboratory abnormality majority patient nxg depending studied population monoclonal gammopathy often igg kappa igg lambda elevated erythrocyte sedimentation rate anemia leukopenia low c c level cryoglobulinemia also frequently present incisional biopsy recommended confirm diagnosis nxg correlation clinical presentation specific histopathologic finding poorly characterized far histopathology show inflammatory infiltrate composed macrophage foam cell plasma cell inflammatory cell well touton foreign body type giant cell dermis subcutaneous tissue necrobiosis usually present nodular lymphoid aggregate common cholesterol cleft asteroid body rare absent epidermis may atrophic normal special stain helpful establishing diagnosis nxg immunohistochemistry cd positive always cd p negative like non x histiocytosis patient without known myeloproliferative disorder bone marrow biopsy may reveal atypical increased plasma cell rarely true multiple myeloma mentioned nxg manifestation multiple myeloma however chronic lymphocyte leukemia b cell lymphoma lymphoproliferative disease also reported patient nxg remarkably hematological disorder may emerge many year onset skin lesion even year according available literature data course disease usually chronic slowly progressive prognosis relatively good absence co occurrence malignant hematological disorder aside hyperlipemic normolipemic xanthoma differential diagnosis nxg includes multifocal necrobiosis lipoidica granuloma annulare foreign body granuloma juvenile xanthogranuloma rheumatoid nodule amyloidosis case literature xanthoma nxg present time despite several hypothesis etiopathogenesis nxg remains unknown reason due rarity disease optimal therapy defined frequently chlorambucil melphalan used alone combination prednisone treatment may result remission symptom skin provide permanent cure also single report successful use thalidomide lenalidomide cyclophosphamide dexamethasone interferon b plasmapheresis hydroxychloroquine azathioprine infliximab autologous bone marrow transplantation methotrexate seems ineffective local therapy including local steroid laser co radiotherapy result partial improvement skin lesion relapsed unresponsive treatment could excised surgically defect resurfaced skin graft:0.0590321973530506",
    "169486": "cryoglobulinemic vasculitis rare small vessel vasculitis leading multi organ dysfunction often associated chronic infection like hepatitis c virus hcv autoimmune disorder case involve mixed monoclonal polyclonal immunoglobulin presenting symptom purpura arthralgia weakness severe organ involvement particularly cardiac rare potentially life threatening report case year old woman without prior medical history presented acute dyspnea generalized petechial purpura sign global heart failure imaging laboratory finding indicated cardiomegaly pericardial effusion significant nephrotic syndrome renal failure diagnosis cryoglobulinaemia confirmed histology serology showing monoclonal igm kappa hypergammaglobulinaemia complement consumption treatment included various immunosuppressant corticosteroid rituximab combined renal replacement therapy following initiation treatment proper management heart failure patient condition significantly improved cardiac involvement cryoglobulinemic vasculitis though rare lead severe heart failure often involves necrotizing vasculitis coronary artery systemic inflammation damaging cardiac muscle observed cardiac manifestation immunosuppressive therapy reversible despite poor long term prognosis patient cardiac lesion conclusion cryoglobulinemic vasculitis grim prognosis due multi organ impact severity lesion early aggressive treatment essential manage life threatening acute presentation even confirming diagnosis biologically histologically:0.0587978133085686",
    "145112": "background amebic colitis infection caused entamoeba histolytica commonly observed region poor sanitation also seen sexually transmitted disease developed country amebic colitis usually chronic course repeated exacerbation remission may also manifest fulminant form rapidly progress lead severe life threatening complication intestinal perforation peritonitis sepsis high mortality rate case summary year old man admitted hospital chest pain acute dyspnea diagnosed acute coronary syndrome acute heart failure bacterial pneumonia respiratory condition worsened despite receiving intensive care intravenous antibiotic fifth day hospitalization diagnosed acute respiratory distress syndrome started steroid therapy subsequently developed bloody stool diagnosed cytomegalovirus cmv enterocolitis based biopsy result peripheral blood cmv pp antigenemia test result although started antiviral therapy ganciclovir successful reducing antigen titer continued bloody diarrhea three week initiation ganciclovir therapy six week admission patient died intestinal perforation posthumously diagnosed amebic colitis cmv enterocolitis based autopsy finding transmural necrosis entire colon massive ameba infiltration conclusion urge clinician consider entamoeba histolytica infection severe colitis progress steroid therapy preemptive treatment recommended:0.0582816016175017",
    "127641": "coronavirus disease covid significant cause global mortality morbidity since first reported december wuhan china covid like previous coronaviruses primarily affect lung causing pneumonia interstitial pneumonitis severe acute respiratory distress syndrome ards however increasing evidence linking covid cardiovascular complication arrhythmia heart failure cardiogenic shock fulminant myocarditis cardiac death given novelty virus paucity data cardiovascular complication covid specifically myocarditis myocarditis inflammatory disease heart muscle heterogenous clinical presentation progression mostly caused viral infection result interaction virus host immune system several case report linking covid myocarditis however true mechanism cardiac injury remains investigation paper review clinical presentation proposed pathophysiology differential diagnosis management myocarditis covid patient:0.0580038433351623",
    "166579": "outbreak coronavirus disease covid occurred december due severe acute respiratory syndrome coronavirus sars cov strain sars cov patient infected virus present wide spectrum manifestation ranging mild flu like symptom cough fever fatigue severe lung injury appearing bilateral interstitial pneumonia acute respiratory failure although sars cov infection predominantly offends respiratory system associated several cardiovascular complication well example patient covid may either develop type myocardial infarction due myocardial oxygen demand supply imbalance acute coronary syndrome resulting excessive inflammatory response primary infection incidence covid related myocarditis estimated accountable average covid related fatal case whereas heart failure hf may develop due infiltration heart inflammatory cell destructive action pro inflammatory cytokine micro thrombosis new onset aggravated endothelial respiratory failure lastly sars cov engender arrhythmia direct myocardial damage causing acute myocarditis hf decompensation secondary respiratory failure severe respiratory distress syndrome comprehensive review summarize covid related cardiovascular complication acute coronary syndrome myocarditis hf arrhythmia discus main underlying pathophysiological mechanism:0.0577129343657699",
    "127308": "introduction year cornerstone medical research due covid pandemic outbreak process understanding condition brought light certain organ involvement like pulmonary kidney damage endocrine disbalances connection type organ impairment remain unclear sars cov previously incriminated cardiac involvement ranging mild symptom severe occurrence myocarditis arrythmias heart failure thus complicating acute phase management worsening patient prognosis despite reported acute manifestation critical covid cardiac tamponade seems also occur long covid complication latter distinct yet unclear entity associated remanent fatigue cough severe sequela like vasculitis polyneuropathy occsur case report report case year old patient admitted intensive care unit severe respiratory renal dysfunction one month initial mild episode covid rt pcr sars cov admission negative initial imaging ct heart ultrasound revealed presence pericardial effusion sign tamponade initially obvious twelve hour later patient state deteriorated cardiocirculatory failure sign obstructive shock agent responsible severe acute respiratory infection sari influenza b adenovirus bordetella pertussis mycoplasma pneumoniae coxsackie virus chlamydia pneumoniae parainfluenza virus ruled surprisingly rt pcr testing sars cov came back positive although initial test negative repeated imaging confirmed massive circumferential pericardial effusion emergency pericardiocentesis performed fluid exudate histopathology reported chronic inflammation rt pcr testing mycoplasma tuberculosis pericardial tissue came back negative conclusion case knowledge among first report cardiac tamponade one month mild covid infection aim case report raise awareness medical community possibility severe complication targeting major organ long covid phase:0.0576758385361719",
    "149694": "review current data clinically suspected european society cardiology esc criterion biopsy proven esc world health organization criterion myocarditis temporally associated severe acute respiratory syndrome coronavirus sars cov infection esc etiological diagnosis viral myocarditis based histological immunohistological evidence nonischemic myocyte necrosis monolymphocytic infiltration e myocarditis plus identification specific cardiotropic virus molecular technique particular polymerase chain reaction pcr situ hybridization endomyocardial biopsy emb autopsy tissue yet definitive emb autopsy proof sars cov cause direct cardiomyocyte damage association histological myocarditis clinical epidemiology data suggest myocarditis uncommon sars cov positive negative pcr case hypothesize rare virus negative biopsy proven case may represent new onset immune mediated latent pre existing autoimmune form triggered fostered hyperinflammatory state severe covid recommend application esc definition diagnostic criterion future report avoid low quality scientific information leading inaccurate estimate myocarditis incidence based misdiagnosis:0.0567704226680275",
    "138970": "cardiac complication including clinically suspected myocarditis described novel coronavirus disease review current data suspected myocarditis course severe acute respiratory syndrome novel coronavirus sars cov infection hypothetical mechanism explain pathogenesis troponin release patient novel coronavirus disease include direct virus induced myocardial injury ie viral myocarditis systemic hyperinflammatory response ie cytokine storm hypoxemia downregulation angiotensin converting enzyme systemic virus induced endothelialitis type type myocardial infarction date despite fact million sars cov infection diagnosed worldwide definitive proof sars cov novel cardiotropic virus causing direct cardiomyocyte damage diagnosis viral myocarditis based molecular assessment endomyocardial biopsy autopsy polymerase chain reaction situ hybridization blood sputum nasal throat swab virology testing insufficient correlate myocardial involvement given pathogen data endomyocardial biopsy autopsy clinically suspected sars cov myocarditis scarce overall current clinical epidemiologic data support hypothesis viral myocarditis caused sars cov common endomyocardial biopsy autopsy data also needed better understanding pathogenesis clinically suspected myocarditis course sars cov infection may include virus negative immune mediated already established subclinical autoimmune form triggered accelerated hyperinflammatory state severe novel coronavirus disease:0.0567694205779557"
  },
  "Topic 25": {
    "6046": "arginine vasopressin avp neuropeptide hormone play important role circulatory sodium homeostasis regulating serum osmolality several clinical condition associated inappropriately elevated level avp including heart failure cirrhosis liver syndrome inappropriate secretion antidiuretic hormone three receptor subtypes mediate action avp identified v v v b activation v receptor located vascular smooth muscle cell myocardium result vasoconstriction increased afterload hypertrophy v receptor located primarily collecting tubule mediate free water absorption v b receptor located anterior pituitary mediate adrenocorticotropin hormone release cardiovascular renal effect avp mediated primarily v v receptor antagonism v receptor result vasodilatation antagonism v receptor resulting aquaresis electrolyte sparing water excretion several non peptide avp antagonist vasopressin receptor antagonist vras also termed vaptans developed vigorously studied primarily treating condition characterised hyponatraemia fluid overload conivaptan combined v v receptor antagonist induces diuresis well haemodynamic improvement shown clinical trial correct euvolaemic hypervolaemic hyponatraemia approved u fda treatment euvolaemic hyponatraemia intravenous infusion tolvaptan selective v receptor antagonist undergone extensive clinical study treatment hyponatraemia heart failure shown effectively decrease fluid volume overloaded patient heart failure correct hyponatraemia large outcome study n patient define role management heart failure lixivaptan satavaptan sr selective v receptor antagonist evaluated treatment hyponatraemia addition potential role vaptans attenuating polyuria nephrogenic diabetes insipidus cyst development polycystic kidney disease explored ongoing clinical trial define scope potential therapeutic role vras:0.0706506966066626",
    "111010": "heart kidney failure continued increasing prevalence today society comorbidity synergistic effect morbidity mortality patient cardiorenal syndrome cr complex disease multifactorial pathophysiology better understanding pathophysiological network crucial successful intervention prevent advancement disease process one major factor process neurohormonal activation predominantly involving renin angiotensin aldosterone system raas arginine vasopressin avp heart failure cause reduced cardiac output cardiac index co ci fall renal perfusion pressure resulting activation baroreceptor raas respectively activated baroreceptor raas stimulate release avp non osmotic pathway act v receptor located renal collecting duct causing fluid retention deterioration heart failure effective blockade avp action v receptor emerged potential treatment option volume overload condition especially setting hyponatremia vasopressin receptor antagonist vras vaptans potent aquaretics causing electrolyte free water diuresis without significant electrolyte abnormality vaptans useful hypervolemic hyponatremic condition like heart failure liver cirrhosis euvolemic hyponatremic condition like syndrome inappropriate anti diuretic hormone secretion tolvaptan conivaptan pharmaceutical agent available treatment condition:0.0683156973542809",
    "24110": "pathogenesis form chronic heart failure high output low output failure accompanied arterial underfilling inducing activation various neurohumoral system renin angiotensin aldosterone system sympathic nervous system non osmotic stimulation vasopressin elevated level neurohormone detrimentally modulate renal function subsequently renal salt volume retention occurs leading main symptom heart failure edema formation dyspnea diuretic therapy diuretic discovered year ago beneficially influence renal salt volume retention effect tubular sodium reabsorption thiazide recommended mild form loop diuretic used severe stage congestive heart failure clinician consider changed pharmacokinetic dynamic property application diuretic patient chronic heart failure addition increased sodium reabsorption occurs immediately cessation diuretic action often nullifying preceding diuresis thus salt volume restriction guaranteed regular application loop diuretic day preferred due short acting nature currently available loop diuretic sometimes diuresis longer occur treatment one substance diuretic resistance although therapeutic goal water excretion achieved ruling factor reducing action diuretic non compliance hyponatremia etc sequential nephron blockade initiated combination loop diuretic thiazide aldosterone receptor antagonist increase diuresis elevate symptom volume overload side effect loop diuretic thiazide often induce mild hypokalemia demonstrated benign thought chronic treatment oral potassium supplement several drawback urine excretion potassium subsequently increased supplementation effective believed diuretic induced hypokalemia seems aldosterone dependent aldosterone level increase diuretic therapy even chronic treatment angiotensin converting enzyme aldosterone escape combined treatment including aldosterone receptor antagonist suggested beneficial effect aldosterone receptor blockade mortality rale trial appear mediated extrarenal renal mechanism suggested beneficial renal mechanism aldosterone receptor blockade discussed detail review conclusion conclusion diuretic therapy patient congestive heart failure effective relieve symptom presumably prolong life renal function pharmacokinetics dynamic diuretic changed heart failure diuretic treatment adapted provide optimal treatment increased level aldosterone appear play important role diuretic induced hypokalemia progression heart renal failure thus aldosterone receptor antagonist used treatment heart failure frequently:0.0643773730691269",
    "44000": "role renin angiotensin aldosterone system raas regulating volume composition extracellular fluid blood pressure bp well onset progression cardiovascular renal disease studied year compound block vital stage raas cascade ace inhibitor acei receptor blocker arb aldosterone receptor antagonist importantly extended treatment option however positive therapeutic effect compound also certain negative consequence administration aceis arb interrupt physiological feedback renal renin release lead reactive elevation circulating active renin greater production angiotensin angiotensin ii subsequent return aldosterone secretion pre treatment level escape phenomenon possible adverse effect intermediary product incomplete raas blockade leading organ complication facilitated effort develop compound blocking initial stage renin angiotensin cascade e direct renin blocker several year unsuccessful attempt recent year seen development first non peptide orally long term effective renin inhibitor aliskiren fumarate monotherapy combination antihypertensive hydrochlorothiazide arb acei aliskiren reduces bp dose dependent manner mg den aliskiren reduces plasma renin activity pra neutralises hydrochlorothiazide induced raas activation daily administration drug lead longer hour activity prolonged blocking effect kidney basis renoprotectivity addition significant antihypertensive effect clinical study also showed range organoprotective property patient left ventricle hypertrophy allay study heart failure aloft study diabetic nephropathy avoid study similar blocker aliskiren minimum adverse side effect aliskiren hypertension therapy launched clinical practice usa tekturna combination formulation tekturnahcl respectively shortly european union rasilez czech republic aliskiren rasilez released clinical use diabetologists nephrologists patient hypertension concomitant diabetes nephropathy proteinuria dos mg per day recommended monotherapy combination antihypertensive treat condition elevated pra including pra elevation following diuretic acei arb administration aliskiren might used patient tolerate aceis well patient angiotensin ii participates pathogenesis disease reno protective property leading reduction proteinuria delaying renal failure progression observed patient diabetic well non diabetic nephropathy drug subject similar precaution contraindication aceis arb e pregnancy bilateral renal artery stenosis make meaningful conclusion far positive contribution new treatment class broad applicability therapy hypertension cardiovascular disease imperative assess long term effect morbidity mortality well compare agent raas blocker long term clinical study represents research effort another year:0.0628411380679178",
    "15666": "vasopressin play physiological role regulation blood pressure fluid volume serum osmolality heart failure inadequate release vasopressin may result excess fluid retention hyponatremia vasopressin receptor antagonist new class orally active drug targeted inhibit one three distinct vasopressin receptor namely v vasoconstriction v b release acth und v receptor inhibition free water reabsorption kidney cardiac decompensation fluid overload selective v lixivaptan satavaptan tolvaptan non selective v v receptor blocker conivaptan shown superior standard therapy allow faster weight loss rapid symptomatic improvement e reduction dyspnea inhibiting free water reabsorption without affecting renal sodium excretion vasopressin receptor antagonist allow controlled normalisation serum natrium euvolemic hypervolemic hyponatremia vasopressin antagonist well tolerated contrast diuretic negative influence renal function serum potassium heart rate blood pressure affected vasopressin receptor antagonist however despite excellent acute clinical effect long term treatment tolvaptan result reduced mortality morbidity heart failure patient mean follow month everest trial:0.0628000018497007",
    "3789": "sr selective orally active non peptide antagonist vasopressin avp v receptor powerful aquaretic property various animal specie human sr belongs new class drug called aquaretics capable inducing free water excretion without affecting electrolyte balance sr display high affinity animal human v receptor exhibit remarkably selective v receptor profile sr h sr used therefore selective probe characterization labeling v receptor various functional study vitro sr behaves potent antagonist inhibits avp stimulated human renal adenylyl cyclase ddavp desamino arginine vasopressin induced relaxation rat aorta sr also behaves inverse agonist cell expressing constitutively activated human v receptor mutant vitro sr rescued misfolded v avp receptor mutant increasing cell surface expression restoring v function normally hydrated conscious rat dog monkey sr either v p administration induced dose dependent aquaresis major change urinary na k excretion unlike classical diuretic cirrhotic rat ascites impaired renal function day treatment sr totally corrected hyponatremia restored normal urine excretion model diabetic nephropathy rat sr strongly reduced albumin excretion sr also effective extrarenal v v like receptor involved vascular relaxation clotting factor release vitro vivo rabbit model ocular hypertension sr either single repeated instillation decreased intraocular pressure acute chronic administration rat dog healthy human volunteer sr well absorbed well tolerated specie studied drug produced pronounced aquaresis without agonist effect thus sr potent orally active selective antagonist v receptor powerful aquaretic property useful tool exploration function renal extrarenal v receptor pure v receptor antagonist likely therapeutically useful several water retaining disease hyponatremia syndrome inappropriate antidiuretic hormone secretion siadh congestive heart failure liver cirrhosis disorder possibly mediated v receptor e g glaucoma:0.0627170897916373",
    "83695": "hyponatremia congestive heart failure chf associated increased morbidity mortality underlining importance adequate assessment treatment electrolyte imbalance patient chf current treatment option hyponatremia chf include hypertonic saline solution loop diuretic fluid restriction pharmacologic agent demeclocycline lithium carbonate urea hypertonic saline solution must administered extreme caution excessively slow rapid sodium correction lead severe neurologic adverse effect loop diuretic useful reducing water retention caused chf however potent diuresis induced agent furosemide result loss sodium essential electrolyte may exacerbate hyponatremia fluid restriction moderately effective often difficult implement hospital setting agent demeclocycline lithium potentially serious renal cardiovascular side effect arginine vasopressin avp receptor antagonist promising new class aquaretic agent increase free water excretion maintaining level sodium essential electrolyte tolvaptan opc lixivaptan vpa conivaptan ym currently development treatment hyponatremia although tolvaptan lixivaptan selective vasopressin v receptor responsible antidiuretic action avp conivaptan demonstrates activity v receptor v receptor responsible vasoconstricting property avp dual receptor activity may particularly useful patient chf patient may benefit increased cardiac output reduced total peripheral resistance reduced mean arterial blood pressure result v receptor blockade well reduced congestion reduced cardiac preload increased sodium concentration induced v receptor antagonism:0.0625363697644525",
    "54623": "lixivaptan vpa developed biogen idec cardiokine license wyeth part pfizer non peptide selective vasopressin v receptor antagonist potential oral treatment hyponatremia associated heart failure arginine vasopressin native v receptor ligand stimulates water reabsorption via activation v receptor expressed collecting duct kidney preclinical study lixivaptan displayed competitive antagonist activity v receptor vitro increased urine volume decreased urine osmolality rat dog therapeutic benefit lixivaptan evaluated patient condition associated water excess hyponatremia phase ii clinical trial patient congestive heart failure liver cirrhosis ascites syndrome inappropriate antidiuretic hormone demonstrated unlike traditional diuretic lixivaptan increase water clearance without affecting renal sodium excretion activating neurohormonal system administration lixivaptan combination diuretic furosemide tested rat well trial healthy volunteer two agent well tolerated ongoing phase iii trial determine role lixivaptan management hyponatremia especially associated heart failure:0.0607573792772362",
    "12751": "kidney key organ maintain balance different electrolyte body acid base balance progressive loss kidney function result number adaptive compensatory renal extrarenal change allow homeostasis maintained glomerular filtration rate range ml min glomerular filtration rate ml min almost always abnormalites body internal environment clinical repercussion water balance disorder advanced chronic kidney disease ckd range urine osmolality progressively approach plasma osmolality becomes isostenuric manifest clinically symptom nocturia polyuria especially tubulointerstitial kidney disease water overload result hyponatremia decrease water intake lead hypernatremia routine analysis serum na level performed patient advanced ckd strength recommendation c except edematous state daily fluid intake liter recommended strength recommendation c hyponatremia usually occur glomerular filtration rate ml min strength recommendation b occurs excessive intake free water considered nonosmotic release vasopressin stimulus pain anesthetic hypoxemia hypovolemia use diuretic hypernatremia less frequent hyponatremia ckd occur provision hypertonic parenteral solution frequently consequence osmotic diuresis due inadequate water intake intercurrent disease circumstance limit access water obtundation immobility sodium balance disorder ckd fractional excretion sodium increase absolute sodium excretion modified glomerular filtration rate ml min strength recommendation b total body content sodium main determinant extracellular volume therefore disturbance sodium balance lead clinical situation volume depletion overload volume depletion due renal sodium loss occurs abrupt restriction salt intake advanced ckd occurs frequently certain tubulointerstitial kidney disease salt losing nephropathy volume overload due sodium retention occur glomerular filtration rate ml min lead edema arterial hypertension heart failure use diuretic volume overload ckd useful force natriuresis strength recommendation b thiazide little effect advanced ckd loop diuretic effective used higher normal dos strength recommendation b combination thiazide loop diuretic useful refractory case strength recommendation b weight volume monitored regularly hospitalized patient ckd strength recommendation c potassium balance disorder ckd ability kidney excrete potassium decrease proportionally loss glomerular filtration stimulation aldosterone increase intestinal excretion potassium main adaptive mechanism maintain potassium homeostasis glomerular filtration rate ml min main cause hyperkalemia ckd following use drug alter ability kidney excrete potassium aceis arb nsaid aldosterone antagonist nonselective beta blocker heparin trimetoprim calcineurin inhibitor determination serum potassium two week initiation treatment aceis arb recommended strength recommendation c routine use aldosterone antagonist advanced ckd recommended strength recommendation c abrupt reduction glomerular filtration rate constipation prolonged fasting metabolic acidosis low potassium diet recommended gfr less ml min gfr less ml min drug raise serum potassium taken strength recommendation c absence symptom electrocardiographic abnormality review medication restriction dietary potassium use oral ion exchange resin usually sufficient therapeutic measure strength recommendation c symptom electrocardiographic abnormality present usual parenteral pharmacological measure used calcium gluconate insulin glucose salbutamol resin diuretic strength recommendation parenteral bicarbonate ion exchange resin enema recommended first line treatment strength recommendation c hemodialysis considered patient glomerular filtration rate ml min strength recommendation c acid base disorder ckd moderate metabolic acidosis bic meq l common glomerular filtration rate ml min favor bone demineralization due release calcium phosphate bone chronic hyperventilation muscular weakness atrophy treatment consists administration sodium bicarbonate usually orally meq kg day goal achieving serum bicarbonate level mmol l strength recommendation c limitation daily protein intake less g kg day also useful strength recommendation c use sevelamer phosphate binder aggravates metabolic acidosis since favor endogenous acid production therefore acidosis monitored corrected occurs strength recommendation c hypocalcemia always corrected metabolic acidosis ckd strength recommendation b metabolic acidosis infrequent disorder requires exogenous alkali administration bicarbonate phosphate binder vomiting:0.0602189760095868",
    "31502": "chronic heart failure chf neurohumoral system help maintain circulatory homeostasis maladaptive responsible disease progression congestion long term activation sympathetic hormone renin angiotensin aldosterone system raas addition non osmotic vasopressin release regulation aquoporine renal sodium transporter renal resistance natriuretic peptide lead salt water avid state primary decrease cardiac output arterial vasodilatation brings arterial underfilling activates neuro humoral reflex system heart disease primum movens kidney end organ responsible increased tubular reabsorption sodium water important hemodynamic alteration kidney constriction glomerular efferent arteriole increase intraglomerular pressure hence glomerular filtration rate resulting change intrarenal oncotic hydrostatic pressure promote tubular reabsorption time gradually falling glomerular filtration rate due chf progression medication chronic kidney injury due comorbidities becomes critical sodium water imbalance moreover long term use diuretic lead diuretic resistant state necessitates use higher dos activating raas often expense worsening renal function however every patient case general pathophysiology hydro saline balance may different subject mechanism prevail others kidney may different response diuretic necessary customize individual long term therapy tailoring medical treatment according clinical profile comorbidities renal function introducing active control body weight patient fluid restriction less restricted sodium intake flexibility diuretic dos early personalized ambulatory follow congestion monitoring bioelectrical impedance vector analysis bnp inferior vena cava ultrasonography echocardiographic e e ratio pulmonary capillary wedge pressure:0.0579165718546045"
  }
}